



1. A compound of formula (I):



or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer, metabolite, polymorph or prodrug thereof, wherein
R1 and R2 are each independently selected from hydrogen, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 haloalkenyl, C2-6 alkynyl, C2-6 haloalkynyl, C3-8 cycloalkyl, C4-14 alkylencycloalkyl, C3-C8 heterocycloalkyl, C4-C14 alkyleneheterocycloalkyl, C6-12 aryl, C7-18 alkylenearyl, C5-10 heteroaryl, and C6-16 alkyleneheteroaryl, said C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 haloalkenyl, C2-6 alkynyl, C2-6 haloalkynyl, C3-8 cycloalkyl, C4-14 alkylencycloalkyl, C3-C8 heterocycloalkyl, C4-C14 alkyleneheterocycloalkyl, C6-12 aryl, C7-18 alkylenearyl, C5-10 heteroaryl, and C6-16 alkyleneheteroaryl each

1. Int'l Pat. App. Pub. No. WO/2018/064465 "Compounds for increasing neural plasticity" (Published April 5, 2018)

From Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa or IIb:




wherein:

L3 is a bond, -C(O)NRb-, -NRbC(O)-, -NHC(O)NRb-, -C(O)O-, -OC(O)-, -NHC(O)O-, -SO2NRb-, -NHSO2-, -SO2-, -O-, -S-, or -NRb-; R8 is hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 alkoxy, C1-C6 aminoalkyl, heterocycloalkyl, aryl, or heteroaryl; Rb is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or C1-C6 alkoxy; R9 is hydrogen, C1-C6 alkyl, or C2-C6 alkenyl; R10 is hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, or C1-C6 haloalkyl; R11 is C1-C6 alkylamino, di-(C1-C6 alkyl)amino, N-(C1-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl; R12 is hydrogen, halogen, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or C1-C6 alkoxy; subscript p is an integer from 0 to 3; subscript q is an integer from 0 to 3; and subscript r is an integer from 1 to 3.

2. Int'l Pat. App. Pub. No. WO/1998/023587 "5-cyclo indole compounds as 5-HT1d receptor ligands" (Published June 4, 1998)

From Claim 1: A compound according to Formula I:



wherein A is selected from a six-membered, non-aromatic, optionally substituted carbocycle and a six-membered, non-aromatic, optionally substituted heterocycle having one or two heteroatoms selected from O, S, SO, SO2 and NR4
R1 is selected from H and OH; n is 0 or 1 as permitted by chemical structure

being optionally substituted with one or more substituents independently selected from halogen, CN, C1-8 alkoxy, C1-8 alkylamino, C1-8 alkylsulfonyl, CO2R4, C(O)N(R4)2, OR4, N(R4)2, NO2, SR4 and SO2R4, said C3-8 cycloalkyl, C4-14 alkylencycloalkyl, C3-C8 heterocycloalkyl, C6-12 aryl, C7-18 alkylenearyl, C5-10 heteroaryl, and C6-16 alkyleneheteroaryl each being further optionally substituted with a substituent independently selected from (O), C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 haloalkenyl, C2-6 alkynyl, C2-6 haloalkynyl, C3-6 cycloalkyl and C3-6 heterocycloalkyl including 1 or 2 ring heteromoieties selected from O, S, N, S(O), SO2 and NR4; alternatively R1 and R2 are combined with the atoms to which they are attached to form a C3-8 heterocycloalkyl including 1 or 2 additional ring heteromoieties selected from O, S, S(O), SO2, N and NR4, said C3-8 heterocycloalkyl being further optionally substituted with a

R2 is selected from CR5R8CH2NR7R8...


R3 is selected from H and benzoyl

R5 and R8 are independently selected from H...

R7 and R8 are independently selected from H and loweralkyl or R7 and R8 form an alkylene bridge which, together with the nitrogen atom to which they are attached, creates an optionally substituted 3- to 6-membered ring...

3. Int'l Pat. App. Pub. No. WO/2020/176599 "Azepino-indoles and other heterocycles for treating brain disorders" (Published September 3, 2020)

From Claim 1: A compound of Formula I:



wherein:

R1 is hydrogen or C1-6 alkyl;

R3a and R3b are each independently hydrogen, C1-6 alkyl, C3-8 cycloalkyl, or C4-14 alkyl-cycloalkyl;

R3c is hydrogen or C1-6 alkyl;

R4, R5, R6 and R7 are each independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, C1-6 haloalkyl, C1-6 alkylamine, C1-6 alkoxy, C1-6 haloalkoxy, -OR8a, -NO2, -CN, -C(O)R8b, -C(O)OR8b, -OC(O)R8b, -OC(O)OR8b, -


S(O)2N(R8bR8c), C3-8 cycloalkyl, C3-14 alkyl-cycloalkyl, C4-10 heterocycloalkyl, C4-16 alkyl-heterocycloalkyl, C6-12 aryl, C7-18 alkyl-aryl, C5-10 heteroaryl, or C4-16 alkyl-heteroaryl, wherein at least one of R4, R5, R6 and R7 is not H; alternatively, R4 and R5, R5 and R6, or R6 and R7 are combined with the atoms to which they are each attached to form a C3-6 cycloalkyl, C3-6 heterocycloalkyl, C6-12 aryl or C5-10 heteroaryl;

R8a, R8b, R8c...are each independently H, C1-6 alkyl;

4. Int'l Pat. App. Pub. No WO/2018/204359 "Compositions and methods for treating ocular pathologies" (Published November 8, 2018)

From Page 21 Line 5: In embodiments, the composition comprises a compound having the following chemical formula

substituent selected from halogen, (O), CN, C1-8 alkoxy, C1-8 alkylamino, C1-8 alkylsulfonyl, CO₂R₄, C(O)N(R₄)₂, OR₄, N(R₄)₂, NO₂, SR₄, SO₂R₄, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 haloalkenyl, C2-6 alkynyl, C2-6 haloalkynyl, C1-8 alkylamino, C1-8 alkylsulfonyl, C3-6 cycloalkyl and C3-6 heterocycloalkyl including 1 or 2 ring heteromoieties selected from O, S, N, S(O), SO₂ and NR₄; R₃ is selected from hydrogen, C1-6 alkyl, C3-8 cycloalkyl, or C4-14 alkylencycloalkyl; alternatively R₃ and one of R₁ and R₂ are combined with the atoms to which they are attached to form a C3-12 heterocycloalkyl, said C3-12 heterocycloalkyl being further optionally substituted with a substituent selected from halogen, (O), CN, C1-8 alkoxy, C1-8 alkylamino, C1-8 alkylsulfonyl, CO₂R₄, C(O)N(R₄)₂, OR₄, N(R₄)₂, NO₂, SR₄, SO₂R₄, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 haloalkenyl, C2-6 alkynyl, C2-6 haloalkynyl, C3-6 cycloalkyl and C3-6



In some embodiments, R_{N1} of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl
R_{N2} of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4- haloalkyl
R_a of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl
R₄ of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl
R₅ of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl
R₆ of formula (III) can be H, C1-C6- alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl
and R₇ of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl.

heterocycloalkyl including 1 or 2 ring heteromoieties selected from O, S, N, S(O), SO₂ and NR₄; each R₄ is independently selected from hydrogen, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 haloalkenyl, C2-6 alkynyl, C2-6 haloalkynyl, C3-7 cycloalkyl, and C3-7 heterocycloalkyl including 1 or 2 ring heteromoieties selected from O, S, S(O), SO₂, N and NR₅, said C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 haloalkenyl, C2-6 alkynyl, C2-6 haloalkynyl, C3-7 cycloalkyl and C3-7 heterocycloalkyl each being optionally substituted with one or more substituents independently selected from halogen, CN, C1-8 alkoxy, C1-8 alkylamino, C1-8 alkylsulfonyl, CO₂R₅, C(O)N(R₅)₂, OR₅, N(R₅)₂, NO₂, SR₅ and SO₂R₅, said C3-C7 cycloalkyl and C3-7 heterocycloalkyl each being further optionally substituted with a substituent independently selected from (O), C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 haloalkenyl, C2-6 alkynyl, C2-6

haloalkynyl, C3-6
cycloalkyl and C3-6
heterocycloalkyl
including 1 or 2 ring
heteromoieties selected
from O, S, S(O), SO₂,
N and NR₅;
each R₅ is
independently selected
from hydrogen, C1-6
alkyl, C2-6 alkenyl,
C2-6 alkynyl, C1-6
haloalkyl, C3-8
cycloalkyl, C5-10
heterocycloalkyl, C6-12
aryl and C5-10
heteroaryl,
said C1-6 alkyl, C2-6
alkenyl, C2-6 alkynyl,
C1-6 haloalkyl, C3-8
cycloalkyl, C5-10
heterocycloalkyl, C6-12
aryl and C5-10
heteroaryl each being
optionally substituted
with one or more
substituents
independently selected
from halogen, CN, C1-
8 alkoxy, C1-8
alkylamino, C1-8
alkylsulfonyl, CO₂H,
CO₂CH₃, C(O)NH₂,
C(O)N(CH₃)₂,
C(O)NHCH₃, OH,
NH₂, N(CH₃)₂,
NHCH₃, NO₂, SH,
SCH₃, SO₂CH₃,
SOCH₃, C1-6 alkyl,
C1-6 haloalkyl, C2-6
alkenyl, C2-6
haloalkenyl, C2-6
alkynyl, C2-6
haloalkynyl, C3-6
cycloalkyl and C3-6
heterocycloalkyl
including 1 or 2 ring
heteromoieties selected

from O, S, S(O), SO₂, N, NH and NCH₃;
L is selected from C1-4 alkylene, C2-C4 alkenylene and C2-C4 alkynylene;
R6 is selected from hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkyleneP(O)(OR₁₂)₂, C(O)R₁₂, CO₂R₁₂, C(O)N(R₁₂)₂, S(O)R₁₂ and SO₂R₁₂, C3-6 cycloalkyl, C6-9 alkylencycloalkyl, C3-6 heterocyclyl, C6-9 alkyleneheterocycloalkyl, C4-7 heterocyclyl, C7-10 alkyneneheterocycloalkyl, C6-12 aryl, C7-18 alkylenearyl, C5-10 heteroaryl, and C6-16 alkyleneheteroaryl, said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, C6-9 alkylencycloalkyl, C3-6 heterocyclyl, C6-9 alkyleneheterocycloalkyl, C4-7 heterocyclyl, C7-10 alkyneneheterocycloalkyl, C6-12 aryl, C7-18 alkylenearyl, C5-10 heteroaryl, and C6-16 alkyleneheteroaryl each being optionally substituted with one or more substituents independently selected from halogen, CN, C1-8 alkoxy, C1-8 alkylamino, C1-8 alkylsulfonyl, CO₂R₁₂, C(O)N(R₁₂)₂, OR₁₂, N(R₁₂)₂, NO₂, SR₁₂ and SO₂R₁₂,

said C3-6 cycloalkyl, C6-9 alkylencycloalkyl, C3-6 heterocyclyl, C6-9 alkyleneheterocycloalkyl, C4-7 heterocyclyl, C7-10 alkyneneheterocycloalkyl, C6-12 aryl, C7-18 alkylenearyl, C5-10 heteroaryl, and C6-16 alkyleneheteroaryl each being further optionally substituted with a substituent independently selected from (O), C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 haloalkenyl, C2-6 alkynyl, C2-6 haloalkynyl, C3-6 cycloalkyl and C3-6 heterocycloalkyl including 1 or 2 ring heteromoieties selected from O, S, N, S(O), SO₂ and NR₁₂; each R₁₂ is independently selected from hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-8 cycloalkyl, C4-14 alkylencycloalkyl, C3-10 heterocycloalkyl, C4-16 alkyleneheterocycloalkyl, C6-12 aryl, C7-18 alkylenearyl, C5-10 heteroaryl, and C6-16 alkyleneheteroaryl, said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-8 cycloalkyl, C4-14 alkylencycloalkyl, C3-10 heterocycloalkyl,

<p>C4-16 alkyleneheterocycloalkyl, C6-12 aryl, C7-18 alkylenearyl, C5-10 heteroaryl, and C6-16 alkyleneheteroaryl each being optionally substituted with one or more substituents independently selected from halogen, CN, C1-8 alkoxy, C1-8 alkylamino, C1-8 alkylsulfonyl, CO₂H, CO₂CH₃, C(O)NH₂, C(O)N(CH₃)₂, C(O)NHCH₃, OH, NH₂, N(CH₃)₂, NHCH₃, NO₂, SH, SCH₃, SO₂CH₃, SOCH₃, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 haloalkenyl, C2-6 alkynyl, C2-6 haloalkynyl, C3-6 cycloalkyl and C3-6 heterocycloalkyl including 1 or 2 ring heteromoieties selected from O, S, S(O), SO₂, N, NH and NCH₃; wherein one of (B) and (C) apply: (B) (i) one of R₇, R₈, R₉, R₁₀ and R₁₁ is selected from OR₁₃, N(R₁₃)₂, SR₁₃, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-C6 haloalkenyl, C2-6 alkynyl, C2-6 haloalkynyl, C1-6 alkylamine, C1-6 alkoxy, C1-6 haloalkoxy, CO₂R₁₃, C(O)R₁₃, C(O)N(R₁₃)₂, C(O)C(O)N(R₁₃)₂,</p>	
---	--

OC(O)R13,
OC(O)OR13,
OC(O)N(R13)2,
OS(O)R13,
OS(O)N(R13)2,
OSO2R13,
OP(O)(OR13)2, OC1-
6alkyleneP(O)(OR13)2,
S(O)R13,
S(O)N(R13)2,
SO2R13, N(R13)2,
N(R13)C(O)R13,
N(R13)C(O)OR13,
N(R13)C(O)N(R13)2,
NO2, C3-8 cycloalkyl,
C3-14
alkylenecycloalkyl, C3-
10 heterocycloalkyl,
C4-16
alkyleneheterocycloalk
yl, C6-12 aryl, C7-18
alkylenearyl, C5-10
heteroaryl, C4-16
alkyleneheteroaryl,
said C1-6 alkyl, C1-6
haloalkyl, C2-6 alkenyl,
C2-C6 haloalkenyl, C2-
6 alkynyl, C2-6
haloalkynyl, C1-6
alkylamine, C1-6
alkoxy, C1-6
haloalkoxy, C3-8
cycloalkyl, C3-14
alkylenecycloalkyl, C3-
10 heterocycloalkyl,
C4-16
alkyleneheterocycloalk
yl, C6-12 aryl, C7-18
alkylenearyl, C5-10
heteroaryl, and C4-16
alkyleneheteroaryl
being optionally
substituted with one or
more substituents
independently selected
from halogen, CN, C1-
8 alkoxy, C1-8
alkylamino, C1-8
alkylsulfonyl, CO2R13,


C(O)N(R13)2, OR13, N(R13)2, NO2, SR13 and SO2R13, said C3-8 cycloalkyl, C3-14 alkylencycloalkyl, C3-10 heterocycloalkyl, C4-16 alkyleneheterocycloalkyl, C6-12 aryl, C7-18 alkylenearyl, C5-10 heteroaryl, and C4-16 alkyleneheteroaryl each being further optionally substituted with a substituent selected from (O), C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 haloalkenyl, C2-6 alkynyl, C2-6 haloalkynyl, C3-6cycloalkyl and C3-6 heterocycloalkyl including 1 or 2 ring heteromoeities selected from O, S, S(O), SO2, N, and NR13; each R13 is independently selected from hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-8 cycloalkyl, C4-14 alkylencycloalkyl, C3-10 heterocycloalkyl, C4-16 alkyleneheterocycloalkyl, C6-12 aryl, C7-18 alkylenearyl, C5-10 heteroaryl, and C6-16 alkyleneheteroaryl, said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-8 cycloalkyl, C4-14 alkylencycloalkyl, C3-10 heterocycloalkyl,

<p>C4-16 alkyleneheterocycloalkyl, C6-12 aryl, C7-18 alkylenearyl, C5-10 heteroaryl, and C6-16 alkyleneheteroaryl each being optionally substituted with one or more substituents independently selected from halogen, CN, C1-8 alkoxy, C1-8 alkylamino, C1-8alkylsulfonyl, CO₂H, CO₂CH₃, C(O)NH₂, C(O)N(CH₃)₂, C(O)NHCH₃, OH, NH₂, N(CH₃)₂, NHCH₃, NO₂, SH, SCH₃, SO₂CH₃, SOCH₃, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 haloalkenyl, C2-6 alkynyl, C2-6 haloalkynyl, C3-6 cycloalkyl and C3-6 heterocycloalkyl including 1 or 2 ring heteromoieties selected from O, S, S(O), SO₂, N, NH and NCH₃; and (ii) the other of R7, R8, R9, R10 and R11 are each hydrogen, alternatively, R6 and R7 are combined with the atoms to which they are each attached to form a C4-10 heterocycloalkyl or a C5-10 heteroaryl, said C4-10 heterocycloalkyl and C5-10 heteroaryl each being further optionally substituted with a substituent selected from halogen, (O), CN,</p>	
---	--


C1-8 alkoxy, C1-8 alkylamino, C1-8 alkylsulfonyl, CO₂R₁₄, C(O)N(R₁₄)₂, OR₁₄, N(R₁₄)₂, NO₂, SR₁₄, SO₂R₁₄, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 haloalkenyl, C2-6 alkynyl, C2-6 haloalkynyl, C3-6 cycloalkyl and C3-6 heterocycloalkyl including 1 or 2 ring heteromoieties selected from O, S, N, S(O), SO₂ and NR₁₄; alternatively, R₇ and one of R₁, R₂, or R₃ are combined with the atoms to which they are attached to form a C5-8 heterocycloalkyl, said C5-8 heterocyclyalkyl being further optionally substituted with one or more substituents selected from halogen, (O), CN, C1-8 alkoxy, C1-8 alkylamino, C1-8 alkylsulfonyl, CO₂R₁₄, C(O)N(R₁₄)₂, OR₁₄, N(R₁₄)₂, NO₂, SR₁₄, SO₂R₁₄, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 haloalkenyl, C2-6 alkynyl, C2-6 haloalkynyl, C3-6 cycloalkyl and C3-6 heterocycloalkyl including 1 or 2 ring heteromoieties selected from O, S, N, S(O), SO₂ and NR₁₄; each R₁₄ is independently selected from hydrogen, C1-6

alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C3-C7cycloalkyl, C3-10 heterocycloalkyl, C6-12 aryl and C5-10 heteroaryl;
said C1-6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C3-C7cycloalkyl, C3-10 heterocycloalkyl, C6-12 aryl and C5-10 heteroaryl each being optionally substituted with one or more substituents independently selected from halogen, CN, C1-8 alkoxy, C1-8 alkylamino, C1-8 alkylsulfonyl, CO₂H, CO₂CH₃, C(O)NH₂, C(O)N(CH₃)₂, C(O)NHCH₃, OH, NH₂, N(CH₃)₂, NHCH₃, NO₂, SH, SCH₃, SO₂CH₃, SOCH₃, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 haloalkenyl, C2-6 alkynyl, C2-6 haloalkynyl, C3-6 cycloalkyl and C3-6 heterocycloalkyl including 1 or 2 ring heteromoieties selected from O, S, S(O), SO₂, N, NH and NCH₃,
wherein:
when R₁ and R₂ are each methyl, and R₃ and R₆ are each hydrogen, then R₈ is not OH or OCH₃ and R₉ is not OH;
when R₁ and R₂ are each ethyl, isobutyl or


(sec)butyl, and R3 and R6 are each hydrogen, then R8 is not OH;
 when R1 and R2 are each isopropyl, and R3 and R6 are each hydrogen, then R9 is not OH;
 when R1 and R2 together with the nitrogen to which they are attached form




and R3 and R6 are each hydrogen, then R9 is not OCH3;
 when R1 and R2 together with the nitrogen to which they are attached form



and R3 and R6 are each hydrogen, then R8 is not OH;
 when R1 and R2 together with the nitrogen to which they are attached form




and R3 and R6 are each hydrogen, then R8 is not OH, R9 is not CH3 or OCH3, and R10 is not OCH3;
 when R1 and R2 together with the nitrogen to which they are attached form




and R3 and R6 are each hydrogen, then R7, R8, R9, R10 and R11 are

not selected from OH, OCH₃, OC(O)CH₃, OP(O)(OH)₂, NH₂, halogen, CH₃, CN and CF₃;

when R1 and R2 together with the nitrogen to which they are attached form any one of



R3 is hydrogen, and R6 is methyl, then R8 is not OH or OBn; when R1 and R2 are each methyl, R3 is hydrogen, and R6 is selected from ethyl, CH₂CHF₂, propyl, isopropyl, butyl, cyclopropyl, methylenecyclopropyl, cyclobutyl, oxetanyl and butenyl, then R8 is not OH or OBn; when R1 and R2 are each methyl, R3 is hydrogen, and R6 is hydrogen or CH₂P(O)(OH)₂, then R8 is not selected from



and $\text{OC(O)N(CH}_3)_2$;


and

when R1, R2 and R3

together with the atoms

to which they are


attached form



and R6 is hydrogen or

$\text{CH}_2\text{P(O)(OH)}_2$, then

R8 is not selected from



and $\text{O(O)N(CH}_3)_2$;

(C) R7, R8, R9, R10

and R11 are each


hydrogen,

wherein:


when R3 and R6 are

each hydrogen, then R1


and R2 are not each methyl, ethyl, propyl, isopropyl, cyclopropyl or




and R1 and R2 together with the nitrogen to which they are attached do not form pyrrolidyl, piperidyl or 2,5-dimethylpyrrolyl; when R6 is hydrogen, and R3 is methyl, then R1 and R2 are not each hydrogen; when R3 and R6 are each hydrogen, and one of R1 and R2 is methyl, then the other of R1 and R2 is not propyl, isopropyl, cyclopropyl, methylenecyclopropyl,



when R3 and R6 are each hydrogen, and one of R1 and R2 is ethyl or propyl, then the other of R1 and R2 is not isopropyl, cyclopropyl, methylenecyclopropyl,



when R3 and R6 are each hydrogen, and one of R1 and R2 is isopropyl, then the other of R1 and R2 is not propyl, cyclopropyl, methylenecyclopropyl,




2. The compound of claim 1, wherein:

1. Int'l Pat. App. Pub. No. WO/2018/064465 "Compounds for increasing neural plasticity" (Published April 5, 2018)

R7, R8, R9, R10 and R11 are each independently selected from hydrogen, halogen, CN, OR13, N(R13)2, SR13, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-C6 haloalkenyl, C2-6 alkynyl, C2-6 haloalkynyl, C1-6 alkylamine, C1-6 alkoxy, C1-6 haloalkoxy, CO2R13, C(O)R13, C(O)N(R13)2, C(O)C(O)N(R13)2, OC(O)R13, OC(O)OR13, OC(O)N(R13)2, OS(O)R13, OS(O)N(R13)2, OSO2R13, OP(O)(OR13)2, OC1-6alkyleneP(O)(OR13)2, S(O)R13, S(O)N(R13)2, SO2R13, N(R13)2, N(R13)C(O)R13, N(R13)C(O)OR13, N(R13)C(O)N(R13)2, NO2, C3-8 cycloalkyl, C3-14 alkylencycloalkyl, C3-10 heterocycloalkyl, C4-16 alkyleneheterocycloalkyl, C6-12 aryl, C7-18 alkylenearyl, C5-10 heteroaryl, C4-16 alkyleneheteroaryl, said C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-C6 haloalkenyl, C2-6 alkynyl, C2-6 haloalkynyl, C1-6 alkylamine, C1-6 alkoxy, C1-6 haloalkoxy, C3-8

From Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa or IIb:



wherein:

L3 is a bond, -C(O)NRb-, -NRbC(O)-, -NHC(O)NRb-, -C(O)O-, -OC(O)-, -NHC(O)O-, -SO2NRb-, -NHSO2-, -SO2-, -O-, -S-, or -NRb-; **R8** is hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 alkoxy, C1-C6 aminoalkyl, heterocycloalkyl, aryl, or heteroaryl;

Rb is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or C1-C6 alkoxy;

R9 is hydrogen, C1-C6 alkyl, or C2-C6 alkenyl;

R10 is hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, or C1-C6 haloalkyl;

R11 is C1-C6 alkylamino, di-(C1-C6 alkyl)amino, N-(C1-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl;

R12 is hydrogen, halogen, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or C1-C6 alkoxy;


subscript **p** is an integer from 0 to 3;

subscript **q** is an integer from 0 to 3; and

subscript **r** is an integer from 1 to 3.

2. Int'l Pat. App. Pub. No. WO/1998/023587 "5-cyclo indole compounds as 5-HT1d receptor ligands" (Published June 4, 1998)

From Claim 1: A compound according to Formula I:



wherein **A** is selected from a six-membered, non-aromatic, optionally substituted carbocycle and a six-membered, non-aromatic, optionally substituted heterocycle having one or two heteroatoms selected from O, S, SO, SO2 and NR4

R1 is selected from H and OH; **n** is 0 or 1 as permitted by chemical structure

R2 is selected from CR5R8CH2NR7R8...

R3 is selected from H and benzoyl

R5 and **R8** are independently selected from H...


R7 and **R8** are independently selected from H and loweralkyl or **R7** and **R8** form an alkylene bridge which, together with the nitrogen atom to

cycloalkyl, C3-14
 alkylencycloalkyl, C3-10 heterocycloalkyl, C4-16
 alkyleneheterocycloalkyl, C6-12 aryl, C7-18 alkylenearyl, C5-10 heteroaryl, and C4-16 alkyleneheteroaryl being optionally substituted with one or more substituents independently selected from halogen, CN, C1-8 alkoxy, C1-8 alkylamino, C1-8 alkylsulfonyl, CO₂R₁₃, C(O)N(R₁₃)₂, OR₁₃, N(R₁₃)₂, NO₂, SR₁₃ and SO₂R₁₃, said C3-8 cycloalkyl, C3-14
 alkylencycloalkyl, C3-10 heterocycloalkyl, C4-16
 alkyleneheterocycloalkyl, C6-12 aryl, C7-18 alkylenearyl, C5-10 heteroaryl, and C4-16 alkyleneheteroaryl each being further optionally substituted with a substituent selected from (O), C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 haloalkenyl, C2-6 alkynyl, C2-6 haloalkynyl, C3-6cycloalkyl and C3-6 heterocycloalkyl including 1 or 2 ring heteromoeities selected from O, S, S(O), SO₂, N, and NR₁₃; each R₁₃ is independently selected from hydrogen, C1-6 alkyl, C2-6 alkenyl,

which they are attached, creates an optionally substituted 3- to 6-membered ring...

3. Int'l Pat. App. Pub. No. WO/2020/176599 "Azepino-indoles and other heterocycles for treating brain disorders" (Published September 3, 2020)

From Claim 1: A compound of Formula I:



wherein:

R1 is hydrogen or C1-6 alkyl;

R3a and **R3b** are each independently hydrogen, C1-6 alkyl, C3-8 cycloalkyl, or C4-14 alkyl-cycloalkyl;

R3c is hydrogen or C1-6 alkyl;


R4, **R5**, **R6** and **R7** are each independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, C1-6 haloalkyl, C1-6 alkylamine, C1-6 alkoxy, C1-6 haloalkoxy, -OR_{8a}, -NO₂, -CN, -C(O)R_{8b}, -C(O)OR_{8b}, -OC(O)R_{8b}, -OC(O)OR_{8b}, -

S(O)₂N(R_{8b}R_{8c}), C3-8 cycloalkyl, C3-14 alkyl-cycloalkyl, C4-10 heterocycloalkyl, C4-16 alkyl-heterocycloalkyl, C6-12 aryl, C7-18 alkyl-aryl, C5-10 heteroaryl, or C4-16 alkyl-heteroaryl, wherein at least one of **R4**, **R5**, **R6** and **R7** is not H; alternatively, **R4** and **R5**, **R5** and **R6**, or **R6** and **R7** are combined with the atoms to which they are each attached to form a C3-6 cycloalkyl, C3-6 heterocycloalkyl, C6-12 aryl or C5-10 heteroaryl;

R8a, **R8b**, **R8c**...are each independently H, C1-6 alkyl;

4. Int'l Pat. App. Pub. No WO/2018/204359 "Compositions and methods for treating ocular pathologies" (Published November 8, 2018)

From Page 21 Line 5: In embodiments, the composition comprises a compound having the following chemical formula




In some embodiments, RN1 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl

<p>C2-6 alkynyl, C1-6 haloalkyl, C3-8 cycloalkyl, C4-14 alkylencycloalkyl, C3-10 heterocycloalkyl, C4-16 alkyleneheterocycloalkyl, C6-12 aryl, C7-18 alkylenearyl, C5-10 heteroaryl, and C6-16 alkyleneheteroaryl, said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-8 cycloalkyl, C4-14 alkylencycloalkyl, C3-10 heterocycloalkyl, C4-16 alkyleneheterocycloalkyl, C6-12 aryl, C7-18 alkylenearyl, C5-10 heteroaryl, and C6-16 alkyleneheteroaryl each being optionally substituted with one or more substituents independently selected from halogen, CN, C1-8 alkoxy, C1-8 alkylamino, C1-8 alkylsulfonyl, CO₂H, CO₂CH₃, C(O)NH₂, C(O)N(CH₃)₂, C(O)NHCH₃, OH, NH₂, N(CH₃)₂, NHCH₃, NO₂, SH, SCH₃, SO₂CH₃, SOCH₃, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 haloalkenyl, C2-6 alkynyl, C2-6 haloalkynyl, C3-6 cycloalkyl and C3-6 heterocycloalkyl including 1 or 2 ring heteromoieties selected from O, S, S(O), SO₂, N, NH and NCH₃;</p>	<p>RN2 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4- haloalkyl Ra of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or Ci-C4-haloalkyl R4 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl R5 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C,-C4-haloalkyl R6 of formula (III) can be H, C1-C6- alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-hatoalkyl and R7 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl.</p>
---	---

alternatively, R6 and R7 are combined with the atoms to which they are each attached to form a C4-10 heterocycloalkyl or a C5-10 heteroaryl, said C4-10 heterocycloalkyl and C5-10 heteroaryl each being further optionally substituted with a substituent selected from halogen, (O), CN, C1-8 alkoxy, C1-8 alkylamino, C1-8 alkylsulfonyl, CO₂R₁₄, C(O)N(R₁₄)₂, OR₁₄, N(R₁₄)₂, NO₂, SR₁₄, SO₂R₁₄, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 haloalkenyl, C2-6 alkynyl, C2-6 haloalkynyl, C3-6 cycloalkyl and C3-6 heterocycloalkyl including 1 or 2 ring heteromoieties selected from O, S, N, S(O), SO₂ and NR₁₄;

alternatively, R7 and one of R1, R2, or R3 are combined with the atoms to which they are attached to form a C5-8 heterocycloalkyl, said C5-8 heterocyclyalkyl being further optionally substituted with one or more substituents selected from halogen, (O), CN, C1-8 alkoxy, C1-8 alkylamino, C1-8 alkylsulfonyl, CO₂R₁₄, C(O)N(R₁₄)₂, OR₁₄, N(R₁₄)₂, NO₂, SR₁₄, SO₂R₁₄, C1-6 alkyl,

C1-6 haloalkyl, C2-6 alkenyl, C2-6 haloalkenyl, C2-6 alkynyl, C2-6 haloalkynyl, C3-6 cycloalkyl and C3-6 heterocycloalkyl including 1 or 2 ring heteromoieties selected from O, S, N, S(O), SO₂ and NR₁₄; each R₁₄ is independently selected from hydrogen, C1-6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C3-C7cycloalkyl, C3-10 heterocycloalkyl, C6-12 aryl and C5-10 heteroaryl, said C1-6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C3-C7cycloalkyl, C3-10 heterocycloalkyl, C6-12 aryl and C5-10 heteroaryl each being optionally substituted with one or more substituents independently selected from halogen, CN, C1-8 alkoxy, C1-8 alkylamino, C1-8 alkylsulfonyl, CO₂H, CO₂CH₃, C(O)NH₂, C(O)N(CH₃)₂, C(O)NHCH₃, OH, NH₂, N(CH₃)₂, NHCH₃, NO₂, SH, SCH₃, SO₂CH₃, SOCH₃, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 haloalkenyl, C2-6 alkynyl, C2-6 haloalkynyl, C3-6 cycloalkyl and C3-6


<p>heterocycloalkyl including 1 or 2 ring heteromoieties selected from O, S, S(O), SO₂, N, NH and NCH₃; wherein at least two or more of R₇, R₈, R₉, R₁₀ and R₁₁ are not hydrogen; and wherein: when R₁ and R₂ are each methyl, R₃ is hydrogen, R₆ is selected from hydrogen, methyl, ethyl and propyl, and one of R₉, R₁₀ or R₁₁ is fluoro and the other of R₉, R₁₀ or R₁₁ are hydrogen, then R₈ is not selected from OH, OCH₃, OCH₂CH₃, OCH₂CH₂CH₃ and OBn; and when R₁ and R₂ are each methyl, R₃ is hydrogen, R₆ is selected from hydrogen, methyl, ethyl and propyl, R₉ is fluoro, and R₁₁ is hydrogen, then R₁₀ is not selected from OH, OCH₃, OCH₂CH₃, OCH₂CH₂CH₃ and OBn.</p>	
<p>3. The compound of claim 2, wherein: R₇, R₈ R₉, R₁₀ and R₁₁ are each independently selected from hydrogen, halogen, CN, OR₁₃, N(R₁₃)₂, SR₁₃, C₁-6 alkyl, C₁-6 haloalkyl, C₂-6 alkenyl, C₂-C₆ haloalkenyl, C₂-6 alkynyl, C₂-6 haloalkynyl, C₁-6</p>	<p>1. Int'l Pat. App. Pub. No. WO/2018/064465 "Compounds for increasing neural plasticity" (Published April 5, 2018)</p> <p>From Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa or IIb:</p> <div style="text-align: center;">  <p>(IIa)</p> </div> <p>wherein:</p>

alkylamine, C1-6 alkoxy, C1-6 haloalkoxy, CO₂R₁₃, C(O)N(R₁₃)₂, OC(O)R₁₃, OSO₂R₁₃, OP(O)(OR₁₃)₂, OC1-6alkyleneP(O)(OR₁₃)₂, S(O)R₁₃, SO₂R₁₃, N(R₁₃)₂, NO₂, C3-8 cycloalkyl, C3-14 alkylencycloalkyl, C3-10 heterocycloalkyl, C4-16 alkyleneheterocycloalkyl, C6-12 aryl, C7-18 alkylenearyl, C5-10 heteroaryl, C4-16 alkyleneheteroaryl, said C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-C6 haloalkenyl, C2-6 alkynyl, C2-6 haloalkynyl, C1-6 alkylamine, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, C3-14 alkylencycloalkyl, C3-10 heterocycloalkyl, C4-16 alkyleneheterocycloalkyl, C6-12 aryl, C7-18 alkylenearyl, C5-10 heteroaryl, and C4-16 alkyleneheteroaryl being optionally substituted with one or more substituents independently selected from halogen, CN, C1-8 alkoxy, C1-8 alkylamino, C1-8 alkylsulfonyl, CO₂H, CO₂CH₃, C(O)NH₂, C(O)N(CH₃)₂, C(O)NHCH₃, OH, NH₂, N(CH₃)₂, NO₂, NHCH₃, SH, SCH₃, SO₂CH₃, and SOCH₃,

L3 is a bond, -C(O)NR_b-, -NR_bC(O)-, -NHC(O)NR_b-, -C(O)O-, -OC(O)-, -NHC(O)O-, -SO₂NR_b-, -NHSO₂-, -SO₂-, -O-, -S-, or -NR_b-; R8 is hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 alkoxy, C1-C6 aminoalkyl, heterocycloalkyl, aryl, or heteroaryl; R_b is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or C1-C6 alkoxy; R9 is hydrogen, C1-C6 alkyl, or C2-C6 alkenyl; R10 is hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, or C1-C6 haloalkyl; R11 is C1-C6 alkylamino, di-(C1-C6 alkyl)amino, N-(C1-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl; R12 is hydrogen, halogen, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or C1-C6 alkoxy; subscript p is an integer from 0 to 3; subscript q is an integer from 0 to 3; and subscript r is an integer from 1 to 3.

2. Int'l Pat. App. Pub. No. WO/1998/023587 "5-cyclo indole compounds as 5-ht1d receptor ligands" (Published June 4, 1998)

From Claim 1: A compound according to Formula I:



wherein A is selected from a six-membered, non-aromatic, optionally substituted carbocycle and a six-membered, non-aromatic, optionally substituted heterocycle having one or two heteroatoms selected from O, S, SO, SO₂ and NR₄

R₁ is selected from H and OH; n is 0 or 1 as permitted by chemical structure

R₂ is selected from CR₅R₈CH₂NR₇R₈...

R₃ is selected from H and benzoyl


R₅ and R₈ are independently selected from H...

R₇ and R₈ are independently selected from H and loweralkyl or R₇ and R₈ form an alkylene bridge which, together with the nitrogen atom to which they are attached, creates an optionally substituted 3- to 6-membered ring...

3. Int'l Pat. App. Pub. No. WO/2020/176599 "Azepino-indoles and other heterocycles for treating brain disorders" (Published September 3, 2020)

From Claim 1: A compound of Formula I:

said C3-8 cycloalkyl, C3-14 alkylencycloalkyl, C3-10 heterocycloalkyl, C4-16 alkyleneheterocycloalkyl, C6-12 aryl, C7-18 alkylenearyl, C5-10 heteroaryl, and C4-16 alkyleneheteroaryl each being further optionally substituted with a substituent selected from (O), C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 haloalkenyl, C2-6 alkynyl, C2-6 haloalkynyl, C3-6 cycloalkyl and C3-6 heterocycloalkyl including 1 or 2 ring heteromoeities selected from O, S, S(O), SO₂, N, NH and NCH₃; wherein R13 is as defined in claim 2; wherein at least two or more of R7, R8, R9, R10 and R11 are not hydrogen; and wherein: when R1 and R2 are each methyl, R3 is hydrogen, R6 is selected from hydrogen, methyl, ethyl and propyl, and when one of R9, R10 and R11 is fluoro and the other of R9, R10 and R11 are hydrogen, then R8 is not selected from OH, OCH₃, OCH₂CH₃, OCH₂CH₂CH₃ or OBn; and when R1 and R2 are each methyl, R3 is



wherein:

R1 is hydrogen or C1-6 alkyl;

R3a and R3b are each independently hydrogen, C1-6 alkyl, C3-8 cycloalkyl, or C4-14 alkyl-cycloalkyl;

R3c is hydrogen or C1-6 alkyl;


R4, R5, R6 and R7 are each independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, C1-6 haloalkyl, C1-6 alkylamine, C1-6 alkoxy, C1-6 haloalkoxy, -OR8a, -NO₂, -CN, -C(O)R8b, -C(O)OR8b, -OC(O)R8b, -OC(O)OR8b, -

S(O)2N(R8bR8c), C3-8 cycloalkyl, C3-14 alkyl-cycloalkyl, C4-10 heterocycloalkyl, C4-16 alkyl-heterocycloalkyl, C6-12 aryl, C7-18 alkyl-aryl, C5-10 heteroaryl, or C4-16 alkyl-heteroaryl, wherein at least one of R4, R5, R6 and R7 is not H; alternatively, R4 and R5, R5 and R6, or R6 and R7 are combined with the atoms to which they are each attached to form a C3-6 cycloalkyl, C3-6 heterocycloalkyl, C6-12 aryl or C5-10 heteroaryl;

R8a, R8b, R8c...are each independently H, C1-6 alkyl;

4. Int'l Pat. App. Pub. No WO/2018/204359 "Compositions and methods for treating ocular pathologies" (Published November 8, 2018)

From Page 21 Line 5: In embodiments, the composition comprises a compound having the following chemical formula





In some embodiments, RN1 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl

RN2 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl

Ra of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or Ci-C4-haloalkyl

R4 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl

<p>hydrogen, R6 is selected from hydrogen, methyl, ethyl and propyl, R9 is fluoro, and R11 is hydrogen, then R10 is not selected from OH, OCH3, OCH2CH3, OCH2CH2CH3 and OBn.</p>	<p>R5 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C,-C4-haloalkyl R6 of formula (III) can be H, C1-C6- alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-hatoalkyl and R7 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl.</p>
<p>4. The compound of claim 3, wherein R7, R8, R9, R10 and R11 are each independently selected from hydrogen, halogen, C1-6 alkyl, C1-6 haloalkyl and OR13 wherein R13 is selected from hydrogen, C1-6 alkyl and C1-6 haloalkyl.</p>	<p>1. Int'l Pat. App. Pub. No. WO/2018/064465 "Compounds for increasing neural plasticity" (Published April 5, 2018)</p> <p>From Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa or IIb:</p> <div style="text-align: center;">  <p>(IIa)</p> </div> <p>wherein: L3 is a bond...-O-... R8 is hydrogen, halogen, C1-C6 alkyl...C1-C6 haloalkyl... R9 is hydrogen, C1-C6 alkyl, or C2-C6 alkenyl; R10 is hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, or C1-C6 haloalkyl; R11 is C1-C6 alkylamino, di-(C1-C6 alkyl)amino, N-(C1-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl; R12 is hydrogen, halogen...C1-C6 alkyl, C1-C6 haloalkyl...or C1-C6 alkoxy; subscript p is an integer from 0 to 3; subscript q is an integer from 0 to 3; and subscript r is an integer from 1 to 3.</p> <p>3. Int'l Pat. App. Pub. No. WO/2020/176599 "Azepino-indoles and other heterocycles for treating brain disorders" (Published September 3, 2020)</p> <p>From Claim 1: A compound of Formula I:</p> <div style="text-align: center;">  <p>(I)</p> </div> <p>wherein: R1 is hydrogen or C1-6 alkyl;</p>

R3a and R3b are each independently hydrogen, C1-6 alkyl, C3-8 cycloalkyl, or C4-14 alkyl-cycloalkyl;


R3c is hydrogen or C1-6 alkyl;

R4, R5, R6 and R7 are each independently hydrogen, C1-6 alkyl...halogen...-OR8a...

R8a, R8b, R8c...are each independently...C1-6 alkyl;

4. Int'l Pat. App. Pub. No WO/2018/204359 "Compositions and methods for treating ocular pathologies" (Published November 8, 2018)

From Page 21 Line 5: In embodiments, the composition comprises a compound having the following chemical formula



In some embodiments, RN1 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl

RN2 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4- haloalkyl

Ra of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl

R4 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl

R5 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl


R6 of formula (III) can be H, C1-C6- alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-hatoalkyl

and R7 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl.

5. The compound of claim 4, wherein R8 is selected from halogen, C1-6 alkyl and OR13 wherein R13 is selected from hydrogen, C1-6 alkyl and C1-6 haloalkyl.

1. Int'l Pat. App. Pub. No. WO/2018/064465 "Compounds for increasing neural plasticity" (Published April 5, 2018)

From Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa or IIb:



wherein:

L3 is a bond...-O...

R8 is hydrogen...C1-C6 alkyl...C1-C6 haloalkyl...

R9 is hydrogen, C1-C6 alkyl, or C2-C6 alkenyl;

R10 is hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, or C1-C6 haloalkyl;

R11 is C1-C6 alkylamino, di-(C1-C6 alkyl)amino, N-(C1-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl;

R12 is...halogen...C1-C6 alkyl, C1-C6 haloalkyl...or C1-C6 alkoxy;


subscript p is an integer from 0 to 3;

subscript q is an integer from 0 to 3; and

subscript r is an integer from 1 to 3.

3. Int'l Pat. App. Pub. No. WO/2020/176599 "Azepino-indoles and other heterocycles for treating brain disorders" (Published September 3, 2020)

From Claim 1: A compound of Formula I:



wherein:

R1 is hydrogen or C1-6 alkyl;

R3a and R3b are each independently hydrogen, C1-6 alkyl, C3-8 cycloalkyl, or C4-14 alkyl-cycloalkyl;


R3c is hydrogen or C1-6 alkyl;



R4, R5, R6 and R7 are each independently hydrogen, C1-6 alkyl...-OR8a...


R8a...are each independently H, C1-6 alkyl;

4. Int'l Pat. App. Pub. No WO/2018/204359 "Compositions and methods for treating ocular pathologies" (Published November 8, 2018)


From Page 21 Line 5: In embodiments, the composition comprises a compound having the following chemical formula



	<p>In some embodiments, RN1 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl RN2 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4- haloalkyl Ra of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl R4 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl R5 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl)... R6 of formula (III) can be H, C1-C6- alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-hatoalkyl and R7 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl.</p>
<p>6. The compound of claim 4, wherein R9 is selected from halogen, C1-6 alkyl and OR13 wherein R13 is selected from hydrogen, C1-6 alkyl and C1-6 haloalkyl.</p>	<p>1. Int'l Pat. App. Pub. No. WO/2018/064465 "Compounds for increasing neural plasticity" (Published April 5, 2018)</p> <p>From Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa or IIb:</p>  <p style="text-align: center;">(IIa)</p> <p>wherein: L3 is a bond...-O-... R8 is hydrogen, halogen, C1-C6 alkyl...C1-C6 haloalkyl... R9 is hydrogen, C1-C6 alkyl, or C2-C6 alkenyl; R10 is hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, or C1-C6 haloalkyl; R11 is C1-C6 alkylamino, di-(C1-C6 alkyl)amino, N-(C1-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl; R12 is...halogen...C1-C6 alkyl, C1-C6 haloalkyl...or C1-C6 alkoxy; subscript p is an integer from 0 to 3; subscript q is an integer from 0 to 3; and subscript r is an integer from 1 to 3.</p> <p>3. Int'l Pat. App. Pub. No. WO/2020/176599 "Azepino-indoles and other heterocycles for treating brain disorders" (Published September 3, 2020)</p> <p>From Claim 1: A compound of Formula I:</p>  <p style="text-align: center;">(I)</p>

	<p>wherein: R1 is hydrogen or C1-6 alkyl; R3a and R3b are each independently hydrogen, C1-6 alkyl, C3-8 cycloalkyl, or C4-14 alkyl-cycloalkyl; R3c is hydrogen or C1-6 alkyl; R4, R5, R6 and R7 are each independently hydrogen, C1-6 alkyl...halogen...-OR8a... R8a, R8b, R8c...are each independently...C1-6 alkyl;</p> <p>4. Int'l Pat. App. Pub. No WO/2018/204359 "Compositions and methods for treating ocular pathologies" (Published November 8, 2018)</p> <p>From Page 21 Line 5: In embodiments, the composition comprises a compound having the following chemical formula</p>  <p>In some embodiments, RN1 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl RN2 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4- haloalkyl Ra of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl R4 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl R5 of formula (III) can be...C1-C6-alkyl...O-(C1-C6-alkyl), halogen... R6 of formula (III) can be H, C1-C6- alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-hatoalkyl and R7 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl.</p>
<p>7. The compound of claim 1, wherein: (i) one of R7, R8, R9, R10 and R11 is selected from OR13, N(R13)2, SR13, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-C6 haloalkenyl, C2-6 alkynyl, C2-6 haloalkynyl, C1-6</p>	<p>1. Int'l Pat. App. Pub. No. WO/2018/064465 "Compounds for increasing neural plasticity" (Published April 5, 2018)</p> <p>From Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa or IIb:</p>

alkylamine, C1-6
 alkoxy, C1-6
 haloalkoxy, CO₂R₁₃,
 C(O)R₁₃,
 C(O)N(R₁₃)₂,
 C(O)C(O)N(R₁₃)₂,
 OC(O)R₁₃,
 OC(O)OR₁₃,
 OC(O)N(R₁₃)₂,
 OS(O)R₁₃,
 OS(O)N(R₁₃)₂,
 OSO₂R₁₃,
 OP(O)(OR₁₃)₂, OC1-
 6alkyleneP(O)(OR₁₃)₂,
 S(O)R₁₃,
 S(O)N(R₁₃)₂,
 SO₂R₁₃, N(R₁₃)₂,
 N(R₁₃)C(O)R₁₃,
 N(R₁₃)C(O)OR₁₃,
 N(R₁₃)C(O)N(R₁₃)₂,
 NO₂, C3-8 cycloalkyl,
 C3-14
 alkylencycloalkyl, C3-
 10 heterocycloalkyl,
 C4-16
 alkyleneheterocycloalkyl,
 C6-12 aryl, C7-18
 alkylenearyl, C5-10
 heteroaryl, C4-16
 alkyleneheteroaryl,
 said C1-6 alkyl, C1-6
 haloalkyl, C2-6 alkenyl,
 C2-6 haloalkenyl, C2-
 6 alkynyl, C2-6
 haloalkynyl, C1-6
 alkylamine, C1-6
 alkoxy, C1-6
 haloalkoxy, C3-8
 cycloalkyl, C3-14
 alkylencycloalkyl, C3-
 10 heterocycloalkyl,
 C4-16
 alkyleneheterocycloalkyl,
 C6-12 aryl, C7-18
 alkylenearyl, C5-10
 heteroaryl, and C4-16
 alkyleneheteroaryl
 being optionally
 substituted with one or



wherein:

L3 is a bond, -C(O)NRb-, -NRbC(O)-, -NHC(O)NRb-, -C(O)O-, -OC(O)-, -NHC(O)O-, -SO₂NRb-, -NHSO₂-, -SO₂-, -O-, -S-, or -NRb-; **R8** is hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 alkoxy, C1-C6 aminoalkyl, heterocycloalkyl, aryl, or heteroaryl;

Rb is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or C1-C6 alkoxy;

R9 is hydrogen, C1-C6 alkyl, or C2-C6 alkenyl;

R10 is...halogen, C1-C6 alkyl, C2-C6 alkenyl, or C1-C6 haloalkyl;

R11 is C1-C6 alkylamino, di-(C1-C6 alkyl)amino, N-(C1-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl;

R12 is hydrogen, halogen, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or C1-C6 alkoxy;


subscript **p** is an integer from 0 to 3;

subscript **q** is an integer from 0 to 3; and

subscript **r** is an integer from 1 to 3.

2. Int'l Pat. App. Pub. No. WO/1998/023587 "5-cyclo indole compounds as 5-HT_{1d} receptor ligands" (Published June 4, 1998)

From Claim 1: A compound according to Formula I:



wherein **A** is selected from a six-membered, non-aromatic, optionally substituted carbocycle and a six-membered, non-aromatic, optionally substituted heterocycle having one or two heteroatoms selected from O, S, SO, SO₂ and NR₄

R1 is selected from H and OH; **n** is 0 or 1 as permitted by chemical structure

R2 is selected from CR₅R₈CH₂NR₇R₈...

R3 is selected from H and benzoyl


R5 and **R8** are independently selected from H...

R7 and **R8** are independently selected from H and loweralkyl or **R7** and **R8** form an alkylene bridge which, together with the nitrogen atom to which they are attached, creates an optionally substituted 3- to 6-membered ring...

more substituents independently selected from halogen, CN, C1-8 alkoxy, C1-8 alkylamino, C1-8 alkylsulfonyl, CO₂R₁₃, C(O)N(R₁₃)₂, OR₁₃, N(R₁₃)₂, NO₂, SR₁₃ and SO₂R₁₃, said C3-8 cycloalkyl, C3-14 alkylencycloalkyl, C3-10 heterocycloalkyl, C4-16 alkyleneheterocycloalkyl, C6-12 aryl, C7-18 alkylenearyl, C5-10 heteroaryl, and C4-16 alkyleneheteroaryl each being further optionally substituted with a substituent selected from (O), C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 haloalkenyl, C2-6 alkynyl, C2-6 haloalkynyl, C3-6 cycloalkyl and C3-6 heterocycloalkyl including 1 or 2 ring heteromoeities selected from O, S, S(O), SO₂, N, and NR₁₃; each R₁₃ is independently selected from hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-8 cycloalkyl, C4-14 alkylencycloalkyl, C3-10 heterocycloalkyl, C4-16 alkyleneheterocycloalkyl, C6-12 aryl, C7-18 alkylenearyl, C5-10 heteroaryl, and C6-16 alkyleneheteroaryl,

3. Int'l Pat. App. Pub. No. WO/2020/176599 "Azepino-indoles and other heterocycles for treating brain disorders" (Published September 3, 2020)

From Claim 1: A compound of Formula I:



wherein:

R1 is hydrogen or C1-6 alkyl;

R3a and R3b are each independently hydrogen, C1-6 alkyl, C3-8 cycloalkyl, or C4-14 alkyl-cycloalkyl;

R3c is hydrogen or C1-6 alkyl;


R4, R5, R6 and R7 are each independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, C1-6 haloalkyl, C1-6 alkylamine, C1-6 alkoxy, C1-6 haloalkoxy, -OR8a, -NO₂, -CN, -C(O)R8b, -C(O)OR8b, -OC(O)R8b, -OC(O)OR8b, -

S(O)₂N(R8bR8c), C3-8 cycloalkyl, C3-14 alkyl-cycloalkyl, C4-10 heterocycloalkyl, C4-16 alkyl-heterocycloalkyl, C6-12 aryl, C7-18 alkyl-aryl, C5-10 heteroaryl, or C4-16 alkyl-heteroaryl, wherein at least one of R4, R5, R6 and R7 is not H; alternatively, R4 and R5, R5 and R6, or R6 and R7 are combined with the atoms to which they are each attached to form a C3-6 cycloalkyl, C3-6 heterocycloalkyl, C6-12 aryl or C5-10 heteroaryl;

R8a, R8b, R8c...are each independently H, C1-6 alkyl;

4. Int'l Pat. App. Pub. No WO/2018/204359 "Compositions and methods for treating ocular pathologies" (Published November 8, 2018)

From Page 21 Line 5: In embodiments, the composition comprises a compound having the following chemical formula



In some embodiments, RN1 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl

RN2 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4- haloalkyl

<p>said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-8 cycloalkyl, C4-14 alkylencycloalkyl, C3-10 heterocycloalkyl, C4-16 alkyleneheterocycloalkyl, C6-12 aryl, C7-18 alkylenearyl, C5-10 heteroaryl, and C6-16 alkyleneheteroaryl each being optionally substituted with one or more substituents independently selected from halogen, CN, C1-8 alkoxy, C1-8 alkylamino, C1-8alkylsulfonyl, CO₂H, CO₂CH₃, C(O)NH₂, C(O)N(CH₃)₂, C(O)NHCH₃, OH, NH₂, N(CH₃)₂, NHCH₃, NO₂, SH, SCH₃, SO₂CH₃, SOCH₃, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 haloalkenyl, C2-6 alkynyl, C2-6 haloalkynyl, C3-6 cycloalkyl and C3-6 heterocycloalkyl including 1 or 2 ring heteromoieties selected from O, S, S(O), SO₂, N, NH and NCH₃; and (ii) the other of R7, R8, R9, R10 and R11 are each hydrogen, alternatively, R6 and R7 are combined with the atoms to which they are each attached to form a C4-10 heterocycloalkyl or a C5-10 heteroaryl,</p>	<p>Ra of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or Ci-C4-haloalkyl R4 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl R5 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C,-C4-haloalkyl R6 of formula (III) can be H, C1-C6- alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-hatoalkyl and R7 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl.</p>
--	--

said C4-10 heterocycloalkyl and C5-10 heteroaryl each being further optionally substituted with a substituent selected from halogen, (O), CN, C1-8 alkoxy, C1-8 alkylamino, C1-8 alkylsulfonyl, CO₂R₁₄, C(O)N(R₁₄)₂, OR₁₄, N(R₁₄)₂, NO₂, SR₁₄, SO₂R₁₄, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 haloalkenyl, C2-6 alkynyl, C2-6 haloalkynyl, C3-6 cycloalkyl and C3-6 heterocycloalkyl including 1 or 2 ring heteromoieties selected from O, S, N, S(O), SO₂ and NR₁₄; alternatively, R₇ and one of R₁, R₂, or R₃ are combined with the atoms to which they are attached to form a C5-8 heterocycloalkyl, said C5-8 heterocyclyalkyl being further optionally substituted with one or more substituents selected from halogen, (O), CN, C1-8 alkoxy, C1-8 alkylamino, C1-8 alkylsulfonyl, CO₂R₁₄, C(O)N(R₁₄)₂, OR₁₄, N(R₁₄)₂, NO₂, SR₁₄, SO₂R₁₄, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 haloalkenyl, C2-6 alkynyl, C2-6 haloalkynyl, C3-6 cycloalkyl and C3-6 heterocycloalkyl


including 1 or 2 ring heteromoieties selected from O, S, N, S(O), SO₂ and NR₁₄; each R₁₄ is independently selected from hydrogen, C1-6 alkyl, C2-C6 alkenyl, C2-C6alkynyl, C1-C6 haloalkyl, C3-C7cycloalkyl, C3-10 heterocycloalkyl, C6-12 aryl and C5-10 heteroaryl; said C1-6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C3-C7cycloalkyl, C3-10 heterocycloalkyl, C6-12 aryl and C5-10 heteroaryl each being optionally substituted with one or more substituents independently selected from halogen, CN, C1-8 alkoxy, C1-8 alkylamino, C1-8 alkylsulfonyl, CO₂H, CO₂CH₃, C(O)NH₂, C(O)N(CH₃)₂, C(O)NHCH₃, OH, NH₂, N(CH₃)₂, NHCH₃, NO₂, SH, SCH₃, SO₂CH₃, SOCH₃, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 haloalkenyl, C2-6 alkynyl, C2-6 haloalkynyl, C3-6 cycloalkyl and C3-6 heterocycloalkyl including 1 or 2 ring heteromoieties selected from O, S, S(O), SO₂, N, NH and NCH₃; wherein:

when R1 and R2 are each methyl, and R3 and R6 are each hydrogen, then R8 is not OH or OCH3, and R9 is not OH;

when R1 and R2 are each ethyl, isobutyl or (sec)butyl, and R3 and R6 are each hydrogen, then R8 is not OH;


when R1 and R2 are each isopropyl, and R3 and R6 are each hydrogen, then R9 is not OH;

when R1 and R2 together with the nitrogen to which they are attached form




and R3 and R6 are each hydrogen, then R9 is not OCH3;

when R1 and R2 together with the nitrogen to which they are attached form




and R3 and R6 are each hydrogen, then R8 is not OH;

when R1 and R2 together with the nitrogen to which they are attached form




and R3 and R6 are each hydrogen, then R8 is not OH, R9 is not CH3

or OCH₃, and R₁₀ is not OCH₃;
 when R₁ and R₂ together with the nitrogen to which they are attached form







and R₃ and R₆ are each hydrogen, then R₇, R₈, R₉, R₁₀ and R₁₁ are not selected from OH, OCH₃, OC(O)CH₃, OP(O)(OH)₂, NH₂, halogen, CH₃, CN and CF₃;

when R₁ and R₂ together with the nitrogen to which they are attached form any



R₃ is hydrogen, and R₆ is methyl, then R₈ is not OH or OBn;
 when R₁ and R₂ are each methyl, R₃ is hydrogen, and R₆ is selected from ethyl, CH₂CHF₂, propyl, isopropyl, butyl, cyclopropyl, methylenecyclopropyl, cyclobutyl, oxetanyl and butenyl, then R₈ is not OH or OBn;
 when R₁ and R₂ are each methyl, R₃ is hydrogen, and R₆ is hydrogen or CH₂P(O)(OH)₂, then R₈ is not selected from


 <p>and OC(O)N(CH3)2; and when R1, R2 and R3 together with the atoms to which they are attached form</p>  <p>and R6 is hydrogen or CH2P(O)(OH)2, then R8 is not selected from</p>  <p>and OC(O)N(CH3)2.</p>	
<p>8. The compound of claim 7, wherein: (i) one of R7, R8, R9, R10 and R11 is selected from OR13, N(R13)2, SR13, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 haloalkenyl, C2-6 alkynyl, C2-6 haloalkynyl, C1-6 alkylamine, C1-6 alkoxy, C1-6 haloalkoxy, CO2R13, C(O)R13, C(O)N(R13)2, C(O)C(O)N(R13)2, OC(O)R13,</p>	<p>1. Int'l Pat. App. Pub. No. WO/2018/064465 "Compounds for increasing neural plasticity" (Published April 5, 2018)</p> <p>From Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa or IIb:</p>  <p>wherein: L3 is a bond, -C(O)NRb-, -NRbC(O)-, -NHC(O)NRb-, -C(O)O-, -OC(O)-, -NHC(O)O-, -SO2NRb-, -NHSO2-, -SO2-, -O-, -S-, or -NRb-; R8 is hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 alkoxy, C1-C6 aminoalkyl, heterocycloalkyl, aryl, or heteroaryl;</p>

OC(O)OR13,
 OC(O)N(R13)2,
 OS(O)R13,
 OS(O)N(R13)2,
 OSO2R13,
 OP(O)(OR13)2, OC1-6alkyleneP(O)(OR13)2,
 S(O)R13,
 S(O)N(R13)2,
 SO2R13, N(R13)2,
 N(R13)C(O)R13,
 N(R13)C(O)OR13,
 N(R13)C(O)N(R13)2,
 NO2, C3-8 cycloalkyl,
 C3-14
 alkylencycloalkyl, C3-10 heterocycloalkyl,
 C4-16
 alkyleneheterocycloalkyl,
 C6-12 aryl, C7-18
 alkylenearyl, C5-10
 heteroaryl, C4-16
 alkyleneheteroaryl,
 said C1-6 alkyl, C1-6
 haloalkyl, C2-6 alkenyl,
 C2-6 haloalkenyl, C2-6
 alkynyl, C2-6
 haloalkynyl, C1-6
 alkylamine, C1-6
 alkoxy, C1-6
 haloalkoxy, C3-8
 cycloalkyl, C3-14
 alkylencycloalkyl, C3-10
 heterocycloalkyl,
 C4-16
 alkyleneheterocycloalkyl,
 C6-12 aryl, C7-18
 alkylenearyl, C5-10
 heteroaryl, and C4-16
 alkyleneheteroaryl
 being optionally
 substituted with one or
 more substituents
 independently selected
 from halogen, CN, C1-8
 alkoxy, C1-8
 alkylamino, C1-8
 alkylsulfonyl, CO2R13,
 C(O)N(R13)2, OR13,

Rb is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or C1-C6 alkoxy;
R9 is hydrogen, C1-C6 alkyl, or C2-C6 alkenyl;
R10 is...halogen, C1-C6 alkyl, C2-C6 alkenyl, or C1-C6 haloalkyl;
R11 is C1-C6 alkylamino, di-(C1-C6 alkyl)amino, N-(C1-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl;
R12 is hydrogen, halogen, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or C1-C6 alkoxy;
subscript p is an integer from 0 to 3;
subscript q is an integer from 0 to 3; and
subscript r is an integer from 1 to 3.

2. Int'l Pat. App. Pub. No. WO/1998/023587 "5-HT1d receptor ligands" (Published June 4, 1998)

From Claim 1: A compound according to Formula I:



wherein A is selected from a six-membered, non-aromatic, optionally substituted carbocycle and a six-membered, non-aromatic, optionally substituted heterocycle having one or two heteroatoms selected from O, S, SO, SO2 and NR4

R1 is selected from H and OH; n is 0 or 1 as permitted by chemical structure

R2 is selected from CR5R8CH2NR7R8...


R3 is selected from H and benzoyl

R5 and R8 are independently selected from H...

R7 and R8 are independently selected from H and loweralkyl or R7 and R8 form an alkylene bridge which, together with the nitrogen atom to which they are attached, creates an optionally substituted 3- to 6-membered ring...

3. Int'l Pat. App. Pub. No. WO/2020/176599 "Azepino-indoles and other heterocycles for treating brain disorders" (Published September 3, 2020)

From Claim 1: A compound of Formula I:




wherein:
R1 is hydrogen or C1-6 alkyl;

N(R13)₂, NO₂, SR13 and SO₂R13, said C3-8 cycloalkyl, C3-14 alkylencycloalkyl, C3-10 heterocycloalkyl, C4-16 alkyleneheterocycloalkyl, C6-12 aryl, C7-18 alkylenearyl, C5-10 heteroaryl, and C4-16 alkyleneheteroaryl each being further optionally substituted with a substituent selected from (O), C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 haloalkenyl, C2-6 alkynyl, C2-6 haloalkynyl, C3-6 cycloalkyl and C3-6 heterocycloalkyl including 1 or 2 ring heteromoeities selected from O, S, S(O), SO₂, N, and NR13; each R13 is independently selected from hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-8 cycloalkyl, C4-14 alkylencycloalkyl, C3-10 heterocycloalkyl, C4-16 alkyleneheterocycloalkyl, C6-12 aryl, C7-18 alkylenearyl, C5-10 heteroaryl, and C6-16 alkyleneheteroaryl, said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-8 cycloalkyl, C4-14 alkylencycloalkyl, C3-10 heterocycloalkyl, C4-16

R3a and R3b are each independently hydrogen, C1-6 alkyl, C3-8 cycloalkyl, or C4-14 alkyl-cycloalkyl;
R3c is hydrogen or C1-6 alkyl;
R4, R5, R6 and R7 are each independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, C1-6 haloalkyl, C1-6 alkylamine, C1-6 alkoxy, C1-6 haloalkoxy, -OR8a, -NO₂, -CN, -C(O)R8b, -C(O)OR8b, -OC(O)R8b, -OC(O)OR8b, -S(O)₂N(R8bR8c), C3-8 cycloalkyl, C3-14 alkyl-cycloalkyl, C4-10 heterocycloalkyl, C4-16 alkyl-heterocycloalkyl, C6-12 aryl, C7-18 alkyl-aryl, C5-10 heteroaryl, or C4-16 alkyl-heteroaryl, wherein at least one of R4, R5, R6 and R7 is not H; alternatively, R4 and R5, R5 and R6, or R6 and R7 are combined with the atoms to which they are each attached to form a C3-6 cycloalkyl, C3-6 heterocycloalkyl, C6-12 aryl or C5-10 heteroaryl;
R8a, R8b, R8c...are each independently H, C1-6 alkyl;

4. Int'l Pat. App. Pub. No WO/2018/204359 "Compositions and methods for treating ocular pathologies" (Published November 8, 2018)


From Page 21 Line 5: In embodiments, the composition comprises a compound having the following chemical formula




In some embodiments, RN1 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl
RN2 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4- haloalkyl
Ra of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or Ci-C4-haloalkyl
R4 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl
R5 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C,-C4-haloalkyl
R6 of formula (III) can be H, C1-C6- alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-hatoalkyl
and R7 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl.

alkyleneheterocycloalkyl, C6-12 aryl, C7-18 alkylenearyl, C5-10 heteroaryl, and C6-16 alkyleneheteroaryl each being optionally substituted with one or more substituents independently selected from halogen, CN, C1-8 alkoxy, C1-8 alkylamino, C1-8alkylsulfonyl, CO₂H, CO₂CH₃, C(O)NH₂, C(O)N(CH₃)₂, C(O)NHCH₃, OH, NH₂, N(CH₃)₂, NHCH₃, NO₂, SH, SCH₃, SO₂CH₃, SOCH₃, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 haloalkenyl, C2-6 alkynyl, C2-6 haloalkynyl, C3-6 cycloalkyl and C3-6 heterocycloalkyl including 1 or 2 ring heteromoieties selected from O, S, S(O), SO₂, N, NH and NCH₃; and (ii) the other of R₇, R₈, R₉, R₁₀ and R₁₁ are each hydrogen; wherein:
when R₁ and R₂ are each methyl, and R₃ and R₆ are each hydrogen, then R₈ is not OH or OCH₃ and R₉ is not OH;
when R₁ and R₂ are each ethyl, isobutyl or (sec)butyl, and R₃ and R₆ are each hydrogen, then R₈ is not OH;
when R₁ and R₂ are each isopropyl, and R₃ and R₆ are each


hydrogen, then R9 is not OH;
 when R1 and R2 together with the nitrogen to which they are attached form




and R3 and R6 are each hydrogen, then R9 is not OCH3;
 when R1 and R2 together with the nitrogen to which they are attached form



and R3 and R6 are each hydrogen, then R8 is not OH;
 when R1 and R2 together with the nitrogen to which they are attached form




and R3 and R6 are each hydrogen, then R8 is not OH, R9 is not CH3 or OCH3, and R10 is not OCH3;
 when R1 and R2 together with the nitrogen to which they are attached form



and R3 and R6 are each hydrogen, then R7, R8, R9, R10 and R11 are not selected from OH, OCH3, OC(O)CH3, OP(O)(OH)2, NH2,

halogen, CH₃, CN and CF₃;


when R₁ and R₂ together with the nitrogen to which they are attached form any one of



R₃ is hydrogen, and R₆ is methyl, then R₈ is not OH;

when R₁ and R₂ are each methyl, R₃ is hydrogen, and R₆ is selected from ethyl, CH₂CHF₂, propyl, isopropyl, butyl, cyclopropyl, methylenecyclopropyl, cyclobutyl, oxetanyl and butenyl, then R₈ is not OH;


when R₁ and R₂ are each methyl, R₃ is hydrogen, and R₆ is hydrogen or CH₂P(O)(OH)₂, then R₈ is not selected from




and OC(O)N(CH₃)₂;

and
when R₁, R₂ and R₃ together with the atoms

to which they are attached form




and R6 is hydrogen or CH₂P(O)(OH)₂, then R8 is not selected from



and OC(O)N(CH₃)₂.


9. The compound of claim 8, wherein:
(i) one of R7, R8, R9, R10 and R11 is selected from C1-6 haloalkyl and OC1-6 haloalkyl, wherein the C1-6 haloalkyl is not CF₃ when R1 and R2 together with the nitrogen to which they are attached form



and R3 and R6 are each hydrogen; and
(ii) the other of R7, R8, R9, R10 and R11 are each hydrogen.

1. Int'l Pat. App. Pub. No. WO/2018/064465 "Compounds for increasing neural plasticity" (Published April 5, 2018)

From Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa or IIb:




wherein:

L3 is a bond, -C(O)NRb-, -NRbC(O)-, -NHC(O)NRb-, -C(O)O-, -OC(O)-, -NHC(O)O-, -SO₂NRb-, -NH₂SO₂-, -SO₂-, -O-, -S-, or -NRb-; R8 is hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 alkoxy, C1-C6 aminoalkyl, heterocycloalkyl, aryl, or heteroaryl;
Rb is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or C1-C6 alkoxy;
R9 is hydrogen, C1-C6 alkyl, or C2-C6 alkenyl;
R10 is...halogen, C1-C6 alkyl, C2-C6 alkenyl, or C1-C6 haloalkyl;
R11 is C1-C6 alkylamino, di-(C1-C6 alkyl)amino, N-(C1-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl;
R12 is hydrogen, halogen, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or C1-C6 alkoxy;
subscript p is an integer from 0 to 3;
subscript q is an integer from 0 to 3; and
subscript r is an integer from 1 to 3.

2. Int'l Pat. App. Pub. No. WO/1998/023587 "5-cyclo indole compounds as 5-HT_{1D} receptor ligands" (Published June 4, 1998)

From Claim 1: A compound according to Formula I:



wherein A is selected from a six-membered, non-aromatic, optionally substituted carbocycle and a six-membered, non-aromatic, optionally substituted heterocycle having one or two heteroatoms selected from O, S, SO, SO₂ and NR₄

R₁ is selected from H and OH; n is 0 or 1 as permitted by chemical structure

R₂ is selected from CR₅R₈CH₂NR₇R₈...


R₃ is selected from H and benzoyl

R₅ and R₈ are independently selected from H...

R₇ and R₈ are independently selected from H and loweralkyl or R₇ and R₈ form an alkylene bridge which, together with the nitrogen atom to which they are attached, creates an optionally substituted 3- to 6-membered ring...

3. Int'l Pat. App. Pub. No. WO/2020/176599 "Azepino-indoles and other heterocycles for treating brain disorders" (Published September 3, 2020)

From Claim 1: A compound of Formula I:



(I)

wherein:

R₁ is hydrogen or C1-6 alkyl;

R_{3a} and R_{3b} are each independently hydrogen, C1-6 alkyl, C3-8 cycloalkyl, or C4-14 alkyl-cycloalkyl;

R_{3c} is hydrogen or C1-6 alkyl;


R₄, R₅, R₆ and R₇ are each independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, C1-6 haloalkyl, C1-6 alkylamine, C1-6 alkoxy, C1-6 haloalkoxy, -OR_{8a}, -NO₂, -CN, -C(O)R_{8b}, -C(O)OR_{8b}, -OC(O)R_{8b}, -

S(O)₂N(R_{8b}R_{8c}), C3-8 cycloalkyl, C3-14 alkyl-cycloalkyl, C4-10 heterocycloalkyl, C4-16 alkyl-heterocycloalkyl, C6-12 aryl, C7-18 alkyl-aryl, C5-10 heteroaryl, or C4-16 alkyl-heteroaryl, wherein at least one of R₄, R₅, R₆ and R₇ is not H; alternatively, R₄ and R₅, R₅ and R₆, or R₆ and R₇ are combined with the atoms to which they are each attached to form a C3-6 cycloalkyl, C3-6 heterocycloalkyl, C6-12 aryl or C5-10 heteroaryl;

R_{8a}, R_{8b}, R_{8c}...are each independently H, C1-6 alkyl;

4. Int'l Pat. App. Pub. No WO/2018/204359 "Compositions and methods for treating ocular pathologies" (Published November 8, 2018)

From Page 21 Line 5: In embodiments, the composition comprises a compound having the following chemical formula



In some embodiments, RN1 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl

RN2 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl

Ra of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl


R4 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl

R5 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl

R6 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl

and R7 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl.


10. The compound of claim 1, wherein:
R7, R8, R9, R10 and R11 are each hydrogen, wherein:
when R3 and R6 are each hydrogen, then R1 and R2 are not each methyl, ethyl, propyl, isopropyl, cyclopropyl or



and R1 and R2 together with the nitrogen to

1. Int'l Pat. App. Pub. No. WO/2018/064465 "Compounds for increasing neural plasticity" (Published April 5, 2018)


From Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa or IIb:




wherein:

L3 is a bond, -C(O)NRb-, -NRbC(O)-, -NHC(O)NRb-, -C(O)O-, -OC(O)-, -NHC(O)O-, -SO2NRb-, -NHSO2-, -SO2-, -O-, -S-, or -NRb-; R8 is hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 alkoxy, C1-C6 aminoalkyl, heterocycloalkyl, aryl, or heteroaryl;


which they are attached do not form pyrrolidyl, piperidyl or 2,5-dimethylpyrrolyl; when R6 is hydrogen, and R3 is methyl, then R1 and R2 are not each hydrogen; when R3 and R6 are each hydrogen, and one of R1 and R2 is methyl, then the other of R1 and R2 is not propyl, isopropyl, cyclopropyl, methylenecyclopropyl,



when R3 and R6 are each hydrogen, and one of R1 and R2 is ethyl or propyl, then the other of R1 and R2 is not isopropyl, cyclopropyl, methylenecyclopropyl



and when R3 and R6 are each hydrogen, and one of R1 and R2 is isopropyl, then the other of R1 and R2 is not propyl, cyclopropyl, methylenecyclopropyl,



Rb is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or C1-C6 alkoxy;

R9 is hydrogen, C1-C6 alkyl, or C2-C6 alkenyl;

R10 is...halogen, C1-C6 alkyl, C2-C6 alkenyl, or C1-C6 haloalkyl;

R11 is C1-C6 alkylamino, di-(C1-C6 alkyl)amino, N-(C1-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl;

R12 is hydrogen, halogen, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or C1-C6 alkoxy;


subscript p is an integer from 0 to 3;

subscript q is an integer from 0 to 3; and

subscript r is an integer from 1 to 3.

2. Int'l Pat. App. Pub. No. WO/1998/023587 "5-HT1d receptor ligands" (Published June 4, 1998)

From Claim 1: A compound according to Formula I:



wherein A is selected from a six-membered, non-aromatic, optionally substituted carbocycle and a six-membered, non-aromatic, optionally substituted heterocycle having one or two heteroatoms selected from O, S, SO, SO2 and NR4

R1 is selected from H and OH; n is 0 or 1 as permitted by chemical structure

R2 is selected from CR5R8CH2NR7R8...


R3 is selected from H and benzoyl

R5 and R8 are independently selected from H...

R7 and R8 are independently selected from H and loweralkyl or R7 and R8 form an alkylene bridge which, together with the nitrogen atom to which they are attached, creates an optionally substituted 3- to 6-membered ring...

3. Int'l Pat. App. Pub. No. WO/2020/176599 "Azepino-indoles and other heterocycles for treating brain disorders" (Published September 3, 2020)

From Claim 1: A compound of Formula I:




wherein:

R1 is hydrogen or C1-6 alkyl;

R3a and R3b are each independently hydrogen, C1-6 alkyl, C3-8 cycloalkyl, or C4-14 alkyl-cycloalkyl;
R3c is hydrogen or C1-6 alkyl;
R4, R5, R6 and R7 are each independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, C1-6 haloalkyl, C1-6 alkylamine, C1-6 alkoxy, C1-6 haloalkoxy, -OR8a, -NO2, -CN, -C(O)R8b, -C(O)OR8b, -OC(O)R8b, -OC(O)OR8b, -S(O)2N(R8bR8c), C3-8 cycloalkyl, C3-14 alkyl-cycloalkyl, C4-10 heterocycloalkyl, C4-16 alkyl-heterocycloalkyl, C6-12 aryl, C7-18 alkyl-aryl, C5-10 heteroaryl, or C4-16 alkyl-heteroaryl, wherein at least one of R4, R5, R6 and R7 is not H; alternatively, R4 and R5, R5 and R6, or R6 and R7 are combined with the atoms to which they are each attached to form a C3-6 cycloalkyl, C3-6 heterocycloalkyl, C6-12 aryl or C5-10 heteroaryl;
R8a, R8b, R8c...are each independently H, C1-6 alkyl;

4. Int'l Pat. App. Pub. No WO/2018/204359 "Compositions and methods for treating ocular pathologies" (Published November 8, 2018)

From Page 21 Line 5: In embodiments, the composition comprises a compound having the following chemical formula




In some embodiments, RN1 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl
RN2 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4- haloalkyl
Ra of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or Ci-C4-haloalkyl
R4 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl
R5 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C,-C4-haloalkyl
R6 of formula (III) can be H, C1-C6- alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-hatoalkyl
and R7 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl.

11. The compound of any one of claims 1 to

1. Int'l Pat. App. Pub. No. WO/2018/064465 "Compounds for increasing neural plasticity" (Published April 5, 2018)

10, wherein R1 and R2 are each independently selected from C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 haloalkenyl, C2-6 alkynyl, C2-6 haloalkynyl, C3-8 cycloalkyl and C4-14 alkylencycloalkyl.

From Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa or IIb:



wherein:

L3 is a bond, -C(O)NRb-, -NRbC(O)-, -NHC(O)NRb-, -C(O)O-, -OC(O)-, -NHC(O)O-, -SO2NRb-, -NHSO2-, -SO2-, -O-, -S-, or -NRb-; R8 is hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 alkoxy, C1-C6 aminoalkyl, heterocycloalkyl, aryl, or heteroaryl;

Rb is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or C1-C6 alkoxy;

R9 is hydrogen, C1-C6 alkyl, or C2-C6 alkenyl;

R10 is...halogen, C1-C6 alkyl, C2-C6 alkenyl, or C1-C6 haloalkyl;

R11 is C1-C6 alkylamino, di-(C1-C6 alkyl)amino, N-(C1-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl;

R12 is hydrogen, halogen, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or C1-C6 alkoxy;


subscript p is an integer from 0 to 3;

subscript q is an integer from 0 to 3; and

subscript r is an integer from 1 to 3.

2. Int'l Pat. App. Pub. No. WO/1998/023587 "5-cyclo indole compounds as 5-HT1d receptor ligands" (Published June 4, 1998)

From Claim 1: A compound according to Formula I:



wherein A is selected from a six-membered, non-aromatic, optionally substituted carbocycle and a six-membered, non-aromatic, optionally substituted heterocycle having one or two heteroatoms selected from O, S, SO, SO2 and NR4

R1 is selected from H and OH; n is 0 or 1 as permitted by chemical structure

R2 is selected from CR5R8CH2NR7R8...

R3 is selected from H and benzoyl


R5 and R8 are independently selected from H...

R7 and R8 are independently selected from H and loweralkyl or R7 and R8 form an alkylene bridge which, together with the nitrogen atom to

which they are attached, creates an optionally substituted 3- to 6-membered ring...

3. Int'l Pat. App. Pub. No. WO/2020/176599 "Azepino-indoles and other heterocycles for treating brain disorders" (Published September 3, 2020)

From Claim 1: A compound of Formula I:



wherein:

R1 is hydrogen or C1-6 alkyl;

R3a and R3b are each independently hydrogen, C1-6 alkyl, C3-8 cycloalkyl, or C4-14 alkyl-cycloalkyl;

R3c is hydrogen or C1-6 alkyl;


R4, R5, R6 and R7 are each independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, C1-6 haloalkyl, C1-6 alkylamine, C1-6 alkoxy, C1-6 haloalkoxy, -OR8a, -NO2, -CN, -C(O)R8b, -C(O)OR8b, -OC(O)R8b, -OC(O)OR8b, -

S(O)2N(R8bR8c), C3-8 cycloalkyl, C3-14 alkyl-cycloalkyl, C4-10 heterocycloalkyl, C4-16 alkyl-heterocycloalkyl, C6-12 aryl, C7-18 alkyl-aryl, C5-10 heteroaryl, or C4-16 alkyl-heteroaryl, wherein at least one of R4, R5, R6 and R7 is not H; alternatively, R4 and R5, R5 and R6, or R6 and R7 are combined with the atoms to which they are each attached to form a C3-6 cycloalkyl, C3-6 heterocycloalkyl, C6-12 aryl or C5-10 heteroaryl;


R8a, R8b, R8c...are each independently H, C1-6 alkyl;


4. Int'l Pat. App. Pub. No WO/2018/204359 "Compositions and methods for treating ocular pathologies" (Published November 8, 2018)

From Page 21 Line 5: In embodiments, the composition comprises a compound having the following chemical formula



In some embodiments, RN1 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl

	<p>RN2 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4- haloalkyl Ra of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or Ci-C4-haloalkyl R4 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl R5 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C,-C4-haloalkyl R6 of formula (III) can be H, C1-C6- alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-hatoalkyl and R7 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl.</p>
<p>12. The compound of claim 11, wherein R1 and R2 are each independently selected from C1-4 alkyl.</p>	<p>1. Int'l Pat. App. Pub. No. WO/2018/064465 "Compounds for increasing neural plasticity" (Published April 5, 2018)</p> <p>From Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa or IIb:</p> <div style="text-align: center;">  <p>(IIa)</p> </div> <p>wherein: L3 is a bond, -C(O)NRb-, -NRbC(O)-, -NHC(O)NRb-, -C(O)O-, -OC(O)-, -NHC(O)O-, -SO2NRb-, -NHSO2-, -SO2-, -O-, -S-, or -NRb-; R8 is hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 alkoxy, C1-C6 aminoalkyl, heterocycloalkyl, aryl, or heteroaryl; Rb is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or C1-C6 alkoxy; R9 is hydrogen, C1-C6 alkyl, or C2-C6 alkenyl; R10 is...halogen, C1-C6 alkyl, C2-C6 alkenyl, or C1-C6 haloalkyl; R11 is C1-C6 alkylamino, di-(C1-C6 alkyl)amino, N-(C1-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl; R12 is hydrogen, halogen, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or C1-C6 alkoxy; subscript p is an integer from 0 to 3; subscript q is an integer from 0 to 3; and subscript r is an integer from 1 to 3.</p> <p>2. Int'l Pat. App. Pub. No. WO/1998/023587 "5-cyclo indole compounds as 5-ht1d receptor ligands" (Published June 4, 1998)</p> <p>From Claim 1: A compound according to Formula I:</p>



wherein A is selected from a six-membered, non-aromatic, optionally substituted carbocycle and a six-membered, non-aromatic, optionally substituted heterocycle having one or two heteroatoms selected from O, S, SO, SO₂ and NR₄

R₁ is selected from H and OH; n is 0 or 1 as permitted by chemical structure

R₂ is selected from CR₅R₈CH₂NR₇R₈...


R₃ is selected from H and benzoyl

R₅ and R₈ are independently selected from H...

R₇ and R₈ are independently selected from H and loweralkyl or R₇ and R₈ form an alkylene bridge which, together with the nitrogen atom to which they are attached, creates an optionally substituted 3- to 6-membered ring...

3. Int'l Pat. App. Pub. No. WO/2020/176599 "Azepino-indoles and other heterocycles for treating brain disorders" (Published September 3, 2020)

From Claim 1: A compound of Formula I:



(I)

wherein:

R₁ is hydrogen or C1-6 alkyl;

R_{3a} and R_{3b} are each independently hydrogen, C1-6 alkyl, C3-8 cycloalkyl, or C4-14 alkyl-cycloalkyl;

R_{3c} is hydrogen or C1-6 alkyl;


R₄, R₅, R₆ and R₇ are each independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, C1-6 haloalkyl, C1-6 alkylamine, C1-6 alkoxy, C1-6 haloalkoxy, -OR_{8a}, -NO₂, -CN, -C(O)R_{8b}, -C(O)OR_{8b}, -OC(O)R_{8b}, -OC(O)OR_{8b}, -

S(O)₂N(R_{8b}R_{8c}), C3-8 cycloalkyl, C3-14 alkyl-cycloalkyl, C4-10 heterocycloalkyl, C4-16 alkyl-heterocycloalkyl, C6-12 aryl, C7-18 alkyl-aryl, C5-10 heteroaryl, or C4-16 alkyl-heteroaryl, wherein at least one of R₄, R₅, R₆ and R₇ is not H; alternatively, R₄ and R₅, R₅ and R₆, or R₆ and R₇ are combined with the atoms to which they are each attached to form a C3-6 cycloalkyl, C3-6 heterocycloalkyl, C6-12 aryl or C5-10 heteroaryl;

R_{8a}, R_{8b}, R_{8c}...are each independently H, C1-6 alkyl;

4. Int'l Pat. App. Pub. No WO/2018/204359 "Compositions and methods for treating ocular pathologies" (Published November 8, 2018)

From Page 21 Line 5: In embodiments, the composition comprises a compound having the following chemical formula



In some embodiments, RN1 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl

RN2 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4- haloalkyl

Ra of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or Ci-C4-haloalkyl


R4 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl

R5 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C,-C4-haloalkyl

R6 of formula (III) can be H, C1-C6- alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-hatoalkyl


and R7 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl.

13. The compound of claim 12, wherein R1 and R2, together with the nitrogen to which they are attached, form any one of the following:



1. Int'l Pat. App. Pub. No. WO/2018/064465 "Compounds for increasing neural plasticity" (Published April 5, 2018)

From Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa or IIb:




wherein:

L3 is a bond, -C(O)NRb-, -NRbC(O)-, -NHC(O)NRb-, -C(O)O-, -OC(O)-, -NHC(O)O-, -SO2NRb-, -NHSO2-, -SO2-, -O-, -S-, or -NRb-; R8 is hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 alkoxy, C1-C6 aminoalkyl, heterocycloalkyl, aryl, or heteroaryl;

Rb is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or C1-C6 alkoxy;
 R9 is hydrogen, C1-C6 alkyl, or C2-C6 alkenyl;
 R10 is...halogen, C1-C6 alkyl, C2-C6 alkenyl, or C1-C6 haloalkyl;
 R11 is C1-C6 alkylamino, di-(C1-C6 alkyl)amino, N-(C1-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl;
 R12 is hydrogen, halogen, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or C1-C6 alkoxy;
 subscript p is an integer from 0 to 3;
 subscript q is an integer from 0 to 3; and
 subscript r is an integer from 1 to 3.

2. Int'l Pat. App. Pub. No. WO/1998/023587 "5-HT1d receptor ligands" (Published June 4, 1998)

From Claim 1: A compound according to Formula I:



wherein A is selected from a six-membered, non-aromatic, optionally substituted carbocycle and a six-membered, non-aromatic, optionally substituted heterocycle having one or two heteroatoms selected from O, S, SO, SO2 and NR4

R1 is selected from H and OH; n is 0 or 1 as permitted by chemical structure

R2 is selected from CR5R8CH2NR7R8...


R3 is selected from H and benzoyl

R5 and R8 are independently selected from H...

R7 and R8 are independently selected from H and loweralkyl or R7 and R8 form an alkylene bridge which, together with the nitrogen atom to which they are attached, creates an optionally substituted 3- to 6-membered ring...

3. Int'l Pat. App. Pub. No. WO/2020/176599 "Azepino-indoles and other heterocycles for treating brain disorders" (Published September 3, 2020)

From Claim 1: A compound of Formula I:




wherein:
 R1 is hydrogen or C1-6 alkyl;

R3a and R3b are each independently hydrogen, C1-6 alkyl, C3-8 cycloalkyl, or C4-14 alkyl-cycloalkyl;
R3c is hydrogen or C1-6 alkyl;
R4, R5, R6 and R7 are each independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, C1-6 haloalkyl, C1-6 alkylamine, C1-6 alkoxy, C1-6 haloalkoxy, -OR8a, -NO2, -CN, -C(O)R8b, -C(O)OR8b, -OC(O)R8b, -OC(O)OR8b, -S(O)2N(R8bR8c), C3-8 cycloalkyl, C3-14 alkyl-cycloalkyl, C4-10 heterocycloalkyl, C4-16 alkyl-heterocycloalkyl, C6-12 aryl, C7-18 alkyl-aryl, C5-10 heteroaryl, or C4-16 alkyl-heteroaryl, wherein at least one of R4, R5, R6 and R7 is not H; alternatively, R4 and R5, R5 and R6, or R6 and R7 are combined with the atoms to which they are each attached to form a C3-6 cycloalkyl, C3-6 heterocycloalkyl, C6-12 aryl or C5-10 heteroaryl;
R8a, R8b, R8c...are each independently H, C1-6 alkyl;

4. Int'l Pat. App. Pub. No WO/2018/204359 "Compositions and methods for treating ocular pathologies" (Published November 8, 2018)

From Page 21 Line 5: In embodiments, the composition comprises a compound having the following chemical formula




In some embodiments, RN1 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl
RN2 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4- haloalkyl
Ra of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or Ci-C4-haloalkyl
R4 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl
R5 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C,-C4-haloalkyl
R6 of formula (III) can be H, C1-C6- alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-hatoalkyl
and R7 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl.

14. The compound of any one of claims 1 to

1. Int'l Pat. App. Pub. No. WO/2018/064465 "Compounds for increasing neural plasticity" (Published April 5, 2018)

13, wherein R3 is hydrogen

From Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa or IIb:



wherein:

L3 is a bond, -C(O)NRb-, -NRbC(O)-, -NHC(O)NRb-, -C(O)O-, -OC(O)-, -NHC(O)O-, -SO₂NRb-, -NHSO₂-, -SO₂-, -O-, -S-, or -NRb-; R8 is hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 alkoxy, C1-C6 aminoalkyl, heterocycloalkyl, aryl, or heteroaryl;

Rb is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or C1-C6 alkoxy;

R9 is hydrogen, C1-C6 alkyl, or C2-C6 alkenyl;

R10 is...halogen, C1-C6 alkyl, C2-C6 alkenyl, or C1-C6 haloalkyl;

R11 is C1-C6 alkylamino, di-(C1-C6 alkyl)amino, N-(C1-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl;

R12 is hydrogen, halogen, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or C1-C6 alkoxy;


subscript p is an integer from 0 to 3;

subscript q is an integer from 0 to 3; and

subscript r is an integer from 1 to 3.

2. Int'l Pat. App. Pub. No. WO/1998/023587 "5-cyclo indole compounds as 5-HT_{1D} receptor ligands" (Published June 4, 1998)

From Claim 1: A compound according to Formula I:



wherein A is selected from a six-membered, non-aromatic, optionally substituted carbocycle and a six-membered, non-aromatic, optionally substituted heterocycle having one or two heteroatoms selected from O, S, SO, SO₂ and NR₄

R1 is selected from H and OH; n is 0 or 1 as permitted by chemical structure

R2 is selected from CR₅R₈CH₂NR₇R₈...

R3 is selected from H and benzoyl


R5 and R8 are independently selected from H...

R7 and R8 are independently selected from H and loweralkyl or R7 and R8 form an alkylene bridge which, together with the nitrogen atom to

which they are attached, creates an optionally substituted 3- to 6-membered ring...

3. Int'l Pat. App. Pub. No. WO/2020/176599 "Azepino-indoles and other heterocycles for treating brain disorders" (Published September 3, 2020)

From Claim 1: A compound of Formula I:



wherein:

R1 is hydrogen or C1-6 alkyl;

R3a and R3b are each independently hydrogen, C1-6 alkyl, C3-8 cycloalkyl, or C4-14 alkyl-cycloalkyl;

R3c is hydrogen or C1-6 alkyl;


R4, R5, R6 and R7 are each independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, C1-6 haloalkyl, C1-6 alkylamine, C1-6 alkoxy, C1-6 haloalkoxy, -OR8a, -NO2, -CN, -C(O)R8b, -C(O)OR8b, -OC(O)R8b, -OC(O)OR8b, -

S(O)2N(R8bR8c), C3-8 cycloalkyl, C3-14 alkyl-cycloalkyl, C4-10 heterocycloalkyl, C4-16 alkyl-heterocycloalkyl, C6-12 aryl, C7-18 alkyl-aryl, C5-10 heteroaryl, or C4-16 alkyl-heteroaryl, wherein at least one of R4, R5, R6 and R7 is not H; alternatively, R4 and R5, R5 and R6, or R6 and R7 are combined with the atoms to which they are each attached to form a C3-6 cycloalkyl, C3-6 heterocycloalkyl, C6-12 aryl or C5-10 heteroaryl;


R8a, R8b, R8c...are each independently H, C1-6 alkyl;


4. Int'l Pat. App. Pub. No WO/2018/204359 "Compositions and methods for treating ocular pathologies" (Published November 8, 2018)

From Page 21 Line 5: In embodiments, the composition comprises a compound having the following chemical formula



In some embodiments, RN1 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl

	<p>RN2 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4- haloalkyl Ra of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or Ci-C4-haloalkyl R4 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl R5 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C,-C4-haloalkyl R6 of formula (III) can be H, C1-C6- alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-hatoalkyl and R7 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl.</p>
<p>15. The compound of any one of claims 1 to 14, wherein L is C1-4 alkylene.</p>	<p>1. Int'l Pat. App. Pub. No. WO/2018/064465 "Compounds for increasing neural plasticity" (Published April 5, 2018)</p> <p>From Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa or IIb:</p> <div style="text-align: center;">  <p>(IIa)</p> </div> <p>wherein: L3 is a bond, -C(O)NRb-, -NRbC(O)-, -NHC(O)NRb-, -C(O)O-, -OC(O)-, -NHC(O)O-, -SO2NRb-, -NHSO2-, -SO2-, -O-, -S-, or -NRb-; R8 is hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 alkoxy, C1-C6 aminoalkyl, heterocycloalkyl, aryl, or heteroaryl; Rb is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or C1-C6 alkoxy; R9 is hydrogen, C1-C6 alkyl, or C2-C6 alkenyl; R10 is hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, or C1-C6 haloalkyl; R11 is C1-C6 alkylamino, di-(C1-C6 alkyl)amino, N-(C1-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl; R12 is hydrogen, halogen, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or C1-C6 alkoxy; subscript p is an integer from 0 to 3; subscript q is an integer from 0 to 3; and subscript r is an integer from 1 to 3.</p> <p>2. Int'l Pat. App. Pub. No. WO/1998/023587 "5-cyclo indole compounds as 5-ht1d receptor ligands" (Published June 4, 1998)</p> <p>From Claim 1: A compound according to Formula I:</p>



wherein A is selected from a six-membered, non-aromatic, optionally substituted carbocycle and a six-membered, non-aromatic, optionally substituted heterocycle having one or two heteroatoms selected from O, S, SO, SO₂ and NR₄

R₁ is selected from H and OH; n is 0 or 1 as permitted by chemical structure

R₂ is selected from CR₅R₈CH₂NR₇R₈...


R₃ is selected from H and benzoyl

R₅ and R₈ are independently selected from H...

R₇ and R₈ are independently selected from H and loweralkyl or R₇ and R₈ form an alkylene bridge which, together with the nitrogen atom to which they are attached, creates an optionally substituted 3- to 6-membered ring...

3. Int'l Pat. App. Pub. No. WO/2020/176599 "Azepino-indoles and other heterocycles for treating brain disorders" (Published September 3, 2020)

From Claim 1: A compound of Formula I:



(I)

wherein:

R₁ is hydrogen or C1-6 alkyl;

R_{3a} and R_{3b} are each independently hydrogen, C1-6 alkyl, C3-8 cycloalkyl, or C4-14 alkyl-cycloalkyl;

R_{3c} is hydrogen or C1-6 alkyl;


R₄, R₅, R₆ and R₇ are each independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, C1-6 haloalkyl, C1-6 alkylamine, C1-6 alkoxy, C1-6 haloalkoxy, -OR_{8a}, -NO₂, -CN, -C(O)R_{8b}, -C(O)OR_{8b}, -OC(O)R_{8b}, -OC(O)OR_{8b}, -

S(O)₂N(R_{8b}R_{8c}), C3-8 cycloalkyl, C3-14 alkyl-cycloalkyl, C4-10 heterocycloalkyl, C4-16 alkyl-heterocycloalkyl, C6-12 aryl, C7-18 alkyl-aryl, C5-10 heteroaryl, or C4-16 alkyl-heteroaryl, wherein at least one of R₄, R₅, R₆ and R₇ is not H; alternatively, R₄ and R₅, R₅ and R₆, or R₆ and R₇ are combined with the atoms to which they are each attached to form a C3-6 cycloalkyl, C3-6 heterocycloalkyl, C6-12 aryl or C5-10 heteroaryl;

R_{8a}, R_{8b}, R_{8c}...are each independently H, C1-6 alkyl;

4. Int'l Pat. App. Pub. No WO/2018/204359 "Compositions and methods for treating ocular pathologies" (Published November 8, 2018)

From Page 21 Line 5: In embodiments, the composition comprises a compound having the following chemical formula



In some embodiments, RN1 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl

RN2 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4- haloalkyl

Ra of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or Ci-C4-haloalkyl

R4 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl

R5 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C,-C4-haloalkyl


R6 of formula (III) can be H, C1-C6- alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-hatoalkyl

and R7 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl.

16. The compound of claim 15, wherein L is methylene.

1. Int'l Pat. App. Pub. No. WO/2018/064465 "Compounds for increasing neural plasticity" (Published April 5, 2018)

From Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa or IIb:




wherein:

L3 is a bond, -C(O)NRb-, -NRbC(O)-, -NHC(O)NRb-, -C(O)O-, -OC(O)-, -NHC(O)O-, -SO₂NRb-, -NH₂SO₂-, -SO₂-, -O-, -S-, or -NRb-; R8 is hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 alkoxy, C1-C6 aminoalkyl, heterocycloalkyl, aryl, or heteroaryl;

Rb is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or C1-C6 alkoxy;
R9 is hydrogen, C1-C6 alkyl, or C2-C6 alkenyl;
R10 is hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, or C1-C6 haloalkyl;
R11 is C1-C6 alkylamino, di-(C1-C6 alkyl)amino, N-(C1-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl;
R12 is hydrogen, halogen, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or C1-C6 alkoxy;
subscript p is an integer from 0 to 3;
subscript q is an integer from 0 to 3; and
subscript r is an integer from 1 to 3.

2. Int'l Pat. App. Pub. No. WO/1998/023587 "5-cyclo indole compounds as 5-HT1d receptor ligands" (Published June 4, 1998)

From Claim 1: A compound according to Formula I:



wherein A is selected from a six-membered, non-aromatic, optionally substituted carbocycle and a six-membered, non-aromatic, optionally substituted heterocycle having one or two heteroatoms selected from O, S, SO, SO₂ and NR₄

R₁ is selected from H and OH; n is 0 or 1 as permitted by chemical structure

R₂ is selected from CR₅R₈CH₂NR₇R₈...


R₃ is selected from H and benzoyl

R₅ and R₈ are independently selected from H...

R₇ and R₈ are independently selected from H and loweralkyl or R₇ and R₈ form an alkylene bridge which, together with the nitrogen atom to which they are attached, creates an optionally substituted 3- to 6-membered ring...

3. Int'l Pat. App. Pub. No. WO/2020/176599 "Azepino-indoles and other heterocycles for treating brain disorders" (Published September 3, 2020)

From Claim 1: A compound of Formula I:




wherein:

R₁ is hydrogen or C1-6 alkyl;

R3a and R3b are each independently hydrogen, C1-6 alkyl, C3-8 cycloalkyl, or C4-14 alkyl-cycloalkyl;
R3c is hydrogen or C1-6 alkyl;
R4, R5, R6 and R7 are each independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, C1-6 haloalkyl, C1-6 alkylamine, C1-6 alkoxy, C1-6 haloalkoxy, -OR8a, -NO2, -CN, -C(O)R8b, -C(O)OR8b, -OC(O)R8b, -OC(O)OR8b, -S(O)2N(R8bR8c), C3-8 cycloalkyl, C3-14 alkyl-cycloalkyl, C4-10 heterocycloalkyl, C4-16 alkyl-heterocycloalkyl, C6-12 aryl, C7-18 alkyl-aryl, C5-10 heteroaryl, or C4-16 alkyl-heteroaryl, wherein at least one of R4, R5, R6 and R7 is not H; alternatively, R4 and R5, R5 and R6, or R6 and R7 are combined with the atoms to which they are each attached to form a C3-6 cycloalkyl, C3-6 heterocycloalkyl, C6-12 aryl or C5-10 heteroaryl;
R8a, R8b, R8c...are each independently H, C1-6 alkyl;

4. Int'l Pat. App. Pub. No WO/2018/204359 "Compositions and methods for treating ocular pathologies" (Published November 8, 2018)

From Page 21 Line 5: In embodiments, the composition comprises a compound having the following chemical formula




In some embodiments, RN1 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl
RN2 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4- haloalkyl
Ra of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or Ci-C4-haloalkyl
R4 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl
R5 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C,-C4-haloalkyl
R6 of formula (III) can be H, C1-C6- alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-hatoalkyl
and R7 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl.

17. The compound of any one of claims 1 to

1. Int'l Pat. App. Pub. No. WO/2018/064465 "Compounds for increasing neural plasticity" (Published April 5, 2018)

16, wherein R6 is selected from hydrogen and C1-6 alkyl.

From Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa or IIb:



wherein:

L3 is a bond, -C(O)NRb-, -NRbC(O)-, -NHC(O)NRb-, -C(O)O-, -OC(O)-, -NHC(O)O-, -SO2NRb-, -NHSO2-, -SO2-, -O-, -S-, or -NRb-; R8 is hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 alkoxy, C1-C6 aminoalkyl, heterocycloalkyl, aryl, or heteroaryl;

Rb is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or C1-C6 alkoxy;

R9 is hydrogen, C1-C6 alkyl, or C2-C6 alkenyl;

R10 is hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, or C1-C6 haloalkyl;

R11 is C1-C6 alkylamino, di-(C1-C6 alkyl)amino, N-(C1-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl;

R12 is hydrogen, halogen, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or C1-C6 alkoxy;


subscript p is an integer from 0 to 3;

subscript q is an integer from 0 to 3; and

subscript r is an integer from 1 to 3.

2. Int'l Pat. App. Pub. No. WO/1998/023587 "5-cyclo indole compounds as 5-HT1d receptor ligands" (Published June 4, 1998)

From Claim 1: A compound according to Formula I:



wherein A is selected from a six-membered, non-aromatic, optionally substituted carbocycle and a six-membered, non-aromatic, optionally substituted heterocycle having one or two heteroatoms selected from O, S, SO, SO2 and NR4

R1 is selected from H and OH; n is 0 or 1 as permitted by chemical structure

R2 is selected from CR5R8CH2NR7R8...

R3 is selected from H and benzoyl


R5 and R8 are independently selected from H...

R7 and R8 are independently selected from H and loweralkyl or R7 and R8 form an alkylene bridge which, together with the nitrogen atom to

which they are attached, creates an optionally substituted 3- to 6-membered ring...

3. Int'l Pat. App. Pub. No. WO/2020/176599 "Azepino-indoles and other heterocycles for treating brain disorders" (Published September 3, 2020)

From Claim 1: A compound of Formula I:



wherein:

R1 is hydrogen or C1-6 alkyl;

R3a and R3b are each independently hydrogen, C1-6 alkyl, C3-8 cycloalkyl, or C4-14 alkyl-cycloalkyl;

R3c is hydrogen or C1-6 alkyl;


R4, R5, R6 and R7 are each independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, C1-6 haloalkyl, C1-6 alkylamine, C1-6 alkoxy, C1-6 haloalkoxy, -OR8a, -NO2, -CN, -C(O)R8b, -C(O)OR8b, -OC(O)R8b, -OC(O)OR8b, -

S(O)2N(R8bR8c), C3-8 cycloalkyl, C3-14 alkyl-cycloalkyl, C4-10 heterocycloalkyl, C4-16 alkyl-heterocycloalkyl, C6-12 aryl, C7-18 alkyl-aryl, C5-10 heteroaryl, or C4-16 alkyl-heteroaryl, wherein at least one of R4, R5, R6 and R7 is not H; alternatively, R4 and R5, R5 and R6, or R6 and R7 are combined with the atoms to which they are each attached to form a C3-6 cycloalkyl, C3-6 heterocycloalkyl, C6-12 aryl or C5-10 heteroaryl;


R8a, R8b, R8c...are each independently H, C1-6 alkyl;


4. Int'l Pat. App. Pub. No WO/2018/204359 "Compositions and methods for treating ocular pathologies" (Published November 8, 2018)

From Page 21 Line 5: In embodiments, the composition comprises a compound having the following chemical formula



In some embodiments, RN1 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl

	<p>RN2 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4- haloalkyl Ra of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or Ci-C4-haloalkyl R4 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl R5 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C,-C4-haloalkyl R6 of formula (III) can be H, C1-C6- alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-hatoalkyl and R7 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl.</p>
<p>18. The compound of claim 17, wherein R6 is hydrogen.</p>	<p>1. Int'l Pat. App. Pub. No. WO/2018/064465 "Compounds for increasing neural plasticity" (Published April 5, 2018)</p> <p>From Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa or IIb:</p> <div style="text-align: center;">  <p>(IIa)</p> </div> <p>wherein: L3 is a bond, -C(O)NRb-, -NRbC(O)-, -NHC(O)NRb-, -C(O)O-, -OC(O)-, -NHC(O)O-, -SO2NRb-, -NHSO2-, -SO2-, -O-, -S-, or -NRb-; R8 is hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 alkoxy, C1-C6 aminoalkyl, heterocycloalkyl, aryl, or heteroaryl; Rb is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or C1-C6 alkoxy; R9 is hydrogen, C1-C6 alkyl, or C2-C6 alkenyl; R10 is hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, or C1-C6 haloalkyl; R11 is C1-C6 alkylamino, di-(C1-C6 alkyl)amino, N-(C1-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl; R12 is hydrogen, halogen, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or C1-C6 alkoxy; subscript p is an integer from 0 to 3; subscript q is an integer from 0 to 3; and subscript r is an integer from 1 to 3.</p> <p>2. Int'l Pat. App. Pub. No. WO/1998/023587 "5-cyclo indole compounds as 5-ht1d receptor ligands" (Published June 4, 1998)</p> <p>From Claim 1: A compound according to Formula I:</p>



wherein A is selected from a six-membered, non-aromatic, optionally substituted carbocycle and a six-membered, non-aromatic, optionally substituted heterocycle having one or two heteroatoms selected from O, S, SO, SO₂ and NR₄

R₁ is selected from H and OH; n is 0 or 1 as permitted by chemical structure

R₂ is selected from CR₅R₈CH₂NR₇R₈...


R₃ is selected from H and benzoyl

R₅ and R₈ are independently selected from H...

R₇ and R₈ are independently selected from H and loweralkyl or R₇ and R₈ form an alkylene bridge which, together with the nitrogen atom to which they are attached, creates an optionally substituted 3- to 6-membered ring...

3. Int'l Pat. App. Pub. No. WO/2020/176599 "Azepino-indoles and other heterocycles for treating brain disorders" (Published September 3, 2020)

From Claim 1: A compound of Formula I:



(I)

wherein:

R₁ is hydrogen or C1-6 alkyl;

R_{3a} and R_{3b} are each independently hydrogen, C1-6 alkyl, C3-8 cycloalkyl, or C4-14 alkyl-cycloalkyl;

R_{3c} is hydrogen or C1-6 alkyl;


R₄, R₅, R₆ and R₇ are each independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, C1-6 haloalkyl, C1-6 alkylamine, C1-6 alkoxy, C1-6 haloalkoxy, -OR_{8a}, -NO₂, -CN, -C(O)R_{8b}, -C(O)OR_{8b}, -OC(O)R_{8b}, -OC(O)OR_{8b}, -

S(O)₂N(R_{8b}R_{8c}), C3-8 cycloalkyl, C3-14 alkyl-cycloalkyl, C4-10 heterocycloalkyl, C4-16 alkyl-heterocycloalkyl, C6-12 aryl, C7-18 alkyl-aryl, C5-10 heteroaryl, or C4-16 alkyl-heteroaryl, wherein at least one of R₄, R₅, R₆ and R₇ is not H; alternatively, R₄ and R₅, R₅ and R₆, or R₆ and R₇ are combined with the atoms to which they are each attached to form a C3-6 cycloalkyl, C3-6 heterocycloalkyl, C6-12 aryl or C5-10 heteroaryl;

R_{8a}, R_{8b}, R_{8c}...are each independently H, C1-6 alkyl;

4. Int'l Pat. App. Pub. No WO/2018/204359 "Compositions and methods for treating ocular pathologies" (Published November 8, 2018)

From Page 21 Line 5: In embodiments, the composition comprises a compound having the following chemical formula



In some embodiments, RN1 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl

RN2 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4- haloalkyl

Ra of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or Ci-C4-haloalkyl

R4 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl

R5 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C,-C4-haloalkyl


R6 of formula (III) can be H, C1-C6- alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-hatoalkyl

and R7 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl.

19. The compound of claim 1 selected from any one of the compounds of Table 1 or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer, metabolite, polymorph or prodrug thereof.

1. Int'l Pat. App. Pub. No. WO/2018/064465 "Compounds for increasing neural plasticity" (Published April 5, 2018)

From Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa or IIb:




wherein:

L3 is a bond, -C(O)NRb-, -NRbC(O)-, -NHC(O)NRb-, -C(O)O-, -OC(O)-, -NHC(O)O-, -SO2NRb-, -NHSO2-, -SO2-, -O-, -S-, or -NRb-; R8 is hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 alkoxy, C1-C6 aminoalkyl, heterocycloalkyl, aryl, or heteroaryl;

Rb is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or C1-C6 alkoxy;
R9 is hydrogen, C1-C6 alkyl, or C2-C6 alkenyl;
R10 is hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, or C1-C6 haloalkyl;
R11 is C1-C6 alkylamino, di-(C1-C6 alkyl)amino, N-(C1-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl;
R12 is hydrogen, halogen, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or C1-C6 alkoxy;
subscript p is an integer from 0 to 3;
subscript q is an integer from 0 to 3; and
subscript r is an integer from 1 to 3.

2. Int'l Pat. App. Pub. No. WO/1998/023587 "5-cyclo indole compounds as 5-HT1d receptor ligands" (Published June 4, 1998)

From Claim 1: A compound according to Formula I:



wherein A is selected from a six-membered, non-aromatic, optionally substituted carbocycle and a six-membered, non-aromatic, optionally substituted heterocycle having one or two heteroatoms selected from O, S, SO, SO₂ and NR₄

R₁ is selected from H and OH; n is 0 or 1 as permitted by chemical structure

R₂ is selected from CR₅R₈CH₂NR₇R₈...


R₃ is selected from H and benzoyl

R₅ and R₈ are independently selected from H...

R₇ and R₈ are independently selected from H and loweralkyl or R₇ and R₈ form an alkylene bridge which, together with the nitrogen atom to which they are attached, creates an optionally substituted 3- to 6-membered ring...

3. Int'l Pat. App. Pub. No. WO/2020/176599 "Azepino-indoles and other heterocycles for treating brain disorders" (Published September 3, 2020)

From Claim 1: A compound of Formula I:




wherein:

R₁ is hydrogen or C1-6 alkyl;

R3a and R3b are each independently hydrogen, C1-6 alkyl, C3-8 cycloalkyl, or C4-14 alkyl-cycloalkyl;
R3c is hydrogen or C1-6 alkyl;
R4, R5, R6 and R7 are each independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, C1-6 haloalkyl, C1-6 alkylamine, C1-6 alkoxy, C1-6 haloalkoxy, -OR8a, -NO2, -CN, -C(O)R8b, -C(O)OR8b, -OC(O)R8b, -OC(O)OR8b, -S(O)2N(R8bR8c), C3-8 cycloalkyl, C3-14 alkyl-cycloalkyl, C4-10 heterocycloalkyl, C4-16 alkyl-heterocycloalkyl, C6-12 aryl, C7-18 alkyl-aryl, C5-10 heteroaryl, or C4-16 alkyl-heteroaryl, wherein at least one of R4, R5, R6 and R7 is not H; alternatively, R4 and R5, R5 and R6, or R6 and R7 are combined with the atoms to which they are each attached to form a C3-6 cycloalkyl, C3-6 heterocycloalkyl, C6-12 aryl or C5-10 heteroaryl;
R8a, R8b, R8c...are each independently H, C1-6 alkyl;

4. Int'l Pat. App. Pub. No WO/2018/204359 "Compositions and methods for treating ocular pathologies" (Published November 8, 2018)

From Page 21 Line 5: In embodiments, the composition comprises a compound having the following chemical formula




In some embodiments, RN1 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl
RN2 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4- haloalkyl
Ra of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or Ci-C4-haloalkyl
R4 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl
R5 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C,-C4-haloalkyl
R6 of formula (III) can be H, C1-C6- alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-hatoalkyl
and R7 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl.

20. A medicament comprising a compound

1. Int'l Pat. App. Pub. No. WO/2018/064465 "Compounds for increasing neural plasticity" (Published April 5, 2018)

of any one of claims 1 to 19, or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer, metabolite, polymorph or prodrug thereof.

From Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa or IIb:



wherein:

L3 is a bond, -C(O)NRb-, -NRbC(O)-, -NHC(O)NRb-, -C(O)O-, -OC(O)-, -NHC(O)O-, -SO₂NRb-, -NHSO₂-, -SO₂-, -O-, -S-, or -NRb-; **R8** is hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 alkoxy, C1-C6 aminoalkyl, heterocycloalkyl, aryl, or heteroaryl;

Rb is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or C1-C6 alkoxy;

R9 is hydrogen, C1-C6 alkyl, or C2-C6 alkenyl;

R10 is hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, or C1-C6 haloalkyl;

R11 is C1-C6 alkylamino, di-(C1-C6 alkyl)amino, N-(C1-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl;

R12 is hydrogen, halogen, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or C1-C6 alkoxy;


subscript **p** is an integer from 0 to 3;

subscript **q** is an integer from 0 to 3; and

subscript **r** is an integer from 1 to 3.

2. Int'l Pat. App. Pub. No. WO/1998/023587 "5-cyclo indole compounds as 5-HT_{1D} receptor ligands" (Published June 4, 1998)

From Claim 1: A compound according to Formula I:



wherein **A** is selected from a six-membered, non-aromatic, optionally substituted carbocycle and a six-membered, non-aromatic, optionally substituted heterocycle having one or two heteroatoms selected from O, S, SO, SO₂ and NR₄

R1 is selected from H and OH; **n** is 0 or 1 as permitted by chemical structure

R2 is selected from CR₅R₈CH₂NR₇R₈...

R3 is selected from H and benzoyl


R5 and **R8** are independently selected from H...

R7 and **R8** are independently selected from H and loweralkyl or **R7** and **R8** form an alkylene bridge which, together with the nitrogen atom to

which they are attached, creates an optionally substituted 3- to 6-membered ring...

3. Int'l Pat. App. Pub. No. WO/2020/176599 "Azepino-indoles and other heterocycles for treating brain disorders" (Published September 3, 2020)

From Claim 1: A compound of Formula I:



wherein:

R1 is hydrogen or C1-6 alkyl;

R3a and R3b are each independently hydrogen, C1-6 alkyl, C3-8 cycloalkyl, or C4-14 alkyl-cycloalkyl;

R3c is hydrogen or C1-6 alkyl;


R4, R5, R6 and R7 are each independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, C1-6 haloalkyl, C1-6 alkylamine, C1-6 alkoxy, C1-6 haloalkoxy, -OR8a, -NO2, -CN, -C(O)R8b, -C(O)OR8b, -OC(O)R8b, -OC(O)OR8b, -

S(O)2N(R8bR8c), C3-8 cycloalkyl, C3-14 alkyl-cycloalkyl, C4-10 heterocycloalkyl, C4-16 alkyl-heterocycloalkyl, C6-12 aryl, C7-18 alkyl-aryl, C5-10 heteroaryl, or C4-16 alkyl-heteroaryl, wherein at least one of R4, R5, R6 and R7 is not H; alternatively, R4 and R5, R5 and R6, or R6 and R7 are combined with the atoms to which they are each attached to form a C3-6 cycloalkyl, C3-6 heterocycloalkyl, C6-12 aryl or C5-10 heteroaryl;


R8a, R8b, R8c...are each independently H, C1-6 alkyl;


4. Int'l Pat. App. Pub. No WO/2018/204359 "Compositions and methods for treating ocular pathologies" (Published November 8, 2018)

From Page 21 Line 5: In embodiments, the composition comprises a compound having the following chemical formula



In some embodiments, RN1 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl

	<p>RN2 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4- haloalkyl Ra of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or Ci-C4-haloalkyl R4 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl R5 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C,-C4-haloalkyl R6 of formula (III) can be H, C1-C6- alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-hatoalkyl and R7 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl.</p>
<p>21. A pharmaceutical composition comprising a compound of any one of claims 1 to 19, or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer, metabolite, polymorph or prodrug thereof, and a pharmaceutically acceptable excipient.</p>	<p>1. Int'l Pat. App. Pub. No. WO/2018/064465 "Compounds for increasing neural plasticity" (Published April 5, 2018)</p> <p>From Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa or IIb:</p> <div style="text-align: center;">  <p>(IIa)</p> </div> <p>wherein: L3 is a bond, -C(O)NRb-, -NRbC(O)-, -NHC(O)NRb-, -C(O)O-, -OC(O)-, -NHC(O)O-, -SO2NRb-, -NHSO2-, -SO2-, -O-, -S-, or -NRb-; R8 is hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 alkoxy, C1-C6 aminoalkyl, heterocycloalkyl, aryl, or heteroaryl; Rb is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or C1-C6 alkoxy; R9 is hydrogen, C1-C6 alkyl, or C2-C6 alkenyl; R10 is hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, or C1-C6 haloalkyl; R11 is C1-C6 alkylamino, di-(C1-C6 alkyl)amino, N-(C1-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl; R12 is hydrogen, halogen, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or C1-C6 alkoxy; subscript p is an integer from 0 to 3; subscript q is an integer from 0 to 3; and subscript r is an integer from 1 to 3.</p> <p>2. Int'l Pat. App. Pub. No. WO/1998/023587 "5-cyclo indole compounds as 5-ht1d receptor ligands" (Published June 4, 1998)</p> <p>From Claim 1: A compound according to Formula I:</p>



wherein A is selected from a six-membered, non-aromatic, optionally substituted carbocycle and a six-membered, non-aromatic, optionally substituted heterocycle having one or two heteroatoms selected from O, S, SO, SO₂ and NR₄

R₁ is selected from H and OH; n is 0 or 1 as permitted by chemical structure

R₂ is selected from CR₅R₈CH₂NR₇R₈...


R₃ is selected from H and benzoyl

R₅ and R₈ are independently selected from H...

R₇ and R₈ are independently selected from H and loweralkyl or R₇ and R₈ form an alkylene bridge which, together with the nitrogen atom to which they are attached, creates an optionally substituted 3- to 6-membered ring...

3. Int'l Pat. App. Pub. No. WO/2020/176599 "Azepino-indoles and other heterocycles for treating brain disorders" (Published September 3, 2020)

From Claim 1: A compound of Formula I:



(I)

wherein:

R₁ is hydrogen or C1-6 alkyl;

R_{3a} and R_{3b} are each independently hydrogen, C1-6 alkyl, C3-8 cycloalkyl, or C4-14 alkyl-cycloalkyl;

R_{3c} is hydrogen or C1-6 alkyl;


R₄, R₅, R₆ and R₇ are each independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, C1-6 haloalkyl, C1-6 alkylamine, C1-6 alkoxy, C1-6 haloalkoxy, -OR_{8a}, -NO₂, -CN, -C(O)R_{8b}, -C(O)OR_{8b}, -OC(O)R_{8b}, -OC(O)OR_{8b}, -

S(O)₂N(R_{8b}R_{8c}), C3-8 cycloalkyl, C3-14 alkyl-cycloalkyl, C4-10 heterocycloalkyl, C4-16 alkyl-heterocycloalkyl, C6-12 aryl, C7-18 alkyl-aryl, C5-10 heteroaryl, or C4-16 alkyl-heteroaryl, wherein at least one of R₄, R₅, R₆ and R₇ is not H; alternatively, R₄ and R₅, R₅ and R₆, or R₆ and R₇ are combined with the atoms to which they are each attached to form a C3-6 cycloalkyl, C3-6 heterocycloalkyl, C6-12 aryl or C5-10 heteroaryl;

R_{8a}, R_{8b}, R_{8c}...are each independently H, C1-6 alkyl;

4. Int'l Pat. App. Pub. No WO/2018/204359 "Compositions and methods for treating ocular pathologies" (Published November 8, 2018)

From Page 21 Line 5: In embodiments, the composition comprises a compound having the following chemical formula



In some embodiments, RN1 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl

RN2 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4- haloalkyl

Ra of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or Ci-C4-haloalkyl


R4 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl

R5 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C,-C4-haloalkyl

R6 of formula (III) can be H, C1-C6- alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-hatoalkyl

and R7 of formula (III) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen, or C1-C4-haloalkyl.


22. A method of treating a disease, disorder or condition by activation of a serotonin receptor, the method comprising administering to a subject in need thereof a compound of formula (I):



or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide,

1. Int'l Pat. App. Pub. No. WO/2018/064465 "Compounds for increasing neural plasticity" (Published April 5, 2018)

From Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa or IIb:



wherein:

L3 is a bond, -C(O)NRb-, -NRbC(O)-, -NHC(O)NRb-, -C(O)O-, -OC(O)-, -NHC(O)O-, -SO2NRb-, -NHSO2-, -SO2-, -O-, -S-, or -NRb-; R8 is hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 alkoxy, C1-C6 aminoalkyl, heterocycloalkyl, aryl, or heteroaryl;


stereoisomer, metabolite, polymorph or prodrug thereof, wherein R1 and R2 are each independently selected from hydrogen, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 haloalkenyl, C2-6 alkynyl, C2-6 haloalkynyl, C3-8 cycloalkyl, C4-14 alkylencycloalkyl, C3-C8 heterocycloalkyl, C4-C14 alkyleneheterocycloalkyl, C6-12 aryl, C7-18 alkylenearyl, C5-10 heteroaryl, and C6-16 alkyleneheteroaryl, said C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 haloalkenyl, C2-6 alkynyl, C2-6 haloalkynyl, C3-8 cycloalkyl, C4-14 alkylencycloalkyl, C3-C8 heterocycloalkyl, C4-C14 alkyleneheterocycloalkyl, C6-12 aryl, C7-18 alkylenearyl, C5-10 heteroaryl, and C6-16 alkyleneheteroaryl each being optionally substituted with one or more substituents independently selected from halogen, CN, C1-8 alkoxy, C1-8 alkylamino, C1-8 alkylsulfonyl, CO₂R₄, C(O)N(R₄)₂, OR₄, N(R₄)₂, NO₂, SR₄ and SO₂R₄, said C3-8 cycloalkyl, C4-14 alkylencycloalkyl, C3-

Rb is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or C1-C6 alkoxy;
R9 is hydrogen, C1-C6 alkyl, or C2-C6 alkenyl;
R10 is hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, or C1-C6 haloalkyl;
R11 is C1-C6 alkylamino, di-(C1-C6 alkyl)amino, N-(C1-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl;
R12 is hydrogen, halogen, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or C1-C6 alkoxy;
subscript p is an integer from 0 to 3;
subscript q is an integer from 0 to 3; and
subscript r is an integer from 1 to 3.

From [0016]: **The present invention provides a method of using non-hallucinogenic analogs of psychedelic compounds for treatment of a brain disorder. The brain disorder can be a psychiatric disorder including depression, anxiety, and/or post-traumatic stress disorder.**

3. Int'l Pat. App. Pub. No. WO/2020/176599 "Azepino-indoles and other heterocycles for treating brain disorders" (Published September 3, 2020)

From Claim 1: **A compound of Formula I:**



wherein:

R1 is hydrogen or C1-6 alkyl;
R3a and R3b are each independently hydrogen, C1-6 alkyl, C3-8 cycloalkyl, or C4-14 alkyl-cycloalkyl;
R3c is hydrogen or C1-6 alkyl;
R4, R5, R6 and R7 are each independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, C1-6 haloalkyl, C1-6 alkylamine, C1-6 alkoxy, C1-6 haloalkoxy, -OR_{8a}, -NO₂, -CN, -C(O)R_{8b}, -C(O)OR_{8b}, -OC(O)R_{8b}, -OC(O)OR_{8b}, -S(O)₂N(R_{8b}R_{8c}), C3-8 cycloalkyl, C3-14 alkyl-cycloalkyl, C4-10 heterocycloalkyl, C4-16 alkyl-heterocycloalkyl, C6-12 aryl, C7-18 alkyl-aryl, C5-10 heteroaryl, or C4-16 alkyl-heteroaryl, wherein at least one of R₄, R₅, R₆ and R₇ is not H; alternatively, R₄ and R₅, R₅ and R₆, or R₆ and R₇ are combined with the atoms to which they are each attached to form a C3-6 cycloalkyl, C3-6 heterocycloalkyl, C6-12 aryl or C5-10 heteroaryl;
R_{8a}, R_{8b}, R_{8c}...are each independently H, C1-6 alkyl;

From [0068]: **"Brain disorder" refers to a neurological disorder which affects the brain's structure and function. Brain disorders can include,**

<p>C8 heterocycloalkyl, C6-12 aryl, C7-18 alkylenearyl, C5-10 heteroaryl, and C6-16 alkyleneheteroaryl each being further optionally substituted with a substituent independently selected from (O), C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 haloalkenyl, C2-6 alkynyl, C2-6 haloalkynyl, C3-6 cycloalkyl and C3-6 heterocycloalkyl including 1 or 2 ring heteromoieties selected from O, S, N, S(O), SO₂ and NR₄; alternatively R₁ and R₂ are combined with the atoms to which they are attached to form a C3-8 heterocycloalkyl including 1 or 2 additional ring heteromoieties selected from O, S, S(O), SO₂, N and NR₄, said C3-8 heterocycloalkyl being further optionally substituted with a substituent selected from halogen, (O), CN, C1-8 alkoxy, C1-8 alkylamino, C1-8 alkylsulfonyl, CO₂R₄, C(O)N(R₄)₂, OR₄, N(R₄)₂, NO₂, SR₄, SO₂R₄, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 haloalkenyl, C2-6 alkynyl, C2-6 haloalkynyl, C1-8 alkylamino, C1-8</p>	<p>but are not limited to, Alzheimer's, Parkinson's disease, psychological disorder, depression, treatment resistant depression, addiction, anxiety, post-traumatic stress disorder, suicidal ideation, major depressive disorder, bipolar disorder, schizophrenia, stroke, traumatic brain injury, and substance use disorder.</p>
---	--

alkylsulfonyl, C3-6 cycloalkyl and C3-6 heterocycloalkyl including 1 or 2 ring heteromoieties selected from O, S, N, S(O), SO₂ and NR₄; R₃ is selected from hydrogen, C1-6 alkyl, C3-8 cycloalkyl, or C4-14 alkylencycloalkyl; alternatively R₃ and one of R₁ and R₂ are combined with the atoms to which they are attached to form a C3-12 heterocycloalkyl, said C3-12 heterocycloalkyl being further optionally substituted with a substituent selected from halogen, (O), CN, C1-8 alkoxy, C1-8 alkylamino, C1-8 alkylsulfonyl, CO₂R₄, C(O)N(R₄)₂, OR₄, N(R₄)₂, NO₂, SR₄, SO₂R₄, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 haloalkenyl, C2-6 alkynyl, C2-6 haloalkynyl, C3-6 cycloalkyl and C3-6 heterocycloalkyl including 1 or 2 ring heteromoieties selected from O, S, N, S(O), SO₂ and NR₄; each R₄ is independently selected from hydrogen, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 haloalkenyl, C2-6 alkynyl, C2-6 haloalkynyl, C3-7 cycloalkyl, and C3-7

heterocycloalkyl including 1 or 2 ring heteromoieties selected from O, S, S(O), SO₂, N and NR₅, said C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 haloalkenyl, C2-6 alkynyl, C2-6 haloalkynyl, C3-7 cycloalkyl and C3-7 heterocycloalkyl each being optionally substituted with one or more substituents independently selected from halogen, CN, C1-8 alkoxy, C1-8 alkylamino, C1-8 alkylsulfonyl, CO₂R₅, C(O)N(R₅)₂, OR₅, N(R₅)₂, NO₂, SR₅ and SO₂R₅, said C3-C7 cycloalkyl and C3-7 heterocycloalkyl each being further optionally substituted with a substituent independently selected from (O), C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 haloalkenyl, C2-6 alkynyl, C2-6 haloalkynyl, C3-6 cycloalkyl and C3-6 heterocycloalkyl including 1 or 2 ring heteromoieties selected from O, S, S(O), SO₂, N and NR₅; each R₅ is independently selected from hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-8 cycloalkyl, C5-10

heterocycloalkyl, C6-12 aryl and C5-10 heteroaryl, said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-8 cycloalkyl, C5-10 heterocycloalkyl, C6-12 aryl and C5-10 heteroaryl each being optionally substituted with one or more substituents independently selected from halogen, CN, C1-8 alkoxy, C1-8 alkylamino, C1-8 alkylsulfonyl, CO₂H, CO₂CH₃, C(O)NH₂, C(O)N(CH₃)₂, C(O)NHCH₃, OH, NH₂, N(CH₃)₂, NHCH₃, NO₂, SH, SCH₃, SO₂CH₃, SOCH₃, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 haloalkenyl, C2-6 alkynyl, C2-6 haloalkynyl, C3-6 cycloalkyl and C3-6 heterocycloalkyl including 1 or 2 ring heteromoieties selected from O, S, S(O), SO₂, N, NH and NCH₃; L is selected from C1-4 alkylene, C2-C4 alkenylene and C2-C4 alkynylene; R₆ is selected from hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkyleneP(O)(OR₁₂)₂, C(O)R₁₂, CO₂R₁₂, C(O)N(R₁₂)₂, S(O)R₁₂ and SO₂R₁₂, C3-6 cycloalkyl, C6-9

alkylenecycloalkyl, C3-6 heterocyclyl, C6-9 alkyleneheterocycloalkyl, C4-7 heterocyclyl, C7-10

alkyneneheterocycloalkyl, C6-12 aryl, C7-18 alkylenearyl, C5-10 heteroaryl, and C6-16 alkyleneheteroaryl, said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, C6-9 alkylenecycloalkyl, C3-6 heterocyclyl, C6-9 alkyleneheterocycloalkyl, C4-7 heterocyclyl, C7-10

alkyneneheterocycloalkyl, C6-12 aryl, C7-18 alkylenearyl, C5-10 heteroaryl, and C6-16 alkyleneheteroaryl each being optionally substituted with one or more substituents independently selected from halogen, CN, C1-8 alkoxy, C1-8 alkylamino, C1-8 alkylsulfonyl, CO₂R₁₂, C(O)N(R₁₂)₂, OR₁₂, N(R₁₂)₂, NO₂, SR₁₂ and SO₂R₁₂, said C3-6 cycloalkyl, C6-9

alkylenecycloalkyl, C3-6 heterocyclyl, C6-9 alkyleneheterocycloalkyl, C4-7 heterocyclyl, C7-10

alkyneneheterocycloalkyl, C6-12 aryl, C7-18 alkylenearyl, C5-10 heteroaryl, and C6-16 alkyleneheteroaryl each being further optionally substituted with a substituent

independently selected from (O), C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 haloalkenyl, C2-6 alkynyl, C2-6 haloalkynyl, C3-6 cycloalkyl and C3-6 heterocycloalkyl including 1 or 2 ring heteromoieties selected from O, S, N, S(O), SO₂ and NR₁₂; each R₁₂ is independently selected from hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-8 cycloalkyl, C4-14 alkylencycloalkyl, C3-10 heterocycloalkyl, C4-16 alkyleneheterocycloalkyl, C6-12 aryl, C7-18 alkylenearyl, C5-10 heteroaryl, and C6-16 alkyleneheteroaryl, said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-8 cycloalkyl, C4-14 alkylencycloalkyl, C3-10 heterocycloalkyl, C4-16 alkyleneheterocycloalkyl, C6-12 aryl, C7-18 alkylenearyl, C5-10 heteroaryl, and C6-16 alkyleneheteroaryl each being optionally substituted with one or more substituents independently selected from halogen, CN, C1-8 alkoxy, C1-8 alkylamino, C1-8 alkylsulfonyl, CO₂H, CO₂CH₃, C(O)NH₂,

C(O)N(CH₃)₂,
C(O)NHCH₃, OH,
NH₂, N(CH₃)₂,
NHCH₃, NO₂, SH,
SCH₃, SO₂CH₃,
SOCH₃, C1-6 alkyl,
C1-6 haloalkyl, C2-6
alkenyl, C2-6
haloalkenyl, C2-6
alkynyl, C2-6
haloalkynyl, C3-6
cycloalkyl and C3-6
heterocycloalkyl
including 1 or 2 ring
heteromoieties selected
from O, S, S(O), SO₂,
N, NH and NCH₃;
wherein one of (B) and
(C) apply:
(B)
(i) one of R₇, R₈, R₉,
R₁₀ and R₁₁ is selected
from OR₁₃, N(R₁₃)₂,
SR₁₃, C1-6 alkyl, C1-6
haloalkyl, C2-6 alkenyl,
C2-C6 haloalkenyl, C2-
6 alkynyl, C2-6
haloalkynyl, C1-6
alkylamine, C1-6
alkoxy, C1-6
haloalkoxy, CO₂R₁₃,
C(O)R₁₃,
C(O)N(R₁₃)₂,
C(O)C(O)N(R₁₃)₂,
OC(O)R₁₃,
OC(O)OR₁₃,
OC(O)N(R₁₃)₂,
OS(O)R₁₃,
OS(O)N(R₁₃)₂,
OSO₂R₁₃,
OP(O)(OR₁₃)₂, OC1-
6alkyleneP(O)(OR₁₃)₂,
S(O)R₁₃,
S(O)N(R₁₃)₂,
SO₂R₁₃, N(R₁₃)₂,
N(R₁₃)C(O)R₁₃,
N(R₁₃)C(O)OR₁₃,
N(R₁₃)C(O)N(R₁₃)₂,
NO₂, C3-8 cycloalkyl,


<p>C3-14 alkylenecycloalkyl, C3-10 heterocycloalkyl, C4-16 alkyleneheterocycloalkyl, C6-12 aryl, C7-18 alkylenearyl, C5-10 heteroaryl, C4-16 alkyleneheteroaryl, said C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-C6 haloalkenyl, C2-6 alkynyl, C2-6 haloalkynyl, C1-6 alkylamine, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, C3-14 alkylenecycloalkyl, C3-10 heterocycloalkyl, C4-16 alkyleneheterocycloalkyl, C6-12 aryl, C7-18 alkylenearyl, C5-10 heteroaryl, and C4-16 alkyleneheteroaryl being optionally substituted with one or more substituents independently selected from halogen, CN, C1-8 alkoxy, C1-8 alkylamino, C1-8 alkylsulfonyl, CO₂R₁₃, C(O)N(R₁₃)₂, OR₁₃, N(R₁₃)₂, NO₂, SR₁₃ and SO₂R₁₃, said C3-8 cycloalkyl, C3-14 alkylenecycloalkyl, C3-10 heterocycloalkyl, C4-16 alkyleneheterocycloalkyl, C6-12 aryl, C7-18 alkylenearyl, C5-10 heteroaryl, and C4-16 alkyleneheteroaryl each being further optionally substituted with a</p>	
--	--

substituent selected from (O), C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 haloalkenyl, C2-6 alkynyl, C2-6 haloalkynyl, C3-6cycloalkyl and C3-6 heterocycloalkyl including 1 or 2 ring heteromoeities selected from O, S, S(O), SO₂, N, and NR₁₃; each R₁₃ is independently selected from hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-8 cycloalkyl, C4-14 alkylencycloalkyl, C3-10 heterocycloalkyl, C4-16 alkyleneheterocycloalkyl, C6-12 aryl, C7-18 alkylenearyl, C5-10 heteroaryl, and C6-16 alkyleneheteroaryl, said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-8 cycloalkyl, C4-14 alkylencycloalkyl, C3-10 heterocycloalkyl, C4-16 alkyleneheterocycloalkyl, C6-12 aryl, C7-18 alkylenearyl, C5-10 heteroaryl, and C6-16 alkyleneheteroaryl each being optionally substituted with one or more substituents independently selected from halogen, CN, C1-8 alkoxy, C1-8 alkylamino, C1-8alkylsulfonyl, CO₂H, CO₂CH₃, C(O)NH₂,


C(O)N(CH₃)₂,
C(O)NHCH₃, OH,
NH₂, N(CH₃)₂,
NHCH₃, NO₂, SH,
SCH₃, SO₂CH₃,
SOCH₃, C1-6 alkyl,
C1-6 haloalkyl, C2-6
alkenyl, C2-6
haloalkenyl, C2-6
alkynyl, C2-6
haloalkynyl, C3-6
cycloalkyl and C3-6
heterocycloalkyl
including 1 or 2 ring
heteromoieties selected
from O, S, S(O), SO₂,
N, NH and NCH₃; and
(ii) the other of R₇, R₈,
R₉, R₁₀ and R₁₁ are
each hydrogen,
alternatively, R₆ and
R₇ are combined with
the atoms to which they
are each attached to
form a C₄₋₁₀
heterocycloalkyl or a
C₅₋₁₀ heteroaryl,
said C₄₋₁₀
heterocycloalkyl and
C₅₋₁₀ heteroaryl each
being further optionally
substituted with a
substituent selected
from halogen, (O), CN,
C1-8 alkoxy, C1-8
alkylamino, C1-8
alkylsulfonyl, CO₂R₁₄,
C(O)N(R₁₄)₂, OR₁₄,
N(R₁₄)₂, NO₂, SR₁₄,
SO₂R₁₄, C1-6 alkyl,
C1-6 haloalkyl, C2-6
alkenyl, C2-6
haloalkenyl, C2-6
alkynyl, C2-6
haloalkynyl, C3-6
cycloalkyl and C3-6
heterocycloalkyl
including 1 or 2 ring
heteromoieties selected

from O, S, N, S(O), SO₂ and NR₁₄; alternatively, R₇ and one of R₁, R₂, or R₃ are combined with the atoms to which they are attached to form a C₅₋₈ heterocycloalkyl, said C₅₋₈ heterocycloalkyl being further optionally substituted with one or more substituents selected from halogen, (O), CN, C₁₋₈ alkoxy, C₁₋₈ alkylamino, C₁₋₈ alkylsulfonyl, CO₂R₁₄, C(O)N(R₁₄)₂, OR₁₄, N(R₁₄)₂, NO₂, SR₁₄, SO₂R₁₄, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ haloalkenyl, C₂₋₆ alkynyl, C₂₋₆ haloalkynyl, C₃₋₆ cycloalkyl and C₃₋₆ heterocycloalkyl including 1 or 2 ring heteromoieties selected from O, S, N, S(O), SO₂ and NR₁₄; each R₁₄ is independently selected from hydrogen, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₆₋₁₂ aryl and C₅₋₁₀ heteroaryl, said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₆₋₁₂ aryl and C₅₋₁₀ heteroaryl each being optionally substituted


with one or more substituents independently selected from halogen, CN, C1-8 alkoxy, C1-8 alkylamino, C1-8 alkylsulfonyl, CO₂H, CO₂CH₃, C(O)NH₂, C(O)N(CH₃)₂, C(O)NHCH₃, OH, NH₂, N(CH₃)₂, NHCH₃, NO₂, SH, SCH₃, SO₂CH₃, SOCH₃, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 haloalkenyl, C2-6 alkynyl, C2-6 haloalkynyl, C3-6 cycloalkyl and C3-6 heterocycloalkyl including 1 or 2 ring heteromoieties selected from O, S, S(O), SO₂, N, NH and NCH₃;
wherein:
when R₁ and R₂ are each methyl, and R₃ and R₆ are each hydrogen, then R₈ is not OH or OCH₃ and R₉ is not OH;
when R₁ and R₂ are each ethyl, isobutyl or (sec)butyl, and R₃ and R₆ are each hydrogen, then R₈ is not OH;
when R₁ and R₂ are each isopropyl, and R₃ and R₆ are each hydrogen, then R₉ is not OH;
when R₁ and R₂ together with the nitrogen to which they are attached form




and R3 and R6 are each hydrogen, then R9 is not OCH3;
when R1 and R2 together with the nitrogen to which they are attached form



and R3 and R6 are each hydrogen, then R8 is not OH;
when R1 and R2 together with the nitrogen to which they are attached form




and R3 and R6 are each hydrogen, then R8 is not OH, R9 is not CH3 or OCH3, and R10 is not OCH3;
when R1 and R2 together with the nitrogen to which they are attached form any one of



is hydrogen, and R6 is methyl, then R8 is not OH;
when R1 and R2 are each methyl, R3 is


hydrogen, and R6 is selected from ethyl, CH₂CHF₂, propyl, isopropyl, butyl, cyclopropyl, methylenecyclopropyl, cyclobutyl, oxetanyl and butenyl, then R8 is not OH;

when R1 and R2 are each methyl, R3 is hydrogen, and R6 is hydrogen or CH₂P(O)(OH)₂, then R8 is not selected from




and OC(O)N(CH₃)₂; and

when R1, R2 and R3 together with the atoms to which they are attached form




and R6 is hydrogen or CH₂P(O)(OH)₂, then R8 is not selected from



and OC(O)N(CH₃)₂; (C) R7, R8, R9, R10 and R11 are each hydrogen,

wherein:
when R6 and R3 are each hydrogen, then R1 and R2 are not each methyl, and R1 and R2 together with the nitrogen to which they are attached do not form




pyrrolidyl, piperidyl or 2,5-dimethylpyrrolyl; and

when R6 is hydrogen, and R3 is methyl, then R1 and R2 are not each hydrogen.

23. The method of claim 22, wherein:
(i) one of R7, R8, R9, R10 and R11 is selected from OR13, N(R13)2, SR13, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-C6 haloalkenyl, C2-6 alkynyl, C2-6 haloalkynyl, C1-6 alkylamine, C1-6 alkoxy, C1-6 haloalkoxy, CO2R13, C(O)R13, C(O)N(R13)2, C(O)C(O)N(R13)2, OC(O)R13, OC(O)OR13, OC(O)N(R13)2, OS(O)R13, OS(O)N(R13)2, OSO2R13, OP(O)(OR13)2, OC1-6alkyleneP(O)(OR13)2, S(O)R13, S(O)N(R13)2, SO2R13, N(R13)2, N(R13)C(O)R13, N(R13)C(O)OR13,

1. Int'l Pat. App. Pub. No. WO/2018/064465 "Compounds for increasing neural plasticity" (Published April 5, 2018)

From Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa or IIb:



wherein:

L3 is a bond, -C(O)NRb-, -NRbC(O)-, -NHC(O)NRb-, -C(O)O-, -OC(O)-, -NHC(O)O-, -SO2NRb-, -NHSO2-, -SO2-, -O-, -S-, or -NRb-; R8 is hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 alkoxy, C1-C6 aminoalkyl, heterocycloalkyl, aryl, or heteroaryl;

Rb is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or C1-C6 alkoxy;

R9 is hydrogen, C1-C6 alkyl, or C2-C6 alkenyl;

R10 is hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, or C1-C6 haloalkyl;

R11 is C1-C6 alkylamino, di-(C1-C6 alkyl)amino, N-(C1-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl;

R12 is hydrogen, halogen, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or C1-C6 alkoxy;

subscript p is an integer from 0 to 3;

subscript q is an integer from 0 to 3; and


subscript r is an integer from 1 to 3.

N(R13)C(O)N(R13)2, NO2, C3-8 cycloalkyl, C3-14 alkylencycloalkyl, C3-10 heterocycloalkyl, C4-16 alkyleneheterocycloalkyl, C6-12 aryl, C7-18 alkylenearyl, C5-10 heteroaryl, C4-16 alkyleneheteroaryl, said C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-C6 haloalkenyl, C2-6 alkynyl, C2-6 haloalkynyl, C1-6 alkylamine, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, C3-14 alkylencycloalkyl, C3-10 heterocycloalkyl, C4-16 alkyleneheterocycloalkyl, C6-12 aryl, C7-18 alkylenearyl, C5-10 heteroaryl, and C4-16 alkyleneheteroaryl being optionally substituted with one or more substituents independently selected from halogen, CN, C1-8 alkoxy, C1-8 alkylamino, C1-8 alkylsulfonyl, CO2R13, C(O)N(R13)2, OR13, N(R13)2, NO2, SR13 and SO2R13, said C3-8 cycloalkyl, C3-14 alkylencycloalkyl, C3-10 heterocycloalkyl, C4-16 alkyleneheterocycloalkyl, C6-12 aryl, C7-18 alkylenearyl, C5-10 heteroaryl, and C4-16 alkyleneheteroaryl each

From [0016]: **The present invention provides a method of using non-hallucinogenic analogs of psychedelic compounds for treatment of a brain disorder. The brain disorder can be a psychiatric disorder including depression, anxiety, and/or post-traumatic stress disorder.**

3. Int'l Pat. App. Pub. No. WO/2020/176599 "Azepino-indoles and other heterocycles for treating brain disorders" (Published September 3, 2020)

From Claim 1: **A compound of Formula I:**



wherein:

R1 is hydrogen or C1-6 alkyl;

R3a and R3b are each independently hydrogen, C1-6 alkyl, C3-8 cycloalkyl, or C4-14 alkyl-cycloalkyl;

R3c is hydrogen or C1-6 alkyl;

R4, R5, R6 and R7 are each independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, C1-6 haloalkyl, C1-6 alkylamine, C1-6 alkoxy, C1-6 haloalkoxy, -OR8a, -NO2, -CN, -C(O)R8b, -C(O)OR8b, -OC(O)R8b, -OC(O)OR8b, -

S(O)2N(R8bR8c), C3-8 cycloalkyl, C3-14 alkyl-cycloalkyl, C4-10 heterocycloalkyl, C4-16 alkyl-heterocycloalkyl, C6-12 aryl, C7-18 alkyl-aryl, C5-10 heteroaryl, or C4-16 alkyl-heteroaryl, wherein at least one of R4, R5, R6 and R7 is not H; alternatively, R4 and R5, R5 and R6, or R6 and R7 are combined with the atoms to which they are each attached to form a C3-6 cycloalkyl, C3-6 heterocycloalkyl, C6-12 aryl or C5-10 heteroaryl;

R8a, R8b, R8c...are each independently H, C1-6 alkyl;


From [0068]: **"Brain disorder" refers to a neurological disorder which affects the brain's structure and function. Brain disorders can include, but are not limited to, Alzheimer's, Parkinson's disease, psychological disorder, depression, treatment resistant depression, addiction, anxiety, post-traumatic stress disorder, suicidal ideation, major depressive disorder, bipolar disorder, schizophrenia, stroke, traumatic brain injury, and substance use disorder.**

being further optionally substituted with a substituent selected from (O), C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 haloalkenyl, C2-6 alkynyl, C2-6 haloalkynyl, C3-6cycloalkyl and C3-6 heterocycloalkyl including 1 or 2 ring heteromoeities selected from O, S, S(O), SO₂, N, and NR₁₃; each R₁₃ is independently selected from hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-8 cycloalkyl, C4-14 alkylencycloalkyl, C3-10 heterocycloalkyl, C4-16 alkyleneheterocycloalkyl, C6-12 aryl, C7-18 alkylenearyl, C5-10 heteroaryl, and C6-16 alkyleneheteroaryl, said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-8 cycloalkyl, C4-14 alkylencycloalkyl, C3-10 heterocycloalkyl, C4-16 alkyleneheterocycloalkyl, C6-12 aryl, C7-18 alkylenearyl, C5-10 heteroaryl, and C6-16 alkyleneheteroaryl each being optionally substituted with one or more substituents independently selected from halogen, CN, C1-8 alkoxy, C1-8 alkylamino, C1-

8alkylsulfonyl, CO₂H, CO₂CH₃, C(O)NH₂, C(O)N(CH₃)₂, C(O)NHCH₃, OH, NH₂, N(CH₃)₂, NHCH₃, NO₂, SH, SCH₃, SO₂CH₃, SOCH₃, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 haloalkenyl, C2-6 alkynyl, C2-6 haloalkynyl, C3-6 cycloalkyl and C3-6 heterocycloalkyl including 1 or 2 ring heteromoieties selected from O, S, S(O), SO₂, N, NH and NCH₃; and (ii) the other of R₇, R₈, R₉, R₁₀ and R₁₁ are each hydrogen, alternatively, R₆ and R₇ are combined with the atoms to which they are each attached to form a C₄₋₁₀ heterocycloalkyl or a C₅₋₁₀ heteroaryl, said C₄₋₁₀ heterocycloalkyl and C₅₋₁₀ heteroaryl each being further optionally substituted with a substituent selected from halogen, (O), CN, C₁₋₈ alkoxy, C₁₋₈ alkylamino, C₁₋₈ alkylsulfonyl, CO₂R₁₄, C(O)N(R₁₄)₂, OR₁₄, N(R₁₄)₂, NO₂, SR₁₄, SO₂R₁₄, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 haloalkenyl, C2-6 alkynyl, C2-6 haloalkynyl, C3-6 cycloalkyl and C3-6 heterocycloalkyl


including 1 or 2 ring heteromoieties selected from O, S, N, S(O), SO₂ and NR₁₄;
alternatively, R₇ and one of R₁, R₂, or R₃ are combined with the atoms to which they are attached to form a C₅-8 heterocycloalkyl, said C₅-8 heterocyclyalkyl being further optionally substituted with one or more substituents selected from halogen, (O), CN, C₁-8 alkoxy, C₁-8 alkylamino, C₁-8 alkylsulfonyl, CO₂R₁₄, C(O)N(R₁₄)₂, OR₁₄, N(R₁₄)₂, NO₂, SR₁₄, SO₂R₁₄, C₁-6 alkyl, C₁-6 haloalkyl, C₂-6 alkenyl, C₂-6 haloalkenyl, C₂-6 alkynyl, C₂-6 haloalkynyl, C₃-6 cycloalkyl and C₃-6 heterocycloalkyl including 1 or 2 ring heteromoieties selected from O, S, N, S(O), SO₂ and NR₁₄;
each R₁₄ is independently selected from hydrogen, C₁-6 alkyl, C₂-C₆ alkenyl, C₂-C₆alkynyl, C₁-C₆ haloalkyl, C₃-C₇cycloalkyl, C₃-10 heterocycloalkyl, C₆-12 aryl and C₅-10 heteroaryl;
said C₁-6 alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₃-C₇cycloalkyl, C₃-10 heterocycloalkyl, C₆-12 aryl and C₅-10

heteroaryl each being optionally substituted with one or more substituents independently selected from halogen, CN, C1-8 alkoxy, C1-8 alkylamino, C1-8 alkylsulfonyl, CO₂H, CO₂CH₃, C(O)NH₂, C(O)N(CH₃)₂, C(O)NHCH₃, OH, NH₂, N(CH₃)₂, NHCH₃, NO₂, SH, SCH₃, SO₂CH₃, SOCH₃, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 haloalkenyl, C2-6 alkynyl, C2-6 haloalkynyl, C3-6 cycloalkyl and C3-6 heterocycloalkyl including 1 or 2 ring heteromoieties selected from O, S, S(O), SO₂, N, NH and NCH₃;
wherein:
when R₁ and R₂ are each methyl, and R₃ and R₆ are each hydrogen, then R₈ is not OH or OCH₃ and R₉ is not OH;
when R₁ and R₂ are each ethyl, isobutyl or (sec)butyl, and R₃ and R₆ are each hydrogen, then R₈ is not OH;
when R₁ and R₂ are each isopropyl, and R₃ and R₆ are each hydrogen, then R₉ is not OH;
when R₁ and R₂ together with the nitrogen to which they are attached form




and R3 and R6 are each hydrogen, then R9 is not OCH3;

when R1 and R2 together with the nitrogen to which they are attached form




and R3 and R6 are each hydrogen, then R8 is not OH;

when R1 and R2 together with the nitrogen to which they are attached form



and R3 and R6 are each hydrogen, then R8 is not OH, R9 is not CH3 or OCH3, and R10 is not OCH3;


when R1 and R2 together with the nitrogen to which they are attached form any one of




is hydrogen, and R6 is methyl, then R8 is not OH;

when R1 and R2 are each methyl, R3 is


hydrogen, and R6 is selected from ethyl, CH₂CHF₂, propyl, isopropyl, butyl, cyclopropyl, methylenecyclopropyl, cyclobutyl, oxetanyl and butenyl, then R8 is not OH;
 when R1 and R2 are each methyl, R3 is hydrogen, and R6 is hydrogen or CH₂P(O)(OH)₂, then R8 is not selected from



and OC(O)N(CH₃)₂;
 and
 when R1, R2 and R3 together with the atoms to which they are attached form



and R6 is hydrogen or CH₂P(O)(OH)₂, then R8 is not selected from




and OC(O)N(CH₃)₂.

24. The method of claim 23, wherein:

1. Int'l Pat. App. Pub. No. WO/2018/064465 "Compounds for increasing neural plasticity" (Published April 5, 2018)

(i) one of R7, R8, R9, R10 and R11 is selected from OR13, N(R13)2, SR13, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-C6 haloalkenyl, C2-6 alkynyl, C2-6 haloalkynyl, C1-6 alkylamine, C1-6 alkoxy, C1-6 haloalkoxy, CO2R13, C(O)R13, C(O)N(R13)2, C(O)C(O)N(R13)2, OC(O)R13, OC(O)OR13, OC(O)N(R13)2, OS(O)R13, OS(O)N(R13)2, OSO2R13, OP(O)(OR13)2, OC1-6alkyleneP(O)(OR13)2, S(O)R13, S(O)N(R13)2, SO2R13, N(R13)2, N(R13)C(O)R13, N(R13)C(O)OR13, N(R13)C(O)N(R13)2, NO2, C3-8 cycloalkyl, C3-14 alkylencycloalkyl, C3-10 heterocycloalkyl, C4-16 alkyleneheterocycloalkyl, C6-12 aryl, C7-18 alkylenearyl, C5-10 heteroaryl, C4-16 alkyleneheteroaryl, said C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-C6 haloalkenyl, C2-6 alkynyl, C2-6 haloalkynyl, C1-6 alkylamine, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, C3-14 alkylencycloalkyl, C3-10 heterocycloalkyl,

From **Claim 16**: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa or IIb:



wherein:

L3 is a bond, -C(O)NRb-, -NRbC(O)-, -NHC(O)NRb-, -C(O)O-, -OC(O)-, -NHC(O)O-, -SO2NRb-, -NHSO2-, -SO2-, -O-, -S-, or -NRb-; **R8** is hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 alkoxy, C1-C6 aminoalkyl, heterocycloalkyl, aryl, or heteroaryl;

Rb is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or C1-C6 alkoxy;

R9 is hydrogen, C1-C6 alkyl, or C2-C6 alkenyl;

R10 is hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, or C1-C6 haloalkyl;

R11 is C1-C6 alkylamino, di-(C1-C6 alkyl)amino, N-(C1-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl;

R12 is hydrogen, halogen, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or C1-C6 alkoxy;

subscript **p** is an integer from 0 to 3;


subscript **q** is an integer from 0 to 3; and

subscript **r** is an integer from 1 to 3.

From [0016]: The present invention provides a method of using non-hallucinogenic analogs of psychedelic compounds for treatment of a brain disorder. The brain disorder can be a psychiatric disorder including depression, anxiety, and/or post-traumatic stress disorder.

3. Int'l Pat. App. Pub. No. WO/2020/176599 "Azepino-indoles and other heterocycles for treating brain disorders" (Published September 3, 2020)

From **Claim 1**: A compound of Formula I:



wherein:

R1 is hydrogen or C1-6 alkyl;

R3a and **R3b** are each independently hydrogen, C1-6 alkyl, C3-8 cycloalkyl, or C4-14 alkyl-cycloalkyl;

R3c is hydrogen or C1-6 alkyl;

<p>C4-16 alkyleneheterocycloalkyl, C6-12 aryl, C7-18 alkylenearyl, C5-10 heteroaryl, and C4-16 alkyleneheteroaryl being optionally substituted with one or more substituents independently selected from halogen, CN, C1-8 alkoxy, C1-8 alkylamino, C1-8 alkylsulfonyl, CO2R13, C(O)N(R13)2, OR13, N(R13)2, NO2, SR13 and SO2R13, said C3-8 cycloalkyl, C3-14 alkylencycloalkyl, C3-10 heterocycloalkyl, C4-16 alkyleneheterocycloalkyl, C6-12 aryl, C7-18 alkylenearyl, C5-10 heteroaryl, and C4-16 alkyleneheteroaryl each being further optionally substituted with a substituent selected from (O), C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 haloalkenyl, C2-6 alkynyl, C2-6 haloalkynyl, C3-6cycloalkyl and C3-6 heterocycloalkyl including 1 or 2 ring heteromoeities selected from O, S, S(O), SO2, N, and NR13; each R13 is independently selected from hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-8 cycloalkyl, C4-14</p>	<p>R4, R5, R6 and R7 are each independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, C1-6 haloalkyl, C1-6 alkylamine, C1-6 alkoxy, C1-6 haloalkoxy, -OR8a, -NO2, -CN, -C(O)R8b, -C(O)OR8b, -OC(O)R8b, -OC(O)OR8b, -S(O)2N(R8bR8c), C3-8 cycloalkyl, C3-14 alkyl-cycloalkyl, C4-10 heterocycloalkyl, C4-16 alkyl-heterocycloalkyl, C6-12 aryl, C7-18 alkyl-aryl, C5-10 heteroaryl, or C4-16 alkyl-heteroaryl, wherein at least one of R4, R5, R6 and R7 is not H; alternatively, R4 and R5, R5 and R6, or R6 and R7 are combined with the atoms to which they are each attached to form a C3-6 cycloalkyl, C3-6 heterocycloalkyl, C6-12 aryl or C5-10 heteroaryl; R8a, R8b, R8c...are each independently H, C1-6 alkyl;</p> <p>From [0068]: “Brain disorder” refers to a neurological disorder which affects the brain’s structure and function. Brain disorders can include, but are not limited to, Alzheimer’s, Parkinson’s disease, psychological disorder, depression, treatment resistant depression, addiction, anxiety, post-traumatic stress disorder, suicidal ideation, major depressive disorder, bipolar disorder, schizophrenia, stroke, traumatic brain injury, and substance use disorder.</p>
--	---

alkylenecycloalkyl, C3-10 heterocycloalkyl, C4-16
alkyleneheterocycloalkyl, C6-12 aryl, C7-18
alkylenearyl, C5-10 heteroaryl, and C6-16
alkyleneheteroaryl, said C1-6 alkyl, C2-6
alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-8
cycloalkyl, C4-14
alkylenecycloalkyl, C3-10 heterocycloalkyl, C4-16
alkyleneheterocycloalkyl, C6-12 aryl, C7-18
alkylenearyl, C5-10 heteroaryl, and C6-16
alkyleneheteroaryl each being optionally
substituted with one or more substituents
independently selected from halogen, CN, C1-8
alkoxy, C1-8 alkylamino, C1-8alkylsulfonyl, CO₂H,
CO₂CH₃, C(O)NH₂, C(O)N(CH₃)₂,
C(O)NHCH₃, OH, NH₂, N(CH₃)₂,
NHCH₃, NO₂, SH, SCH₃, SO₂CH₃,
SOCH₃, C1-6 alkyl, C1-6 haloalkyl, C2-6
alkenyl, C2-6 haloalkenyl, C2-6
alkynyl, C2-6 haloalkynyl, C3-6
cycloalkyl and C3-6 heterocycloalkyl
including 1 or 2 ring heteromoieties selected
from O, S, S(O), SO₂, N, NH and NCH₃; and
(ii) the other of R7, R8, R9, R10 and R11 are
each hydrogen;


wherein:

when R1 and R2 are each methyl, and R3 and R6 are each hydrogen, then R8 is not OH or OCH3 and R9 is not OH;

when R1 and R2 are each ethyl, isobutyl or (sec)butyl, and R3 and R6 are each hydrogen, then R8 is not OH;


when R1 and R2 are each isopropyl, and R3 and R6 are each hydrogen, then R9 is not OH;

when R1 and R2 together with the nitrogen to which they are attached form




and R3 and R6 are each hydrogen, then R9 is not OCH3;

when R1 and R2 together with the nitrogen to which they are attached form




and R3 and R6 are each hydrogen, then R8 is not OH;


when R1 and R2 together with the nitrogen to which they are attached form



when R1, R2 and R3 together with the atoms to which they are attached form



and R6 is hydrogen or CH₂P(O)(OH)₂, then R8 is not




and OC(O)N(CH₃)₂.

25. The method of claim 24, wherein:
 (i) one of R7, R8, R9, R10 and R11 is selected from C1-6 haloalkyl and OC1-6 haloalkyl, and
 (ii) the other of R7, R8, R9, R10 and R11 are each hydrogen.

1. Int'l Pat. App. Pub. No. WO/2018/064465 "Compounds for increasing neural plasticity" (Published April 5, 2018)

From **Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa or IIb:**



wherein:

R9 is hydrogen, C1-C6 alkyl, or C2-C6 alkenyl;

R10 is hydrogen...C1-C6 haloalkyl;

R11 is C1-C6 alkylamino, di-(C1-C6 alkyl)amino, N-(C1-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl;

R12 is hydrogen...C1-C6 haloalkyl...

subscript p is an integer from 0 to 3;

subscript q is an integer from 0 to 3; and


subscript r is an integer from 1 to 3.

From [0016]: **The present invention provides a method of using non-hallucinogenic analogs of psychedelic compounds for treatment of a brain disorder. The brain disorder can be a psychiatric disorder including depression, anxiety, and/or post-traumatic stress disorder.**

26. The method of claim 22, wherein:


1. Int'l Pat. App. Pub. No. WO/2018/064465 "Compounds for increasing neural plasticity" (Published April 5, 2018)

R7, R8, R9, R10 and R11 are each hydrogen, wherein:
when R6 and R3 are each hydrogen, then R1 and R2 are not each methyl, and R1 and R2 together with the nitrogen to which they are attached do not form



pyrrolidyl, piperidyl or 2,5-dimethylpyrrolyl; and
when R6 is hydrogen, and R3 is methyl, then R1 and R2 are not each hydrogen.

From Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa or IIb:



wherein:

L3 is a bond...

R8 is hydrogen...

R9 is hydrogen, C1-C6 alkyl, or C2-C6 alkenyl;

R10 is hydrogen...

R11 is C1-C6 alkylamino, di-(C1-C6 alkyl)amino, N-(C1-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl;

R12 is hydrogen


subscript p is an integer from 0 to 3;

subscript q is an integer from 0 to 3; and

From [0016]: The present invention provides a method of using non-hallucinogenic analogs of psychedelic compounds for treatment of a brain disorder. The brain disorder can be a psychiatric disorder including depression, anxiety, and/or post-traumatic stress disorder.

3. Int'l Pat. App. Pub. No. WO/2020/176599 "Azepino-indoles and other heterocycles for treating brain disorders" (Published September 3, 2020)

From Claim 1: A compound of Formula I:



wherein:


R1 is hydrogen or C1-6 alkyl;


R3a and R3b are each independently hydrogen, C1-6 alkyl, C3-8 cycloalkyl, or C4-14 alkyl-cycloalkyl;

R3c is hydrogen or C1-6 alkyl;

R4, R5, R6 and R7 are each independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, C1-6 haloalkyl, C1-6 alkylamine, C1-6 alkoxy, C1-6 haloalkoxy, -OR8a, -NO2, -CN, -C(O)R8b, -C(O)OR8b, -OC(O)R8b, -OC(O)OR8b, -

S(O)2N(R8bR8c), C3-8 cycloalkyl, C3-14 alkyl-cycloalkyl, C4-10 heterocycloalkyl, C4-16 alkyl-heterocycloalkyl, C6-12 aryl, C7-18 alkyl-aryl, C5-10 heteroaryl, or C4-16 alkyl-heteroaryl, wherein at least one of R4, R5, R6 and R7 is not H; alternatively, R4 and R5, R5 and R6, or

	<p>R6 and R7 are combined with the atoms to which they are each attached to form a C3-6 cycloalkyl, C3-6 heterocycloalkyl, C6-12 aryl or C5-10 heteroaryl; R8a, R8b, R8c...are each independently H, C1-6 alkyl;</p> <p>From [0068]: “Brain disorder” refers to a neurological disorder which affects the brain’s structure and function. Brain disorders can include, but are not limited to, Alzheimer’s, Parkinson’s disease, psychological disorder, depression, treatment resistant depression, addiction, anxiety, post-traumatic stress disorder, suicidal ideation, major depressive disorder, bipolar disorder, schizophrenia, stroke, traumatic brain injury, and substance use disorder.</p>
<p>27. The method of any one of claims 22 to 26, wherein R1 and R2 are each independently selected from C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 haloalkenyl, C2-6 alkynyl, C2-6 haloalkynyl, C3-8 cycloalkyl and C4-14 alkylencycloalkyl.</p>	<p>1. Int’l Pat. App. Pub. No. WO/2018/064465 “Compounds for increasing neural plasticity” (Published April 5, 2018)</p> <p>From Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa or IIb:</p> <div style="text-align: center;">  <p>(IIa)</p> </div> <p>wherein: L3 is a bond... R8 is hydrogen... R9 is hydrogen, C1-C6 alkyl, or C2-C6 alkenyl; R10 is hydrogen... R11 is C1-C6 alkylamino, di-(C1-C6 alkyl)amino, N-(C1-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl; R12 is hydrogen subscript p is an integer from 0 to 3; subscript q is an integer from 0 to 3; and</p> <p>From [0016]: The present invention provides a method of using non-hallucinogenic analogs of psychedelic compounds for treatment of a brain disorder. The brain disorder can be a psychiatric disorder including depression, anxiety, and/or post-traumatic stress disorder.</p> <p>3. Int’l Pat. App. Pub. No. WO/2020/176599 “Azepino-indoles and other heterocycles for treating brain disorders” (Published September 3, 2020)</p> <p>From Claim 1: A compound of Formula I:</p>



(I)

wherein:

R1 is hydrogen or C1-6 alkyl;

R3a and R3b are each independently hydrogen, C1-6 alkyl, C3-8 cycloalkyl, or C4-14 alkyl-cycloalkyl;

R3c is hydrogen or C1-6 alkyl;

R4, R5, R6 and R7 are each independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, C1-6 haloalkyl, C1-6 alkylamine, C1-6 alkoxy, C1-6 haloalkoxy, -OR8a, -NO2, -CN, -C(O)R8b, -C(O)OR8b, -OC(O)R8b, -OC(O)OR8b, -

S(O)2N(R8bR8c), C3-8 cycloalkyl, C3-14 alkyl-cycloalkyl, C4-10 heterocycloalkyl, C4-16 alkyl-heterocycloalkyl, C6-12 aryl, C7-18 alkyl-aryl, C5-10 heteroaryl, or C4-16 alkyl-heteroaryl, wherein at least one of R4, R5, R6 and R7 is not H; alternatively, R4 and R5, R5 and R6, or R6 and R7 are combined with the atoms to which they are each attached to form a C3-6 cycloalkyl, C3-6 heterocycloalkyl, C6-12 aryl or C5-10 heteroaryl;


R8a, R8b, R8c...are each independently H, C1-6 alkyl;

From [0068]: “Brain disorder” refers to a neurological disorder which affects the brain’s structure and function. Brain disorders can include, but are not limited to, Alzheimer’s, Parkinson’s disease, psychological disorder, depression, treatment resistant depression, addiction, anxiety, post-traumatic stress disorder, suicidal ideation, major depressive disorder, bipolar disorder, schizophrenia, stroke, traumatic brain injury, and substance use disorder.

28. The method of claim 27, wherein R1 and R2 are each independently selected from C1-4 alkyl.

1. Int’l Pat. App. Pub. No. WO/2018/064465 “Compounds for increasing neural plasticity” (Published April 5, 2018)

From Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa or IIb:



(IIa)

wherein:

L3 is a bond...

R8 is hydrogen...

R9 is hydrogen, C1-C6 alkyl, or C2-C6 alkenyl;

R10 is hydrogen...

R11 is C1-C6 alkylamino, di-(C1-C6 alkyl)amino, N-(C1-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl;

R12 is hydrogen


subscript p is an integer from 0 to 3;

subscript q is an integer from 0 to 3; and

From [0016]: The present invention provides a method of using non-hallucinogenic analogs of psychedelic compounds for treatment of a brain disorder. The brain disorder can be a psychiatric disorder including depression, anxiety, and/or post-traumatic stress disorder.

3. Int'l Pat. App. Pub. No. WO/2020/176599 "Azepino-indoles and other heterocycles for treating brain disorders" (Published September 3, 2020)

From Claim 1: A compound of Formula I:



wherein:

R1 is hydrogen or C1-6 alkyl;

R3a and R3b are each independently hydrogen, C1-6 alkyl, C3-8 cycloalkyl, or C4-14 alkyl-cycloalkyl;

R3c is hydrogen or C1-6 alkyl;


R4, R5, R6 and R7 are each independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, C1-6 haloalkyl, C1-6 alkylamine, C1-6 alkoxy, C1-6 haloalkoxy, -OR8a, -NO₂, -CN, -C(O)R8b, -C(O)OR8b, -OC(O)R8b, -OC(O)OR8b, -

S(O)₂N(R8bR8c), C3-8 cycloalkyl, C3-14 alkyl-cycloalkyl, C4-10 heterocycloalkyl, C4-16 alkyl-heterocycloalkyl, C6-12 aryl, C7-18 alkyl-aryl, C5-10 heteroaryl, or C4-16 alkyl-heteroaryl, wherein at least one of R4, R5, R6 and R7 is not H; alternatively, R4 and R5, R5 and R6, or R6 and R7 are combined with the atoms to which they are each attached to form a C3-6 cycloalkyl, C3-6 heterocycloalkyl, C6-12 aryl or C5-10 heteroaryl;

R8a, R8b, R8c...are each independently H, C1-6 alkyl;


From [0068]: "Brain disorder" refers to a neurological disorder which affects the brain's structure and function. Brain disorders can include, but are not limited to, Alzheimer's, Parkinson's disease, psychological disorder, depression, treatment resistant depression, addiction, anxiety, post-traumatic stress disorder, suicidal ideation, major depressive disorder, bipolar disorder, schizophrenia, stroke, traumatic brain injury, and substance use disorder.

29. The method of claim 28, wherein R1 and R2, together with the nitrogen to which they are attached, form any one of the following:



1. Int'l Pat. App. Pub. No. WO/2018/064465 "Compounds for increasing neural plasticity" (Published April 5, 2018)

From Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa or IIb:



wherein:

L³ is a bond...

R⁸ is hydrogen...

R⁹ is hydrogen, C1-C6 alkyl, or C2-C6 alkenyl;

R¹⁰ is hydrogen...

R¹¹ is C1-C6 alkylamino, di-(C1-C6 alkyl)amino, N-(C1-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl;

R¹² is hydrogen


subscript p is an integer from 0 to 3;

subscript q is an integer from 0 to 3; and

From [0016]: The present invention provides a method of using non-hallucinogenic analogs of psychedelic compounds for treatment of a brain disorder. The brain disorder can be a psychiatric disorder including depression, anxiety, and/or post-traumatic stress disorder.

3. Int'l Pat. App. Pub. No. WO/2020/176599 "Azepino-indoles and other heterocycles for treating brain disorders" (Published September 3, 2020)

From Claim 1: A compound of Formula I:



wherein:


R¹ is hydrogen or C1-6 alkyl;


R^{3a} and R^{3b} are each independently hydrogen, C1-6 alkyl, C3-8 cycloalkyl, or C4-14 alkyl-cycloalkyl;

R^{3c} is hydrogen or C1-6 alkyl;

R⁴, R⁵, R⁶ and R⁷ are each independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, C1-6 haloalkyl, C1-6 alkylamine, C1-6 alkoxy, C1-6 haloalkoxy, -OR^{8a}, -NO₂, -CN, -C(O)R^{8b}, -C(O)OR^{8b}, -OC(O)R^{8b}, -OC(O)OR^{8b}, -

S(O)₂N(R^{8b}R^{8c}), C3-8 cycloalkyl, C3-14 alkyl-cycloalkyl, C4-10 heterocycloalkyl, C4-16 alkyl-heterocycloalkyl, C6-12 aryl, C7-18 alkyl-

	<p>aryl, C5-10 heteroaryl, or C4- 16 alkyl-heteroaryl, wherein at least one of R4, R5, R6 and R7 is not H; alternatively, R4 and R5, R5 and R6, or R6 and R7 are combined with the atoms to which they are each attached to form a C3-6 cycloalkyl, C3-6 heterocycloalkyl, C6-12 aryl or C5-10 heteroaryl; R8a, R8b, R8c...are each independently H, C1-6 alkyl;</p> <p>From [0068]: “Brain disorder” refers to a neurological disorder which affects the brain’s structure and function. Brain disorders can include, but are not limited to, Alzheimer’s, Parkinson’s disease, psychological disorder, depression, treatment resistant depression, addiction, anxiety, post-traumatic stress disorder, suicidal ideation, major depressive disorder, bipolar disorder, schizophrenia, stroke, traumatic brain injury, and substance use disorder.</p>
<p>30. The method of any one of claims 22 to 29, wherein R3 is hydrogen.</p>	<p>1. Int’l Pat. App. Pub. No. WO/2018/064465 “Compounds for increasing neural plasticity” (Published April 5, 2018)</p> <p>From Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa or IIb:</p> <div style="text-align: center;">  <p>(IIa)</p> </div> <p>wherein: L3 is a bond... R8 is hydrogen... R9 is hydrogen, C1-C6 alkyl, or C2-C6 alkenyl; R10 is hydrogen... R11 is C1-C6 alkylamino, di-(C1-C6 alkyl)amino, N-(C1-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl; R12 is hydrogen subscript p is an integer from 0 to 3; subscript q is an integer from 0 to 3; and</p> <p>From [0016]: The present invention provides a method of using non-hallucinogenic analogs of psychedelic compounds for treatment of a brain disorder. The brain disorder can be a psychiatric disorder including depression, anxiety, and/or post-traumatic stress disorder.</p> <p>3. Int’l Pat. App. Pub. No. WO/2020/176599 “Azepino-indoles and other heterocycles for treating brain disorders” (Published September 3, 2020)</p> <p>From Claim 1: A compound of Formula I:</p>



(I)

wherein:

R1 is hydrogen or C1-6 alkyl;

R3a and R3b are each independently hydrogen, C1-6 alkyl, C3-8 cycloalkyl, or C4-14 alkyl-cycloalkyl;

R3c is hydrogen or C1-6 alkyl;

R4, R5, R6 and R7 are each independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, C1-6 haloalkyl, C1-6 alkylamine, C1-6 alkoxy, C1-6 haloalkoxy, -OR8a, -NO2, -CN, -C(O)R8b, -C(O)OR8b, -OC(O)R8b, -OC(O)OR8b, -

S(O)2N(R8bR8c), C3-8 cycloalkyl, C3-14 alkyl-cycloalkyl, C4-10 heterocycloalkyl, C4-16 alkyl-heterocycloalkyl, C6-12 aryl, C7-18 alkyl-aryl, C5-10 heteroaryl, or C4-16 alkyl-heteroaryl, wherein at least one of R4, R5, R6 and R7 is not H; alternatively, R4 and R5, R5 and R6, or R6 and R7 are combined with the atoms to which they are each attached to form a C3-6 cycloalkyl, C3-6 heterocycloalkyl, C6-12 aryl or C5-10 heteroaryl;


R8a, R8b, R8c...are each independently H, C1-6 alkyl;

From [0068]: “Brain disorder” refers to a neurological disorder which affects the brain’s structure and function. Brain disorders can include, but are not limited to, Alzheimer’s, Parkinson’s disease, psychological disorder, depression, treatment resistant depression, addiction, anxiety, post-traumatic stress disorder, suicidal ideation, major depressive disorder, bipolar disorder, schizophrenia, stroke, traumatic brain injury, and substance use disorder.

32. The method of claim 31, wherein L is methylene.

1. Int’l Pat. App. Pub. No. WO/2018/064465 “Compounds for increasing neural plasticity” (Published April 5, 2018)

From Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa or IIb:



(IIa)

wherein:

L3 is a bond...

R8 is hydrogen...

R9 is hydrogen, C1-C6 alkyl, or C2-C6 alkenyl;

R10 is hydrogen...

R11 is C1-C6 alkylamino, di-(C1-C6 alkyl)amino, N-(C1-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl;

R12 is hydrogen


subscript p is an integer from 0 to 3;

subscript q is an integer from 0 to 3; and

From [0016]: The present invention provides a method of using non-hallucinogenic analogs of psychedelic compounds for treatment of a brain disorder. The brain disorder can be a psychiatric disorder including depression, anxiety, and/or post-traumatic stress disorder.

3. Int'l Pat. App. Pub. No. WO/2020/176599 "Azepino-indoles and other heterocycles for treating brain disorders" (Published September 3, 2020)

From Claim 1: A compound of Formula I:



wherein:

R1 is hydrogen or C1-6 alkyl;

R3a and R3b are each independently hydrogen, C1-6 alkyl, C3-8 cycloalkyl, or C4-14 alkyl-cycloalkyl;

R3c is hydrogen or C1-6 alkyl;

R4, R5, R6 and R7 are each independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, C1-6 haloalkyl, C1-6 alkylamine, C1-6 alkoxy, C1-6 haloalkoxy, -OR8a, -NO₂, -CN, -C(O)R8b, -C(O)OR8b, -OC(O)R8b, -OC(O)OR8b, -

S(O)₂N(R8bR8c), C3-8 cycloalkyl, C3-14 alkyl-cycloalkyl, C4-10 heterocycloalkyl, C4-16 alkyl-heterocycloalkyl, C6-12 aryl, C7-18 alkyl-aryl, C5-10 heteroaryl, or C4-16 alkyl-heteroaryl, wherein at least one of R4, R5, R6 and R7 is not H; alternatively, R4 and R5, R5 and R6, or R6 and R7 are combined with the atoms to which they are each attached to form a C3-6 cycloalkyl, C3-6 heterocycloalkyl, C6-12 aryl or C5-10 heteroaryl;


R8a, R8b, R8c...are each independently H, C1-6 alkyl;

From [0068]: "Brain disorder" refers to a neurological disorder which affects the brain's structure and function. Brain disorders can include, but are not limited to, Alzheimer's, Parkinson's disease, psychological disorder, depression, treatment resistant depression, addiction, anxiety, post-traumatic stress disorder, suicidal ideation, major depressive disorder, bipolar disorder, schizophrenia, stroke, traumatic brain injury, and substance use disorder.

33. The method of any one of claims 22 to 32, wherein R6 is selected from hydrogen and C1-6 alkyl.

1. Int'l Pat. App. Pub. No. WO/2018/064465 "Compounds for increasing neural plasticity" (Published April 5, 2018)

From Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa or IIb:



wherein:

L3 is a bond...

R8 is hydrogen...

R9 is hydrogen, C1-C6 alkyl....

R10 is hydrogen...

R11 is C1-C6 alkylamino, di-(C1-C6 alkyl)amino, N-(C1-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl;

R12 is hydrogen


subscript p is an integer from 0 to 3;

subscript q is an integer from 0 to 3; and

From [0016]: The present invention provides a method of using non-hallucinogenic analogs of psychedelic compounds for treatment of a brain disorder. The brain disorder can be a psychiatric disorder including depression, anxiety, and/or post-traumatic stress disorder.

3. Int'l Pat. App. Pub. No. WO/2020/176599 "Azepino-indoles and other heterocycles for treating brain disorders" (Published September 3, 2020)

From Claim 1: A compound of Formula I:



wherein:


R1 is hydrogen or C1-6 alkyl;


R3a and R3b are each independently hydrogen, C1-6 alkyl, C3-8 cycloalkyl, or C4-14 alkyl-cycloalkyl;

R3c is hydrogen or C1-6 alkyl;

R4, R5, R6 and R7 are each independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, C1-6 haloalkyl, C1-6 alkylamine, C1-6 alkoxy, C1-6 haloalkoxy, -OR8a, -NO2, -CN, -C(O)R8b, -C(O)OR8b, -OC(O)R8b, -OC(O)OR8b, -

S(O)2N(R8bR8c), C3-8 cycloalkyl, C3-14 alkyl-cycloalkyl, C4-10 heterocycloalkyl, C4-16 alkyl-heterocycloalkyl, C6-12 aryl, C7-18 alkyl-

	<p>aryl, C5-10 heteroaryl, or C4- 16 alkyl-heteroaryl, wherein at least one of R4, R5, R6 and R7 is not H; alternatively, R4 and R5, R5 and R6, or R6 and R7 are combined with the atoms to which they are each attached to form a C3-6 cycloalkyl, C3-6 heterocycloalkyl, C6-12 aryl or C5-10 heteroaryl; R8a, R8b, R8c...are each independently H, C1-6 alkyl;</p> <p>From [0068]: “Brain disorder” refers to a neurological disorder which affects the brain’s structure and function. Brain disorders can include, but are not limited to, Alzheimer’s, Parkinson’s disease, psychological disorder, depression, treatment resistant depression, addiction, anxiety, post-traumatic stress disorder, suicidal ideation, major depressive disorder, bipolar disorder, schizophrenia, stroke, traumatic brain injury, and substance use disorder.</p>
<p>34. The method of claim 33, wherein R6 is hydrogen.</p>	<p>1. Int’l Pat. App. Pub. No. WO/2018/064465 “Compounds for increasing neural plasticity” (Published April 5, 2018)</p> <p>From Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa or IIb:</p> <div style="text-align: center;">  <p>(IIa)</p> </div> <p>wherein: L3 is a bond... R8 is hydrogen... R9 is hydrogen... R10 is hydrogen... R11 is C1-C6 alkylamino, di-(C1-C6 alkyl)amino, N-(C1-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl; R12 is hydrogen subscript p is an integer from 0 to 3; subscript q is an integer from 0 to 3; and</p> <p>From [0016]: The present invention provides a method of using non-hallucinogenic analogs of psychedelic compounds for treatment of a brain disorder. The brain disorder can be a psychiatric disorder including depression, anxiety, and/or post-traumatic stress disorder.</p> <p>3. Int’l Pat. App. Pub. No. WO/2020/176599 “Azepino-indoles and other heterocycles for treating brain disorders” (Published September 3, 2020)</p> <p>From Claim 1: A compound of Formula I:</p>



(I)

wherein:

R1 is hydrogen...

R3a and R3b are each independently hydrogen, C1-6 alkyl, C3-8 cycloalkyl, or C4-14 alkyl-cycloalkyl;

R3c is hydrogen or C1-6 alkyl;

R4, R5, R6 and R7 are each independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, C1-6 haloalkyl, C1-6 alkylamine, C1-6 alkoxy, C1-6 haloalkoxy, -OR8a, -NO2, -CN, -C(O)R8b, -C(O)OR8b, -OC(O)R8b, -OC(O)OR8b, -

S(O)2N(R8bR8c), C3-8 cycloalkyl, C3-14 alkyl-cycloalkyl, C4-10 heterocycloalkyl, C4-16 alkyl-heterocycloalkyl, C6-12 aryl, C7-18 alkyl-aryl, C5-10 heteroaryl, or C4-16 alkyl-heteroaryl, wherein at least one of R4, R5, R6 and R7 is not H; alternatively, R4 and R5, R5 and R6, or R6 and R7 are combined with the atoms to which they are each attached to form a C3-6 cycloalkyl, C3-6 heterocycloalkyl, C6-12 aryl or C5-10 heteroaryl;


R8a, R8b, R8c...are each independently H, C1-6 alkyl;

From [0068]: “Brain disorder” refers to a neurological disorder which affects the brain’s structure and function. Brain disorders can include, but are not limited to, Alzheimer’s, Parkinson’s disease, psychological disorder, depression, treatment resistant depression, addiction, anxiety, post-traumatic stress disorder, suicidal ideation, major depressive disorder, bipolar disorder, schizophrenia, stroke, traumatic brain injury, and substance use disorder.

35. The method of claim 22, wherein the compound of formula (I) is selected from any one of compounds 4-5, 15-61 and 119-164 or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer, metabolite, polymorph or prodrug thereof.

1. Int’l Pat. App. Pub. No. WO/2018/064465 “Compounds for increasing neural plasticity” (Published April 5, 2018)

From Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa or IIb:



(IIa)

wherein:


L3 is a bond, -C(O)NRb-, -NRbC(O)-, -NHC(O)NRb-, -C(O)O-, -OC(O)-, -NHC(O)O-, -SO2NRb-, -NHSO2-, -SO2-, -O-, -S-, or -NRb-; R8 is hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C1-

C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 alkoxy, C1-C6 aminoalkyl, heterocycloalkyl, aryl, or heteroaryl;
 Rb is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or C1-C6 alkoxy;
 R9 is hydrogen, C1-C6 alkyl, or C2-C6 alkenyl;
 R10 is hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, or C1-C6 haloalkyl;
 R11 is C1-C6 alkylamino, di-(C1-C6 alkyl)amino, N-(C1-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl;
 R12 is hydrogen, halogen, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or C1-C6 alkoxy;
 subscript p is an integer from 0 to 3;
 subscript q is an integer from 0 to 3; and
 subscript r is an integer from 1 to 3.

From [0016]: The present invention provides a method of using non-hallucinogenic analogs of psychedelic compounds for treatment of a brain disorder. The brain disorder can be a psychiatric disorder including depression, anxiety, and/or post-traumatic stress disorder.


3. Int'l Pat. App. Pub. No. WO/2020/176599 "Azepino-indoles and other heterocycles for treating brain disorders" (Published September 3, 2020)



From Claim 1: A compound of Formula I:



wherein:

R1 is hydrogen or C1-6 alkyl;
 R3a and R3b are each independently hydrogen, C1-6 alkyl, C3-8 cycloalkyl, or C4-14 alkyl-cycloalkyl;
 R3c is hydrogen or C1-6 alkyl;
 R4, R5, R6 and R7 are each independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, C1-6 haloalkyl, C1-6 alkylamine, C1-6 alkoxy, C1-6 haloalkoxy, -OR8a, -NO₂, -CN, -C(O)R8b, -C(O)OR8b, -OC(O)R8b, -OC(O)OR8b, -S(O)₂N(R8bR8c), C3-8 cycloalkyl, C3-14 alkyl-cycloalkyl, C4-10 heterocycloalkyl, C4-16 alkyl-heterocycloalkyl, C6-12 aryl, C7-18 alkyl-aryl, C5-10 heteroaryl, or C4-16 alkyl-heteroaryl, wherein at least one of R4, R5, R6 and R7 is not H; alternatively, R4 and R5, R5 and R6, or R6 and R7 are combined with the atoms to which they are each attached to form a C3-6 cycloalkyl, C3-6 heterocycloalkyl, C6-12 aryl or C5-10 heteroaryl;
 R8a, R8b, R8c...are each independently H, C1-6 alkyl;

	<p>From [0068]: “Brain disorder” refers to a neurological disorder which affects the brain’s structure and function. Brain disorders can include, but are not limited to, Alzheimer’s, Parkinson’s disease, psychological disorder, depression, treatment resistant depression, addiction, anxiety, post-traumatic stress disorder, suicidal ideation, major depressive disorder, bipolar disorder, schizophrenia, stroke, traumatic brain injury, and substance use disorder.</p>
<p>36. A method of treating a disease, disorder or condition by activation of a serotonin receptor, the method comprising administering to a subject in need thereof a compound of formula (I) as defined in any one of claims 22 to 36, or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer, metabolite, polymorph or prodrug thereof, in combination with another known agent useful for treatment of a disease, disorder or condition by activation of a serotonin receptor.</p>	<p>1. Int’l Pat. App. Pub. No. WO/2018/064465 “Compounds for increasing neural plasticity” (Published April 5, 2018)</p> <p>From Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa or IIb:</p> <div style="text-align: center;">  <p>(IIa)</p> </div> <p>wherein: L3 is a bond, -C(O)NRb-, -NRbC(O)-, -NHC(O)NRb-, -C(O)O-, -OC(O)-, -NHC(O)O-, -SO2NRb-, -NHSO2-, -SO2-, -O-, -S-, or -NRb-; R8 is hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 alkoxy, C1-C6 aminoalkyl, heterocycloalkyl, aryl, or heteroaryl; Rb is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or C1-C6 alkoxy; R9 is hydrogen, C1-C6 alkyl, or C2-C6 alkenyl; R10 is hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, or C1-C6 haloalkyl; R11 is C1-C6 alkylamino, di-(C1-C6 alkyl)amino, N-(C1-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl; R12 is hydrogen, halogen, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or C1-C6 alkoxy; subscript p is an integer from 0 to 3; subscript q is an integer from 0 to 3; and subscript r is an integer from 1 to 3.</p> <p>From [0016]: The present invention provides a method of using non-hallucinogenic analogs of psychedelic compounds for treatment of a brain disorder. The brain disorder can be a psychiatric disorder including depression, anxiety, and/or post-traumatic stress disorder.</p> <p>3. Int’l Pat. App. Pub. No. WO/2020/176599 “Azepino-indoles and other heterocycles for treating brain disorders” (Published September 3, 2020)</p> <p>From Claim 1: A compound of Formula I:</p>


	<div style="text-align: center;">  <p>(I)</p> </div> <p>wherein: R1 is hydrogen or C1-6 alkyl; R3a and R3b are each independently hydrogen, C1-6 alkyl, C3-8 cycloalkyl, or C4-14 alkyl-cycloalkyl; R3c is hydrogen or C1-6 alkyl; R4, R5, R6 and R7 are each independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, C1-6 haloalkyl, C1-6 alkylamine, C1-6 alkoxy, C1-6 haloalkoxy, -OR8a, -NO2, -CN, -C(O)R8b, -C(O)OR8b, -OC(O)R8b, -OC(O)OR8b, -S(O)2N(R8bR8c), C3-8 cycloalkyl, C3-14 alkyl-cycloalkyl, C4-10 heterocycloalkyl, C4-16 alkyl-heterocycloalkyl, C6-12 aryl, C7-18 alkyl-aryl, C5-10 heteroaryl, or C4-16 alkyl-heteroaryl, wherein at least one of R4, R5, R6 and R7 is not H; alternatively, R4 and R5, R5 and R6, or R6 and R7 are combined with the atoms to which they are each attached to form a C3-6 cycloalkyl, C3-6 heterocycloalkyl, C6-12 aryl or C5-10 heteroaryl; R8a, R8b, R8c...are each independently H, C1-6 alkyl;</p> <p>From [0068]: “Brain disorder” refers to a neurological disorder which affects the brain’s structure and function. Brain disorders can include, but are not limited to, Alzheimer’s, Parkinson’s disease, psychological disorder, depression, treatment resistant depression, addiction, anxiety, post-traumatic stress disorder, suicidal ideation, major depressive disorder, bipolar disorder, schizophrenia, stroke, traumatic brain injury, and substance use disorder.</p>
<p>37. A method of treating a mental illness, the method comprising administering to a subject in need thereof a compound of formula (I) as defined in any one of claims 22 to 36, or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer, metabolite, polymorph or prodrug thereof.</p>	<p>1. Int’l Pat. App. Pub. No. WO/2018/064465 “Compounds for increasing neural plasticity” (Published April 5, 2018)</p> <p>From Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa or IIb:</p> <div style="text-align: center;">  <p>(IIa)</p> </div> <p>wherein: L3 is a bond, -C(O)NRb-, -NRbC(O)-, -NHC(O)NRb-, -C(O)O-, -OC(O)-, -NHC(O)O-, -SO2NRb-, -NHSO2-, -SO2-, -O-, -S-, or -NRb-; R8 is hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C1-</p>

C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 alkoxy, C1-C6 aminoalkyl, heterocycloalkyl, aryl, or heteroaryl;
 Rb is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or C1-C6 alkoxy;
 R9 is hydrogen, C1-C6 alkyl, or C2-C6 alkenyl;
 R10 is hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, or C1-C6 haloalkyl;
 R11 is C1-C6 alkylamino, di-(C1-C6 alkyl)amino, N-(C1-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl;
 R12 is hydrogen, halogen, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or C1-C6 alkoxy;
 subscript p is an integer from 0 to 3;
 subscript q is an integer from 0 to 3; and
 subscript r is an integer from 1 to 3.

From [0016]: The present invention provides a method of using non-hallucinogenic analogs of psychedelic compounds for treatment of a brain disorder. The brain disorder can be a psychiatric disorder including depression, anxiety, and/or post-traumatic stress disorder.


3. Int'l Pat. App. Pub. No. WO/2020/176599 "Azepino-indoles and other heterocycles for treating brain disorders" (Published September 3, 2020)


From Claim 1: A compound of Formula I:



wherein:

R1 is hydrogen or C1-6 alkyl;
 R3a and R3b are each independently hydrogen, C1-6 alkyl, C3-8 cycloalkyl, or C4-14 alkyl-cycloalkyl;
 R3c is hydrogen or C1-6 alkyl;
 R4, R5, R6 and R7 are each independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, C1-6 haloalkyl, C1-6 alkylamine, C1-6 alkoxy, C1-6 haloalkoxy, -OR8a, -NO₂, -CN, -C(O)R8b, -C(O)OR8b, -OC(O)R8b, -OC(O)OR8b, -S(O)₂N(R8bR8c), C3-8 cycloalkyl, C3-14 alkyl-cycloalkyl, C4-10 heterocycloalkyl, C4-16 alkyl-heterocycloalkyl, C6-12 aryl, C7-18 alkyl-aryl, C5-10 heteroaryl, or C4-16 alkyl-heteroaryl, wherein at least one of R4, R5, R6 and R7 is not H; alternatively, R4 and R5, R5 and R6, or R6 and R7 are combined with the atoms to which they are each attached to form a C3-6 cycloalkyl, C3-6 heterocycloalkyl, C6-12 aryl or C5-10 heteroaryl;
 R8a, R8b, R8c...are each independently H, C1-6 alkyl;

	<p>From [0068]: “Brain disorder” refers to a neurological disorder which affects the brain’s structure and function. Brain disorders can include, but are not limited to, Alzheimer’s, Parkinson’s disease, psychological disorder, depression, treatment resistant depression, addiction, anxiety, post-traumatic stress disorder, suicidal ideation, major depressive disorder, bipolar disorder, schizophrenia, stroke, traumatic brain injury, and substance use disorder.</p>
<p>38. The method of claim 37, wherein the mental illness is selected from anxiety disorders; depression; mood disorders; psychotic disorders; impulse control and addiction disorders; drug addiction; obsessive-compulsive disorder (OCD); post-traumatic stress disorder (PTSD); stress response syndromes; dissociative disorders; depersonalization disorder; factitious disorders; sexual and gender disorders; somatic symptom disorders; hallucinations; delusions; psychosis; and combinations thereof.</p>	<p>1. Int’l Pat. App. Pub. No. WO/2018/064465 “Compounds for increasing neural plasticity” (Published April 5, 2018)</p> <p>From Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa or IIb:</p> <div style="text-align: center;">  <p>(IIa)</p> </div> <p>wherein: L3 is a bond, -C(O)NRb-, -NRbC(O)-, -NHC(O)NRb-, -C(O)O-, -OC(O)-, -NHC(O)O-, -SO2NRb-, -NHSO2-, -SO2-, -O-, -S-, or -NRb-; R8 is hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 alkoxy, C1-C6 aminoalkyl, heterocycloalkyl, aryl, or heteroaryl; Rb is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or C1-C6 alkoxy; R9 is hydrogen, C1-C6 alkyl, or C2-C6 alkenyl; R10 is hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, or C1-C6 haloalkyl; R11 is C1-C6 alkylamino, di-(C1-C6 alkyl)amino, N-(C1-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl; R12 is hydrogen, halogen, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or C1-C6 alkoxy; subscript p is an integer from 0 to 3; subscript q is an integer from 0 to 3; and subscript r is an integer from 1 to 3.</p> <p>From [0016]: The present invention provides a method of using non-hallucinogenic analogs of psychedelic compounds for treatment of a brain disorder. The brain disorder can be a psychiatric disorder including depression, anxiety, and/or post-traumatic stress disorder.</p> <p>3. Int’l Pat. App. Pub. No. WO/2020/176599 “Azepino-indoles and other heterocycles for treating brain disorders” (Published September 3, 2020)</p> <p>From Claim 1: A compound of Formula I:</p>



(I)

wherein:

R1 is hydrogen or C1-6 alkyl;

R3a and R3b are each independently hydrogen, C1-6 alkyl, C3-8 cycloalkyl, or C4-14 alkyl-cycloalkyl;

R3c is hydrogen or C1-6 alkyl;

R4, R5, R6 and R7 are each independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, C1-6 haloalkyl, C1-6 alkylamine, C1-6 alkoxy, C1-6 haloalkoxy, -OR8a, -NO2, -CN, -C(O)R8b, -C(O)OR8b, -OC(O)R8b, -

S(O)2N(R8bR8c), C3-8 cycloalkyl, C3-14 alkyl-cycloalkyl, C4-10 heterocycloalkyl, C4-16 alkyl-heterocycloalkyl, C6-12 aryl, C7-18 alkyl-aryl, C5-10 heteroaryl, or C4-16 alkyl-heteroaryl, wherein at least one of R4, R5, R6 and R7 is not H; alternatively, R4 and R5, R5 and R6, or R6 and R7 are combined with the atoms to which they are each attached to form a C3-6 cycloalkyl, C3-6 heterocycloalkyl, C6-12 aryl or C5-10 heteroaryl;


R8a, R8b, R8c...are each independently H, C1-6 alkyl;

From [0068]: “Brain disorder” refers to a neurological disorder which affects the brain’s structure and function. Brain disorders can include, but are not limited to...psychological disorder, depression, treatment resistant depression, addiction, anxiety, post-traumatic stress disorder, suicidal ideation, major depressive disorder, bipolar disorder, schizophrenia...and substance use disorder.

39. A method for treating a central nervous system (CNS) disease, disorder or condition and/or a neurological disease, disorder or condition, the method comprising administering to a subject in need thereof a compound of formula (I) as defined in any one of claims 22 to 36, or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide,

1. Int’l Pat. App. Pub. No. WO/2018/064465 “Compounds for increasing neural plasticity” (Published April 5, 2018)

From Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa or IIb:



(IIa)

wherein:

L3 is a bond, -C(O)NRb-, -NRbC(O)-, -NHC(O)NRb-, -C(O)O-, -OC(O)-, -NHC(O)O-, -SO2NRb-, -NHSO2-, -SO2-, -O-, -S-, or -NRb-; R8 is hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C1-


stereoisomer,
metabolite, polymorph
or prodrug thereof.

C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 alkoxy, C1-C6 aminoalkyl, heterocycloalkyl, aryl, or heteroaryl;
Rb is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or C1-C6 alkoxy;
R9 is hydrogen, C1-C6 alkyl, or C2-C6 alkenyl;
R10 is hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, or C1-C6 haloalkyl;
R11 is C1-C6 alkylamino, di-(C1-C6 alkyl)amino, N-(C1-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl;
R12 is hydrogen, halogen, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or C1-C6 alkoxy;
subscript p is an integer from 0 to 3;
subscript q is an integer from 0 to 3; and
subscript r is an integer from 1 to 3.

From [0016]: **The present invention provides a method of using non-hallucinogenic analogs of psychedelic compounds for treatment of a brain disorder. The brain disorder can be a psychiatric disorder including depression, anxiety, and/or post-traumatic stress disorder.**


3. Int'l Pat. App. Pub. No. WO/2020/176599 "Azepino-indoles and other heterocycles for treating brain disorders" (Published September 3, 2020)

From Claim 1: **A compound of Formula I:**




wherein:

R1 is hydrogen or C1-6 alkyl;
R3a and R3b are each independently hydrogen, C1-6 alkyl, C3-8 cycloalkyl, or C4-14 alkyl-cycloalkyl;
R3c is hydrogen or C1-6 alkyl;
R4, R5, R6 and R7 are each independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, C1-6 haloalkyl, C1-6 alkylamine, C1-6 alkoxy, C1-6 haloalkoxy, -OR8a, -NO₂, -CN, -C(O)R8b, -C(O)OR8b, -OC(O)R8b, -OC(O)OR8b, -S(O)₂N(R8bR8c), C3-8 cycloalkyl, C3-14 alkyl-cycloalkyl, C4-10 heterocycloalkyl, C4-16 alkyl-heterocycloalkyl, C6-12 aryl, C7-18 alkyl-aryl, C5-10 heteroaryl, or C4-16 alkyl-heteroaryl, wherein at least one of R4, R5, R6 and R7 is not H; alternatively, R4 and R5, R5 and R6, or R6 and R7 are combined with the atoms to which they are each attached to form a C3-6 cycloalkyl, C3-6 heterocycloalkyl, C6-12 aryl or C5-10 heteroaryl;
R8a, R8b, R8c...are each independently H, C1-6 alkyl;

	<p>From [0068]: “Brain disorder” refers to a neurological disorder which affects the brain’s structure and function. Brain disorders can include, but are not limited to, Alzheimer’s, Parkinson’s disease, psychological disorder, depression, treatment resistant depression, addiction, anxiety, post-traumatic stress disorder, suicidal ideation, major depressive disorder, bipolar disorder, schizophrenia, stroke, traumatic brain injury, and substance use disorder.</p>
<p>40. The method of claim 39, wherein the CNS disease, disorder or condition and/or neurological disease, disorder or condition is selected from neurological diseases including neurodevelopmental diseases and neurodegenerative diseases such as Alzheimer's disease; presenile dementia; senile dementia; vascular dementia; Lewy body dementia; cognitive impairment, Parkinson's disease and Parkinsonian related disorders such as Parkinson dementia, corticobasal degeneration, and supranuclear palsy; epilepsy; CNS trauma; CNS infections; CNS inflammation; stroke; multiple sclerosis; Huntington's disease; mitochondrial disorders; Fragile X syndrome; Angelman syndrome; hereditary ataxias; neuro-otological and eye movement disorders; neurodegenerative diseases of the retina amyotrophic lateral sclerosis; tardive</p>	<p>1. Int’l Pat. App. Pub. No. WO/2018/064465 “Compounds for increasing neural plasticity” (Published April 5, 2018)</p> <p>From Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa or IIb:</p> <div style="text-align: center;">  <p>(IIa)</p> </div> <p>wherein: L3 is a bond, -C(O)NRb-, -NRbC(O)-, -NHC(O)NRb-, -C(O)O-, -OC(O)-, -NHC(O)O-, -SO2NRb-, -NHSO2-, -SO2-, -O-, -S-, or -NRb-; R8 is hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 alkoxy, C1-C6 aminoalkyl, heterocycloalkyl, aryl, or heteroaryl; Rb is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or C1-C6 alkoxy; R9 is hydrogen, C1-C6 alkyl, or C2-C6 alkenyl; R10 is hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, or C1-C6 haloalkyl; R11 is C1-C6 alkylamino, di-(C1-C6 alkyl)amino, N-(C1-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl; R12 is hydrogen, halogen, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or C1-C6 alkoxy; subscript p is an integer from 0 to 3; subscript q is an integer from 0 to 3; and subscript r is an integer from 1 to 3.</p> <p>From [0016]: The present invention provides a method of using non-hallucinogenic analogs of psychedelic compounds for treatment of a brain disorder. The brain disorder can be a psychiatric disorder including depression, anxiety, and/or post-traumatic stress disorder.</p> <p>3. Int’l Pat. App. Pub. No. WO/2020/176599 “Azepino-indoles and other heterocycles for treating brain disorders” (Published September 3, 2020)</p> <p>From Claim 1: A compound of Formula I:</p>

dyskinesias;
 hyperkinetic disorders;
 attention deficit
 hyperactivity disorder
 and attention deficit
 disorders; restless leg
 syndrome; Tourette's
 syndrome;
 schizophrenia; autism
 spectrum disorders;
 tuberous sclerosis; Rett
 syndrome; cerebral
 palsy; disorders of the
 reward system
 including eating
 disorders such as
 anorexia nervosa and
 bulimia nervosa; binge
 eating disorder,
 trichotillomania,
 dermatillomania, nail
 biting; migraine;
 fibromyalgia; and
 peripheral neuropathy
 of any etiology, and
 combinations thereof.



(I)

wherein:

R1 is hydrogen or C1-6 alkyl;

R3a and R3b are each independently hydrogen, C1-6 alkyl, C3-8 cycloalkyl, or C4-14 alkyl-cycloalkyl;

R3c is hydrogen or C1-6 alkyl;

R4, R5, R6 and R7 are each independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, C1-6 haloalkyl, C1-6 alkylamine, C1-6 alkoxy, C1-6 haloalkoxy, -OR8a, -NO2, -CN, -C(O)R8b, -C(O)OR8b, -OC(O)R8b, -OC(O)OR8b, -

S(O)2N(R8bR8c), C3-8 cycloalkyl, C3-14 alkyl-cycloalkyl, C4-10 heterocycloalkyl, C4-16 alkyl-heterocycloalkyl, C6-12 aryl, C7-18 alkyl-aryl, C5-10 heteroaryl, or C4-16 alkyl-heteroaryl, wherein at least one of R4, R5, R6 and R7 is not H; alternatively, R4 and R5, R5 and R6, or R6 and R7 are combined with the atoms to which they are each attached to form a C3-6 cycloalkyl, C3-6 heterocycloalkyl, C6-12 aryl or C5-10 heteroaryl;


R8a, R8b, R8c...are each independently H, C1-6 alkyl;

From [0068]: “Brain disorder” refers to a neurological disorder which affects the brain’s structure and function. Brain disorders can include, but are not limited to, Alzheimer’s, Parkinson’s disease, psychological disorder, depression, treatment resistant depression, addiction, anxiety, post-traumatic stress disorder, suicidal ideation, major depressive disorder, bipolar disorder, schizophrenia, stroke, traumatic brain injury, and substance use disorder.

41. A method for increasing neuronal plasticity and/or increasing dendritic spine density, the method comprising contacting a neuronal cell with a compound of formula (I) as defined in any one of claims 22 to 36, or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer, metabolite, polymorph

1. Int’l Pat. App. Pub. No. WO/2018/064465 “Compounds for increasing neuronal plasticity” (Published April 5, 2018)

From Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa or IIb:



(IIa)

wherein:

L3 is a bond, -C(O)NRb-, -NRbC(O)-, -NHC(O)NRb-, -C(O)O-, -OC(O)-, -NHC(O)O-, -SO2NRb-, -NHSO2-, -SO2-, -O-, -S-, or -NRb-; R8 is hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C1-

or prodrug thereof, in an amount sufficient to increase neuronal plasticity and/or increase dendritic spine density of the neuronal cell.


C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 alkoxy, C1-C6 aminoalkyl, heterocycloalkyl, aryl, or heteroaryl;
Rb is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or C1-C6 alkoxy;
R9 is hydrogen, C1-C6 alkyl, or C2-C6 alkenyl;
R10 is hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, or C1-C6 haloalkyl;
R11 is C1-C6 alkylamino, di-(C1-C6 alkyl)amino, N-(C1-C6 alkyl)pyrrolidinyl, or N-(C1-C6 alkyl)piperidinyl;
R12 is hydrogen, halogen, -OH, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or C1-C6 alkoxy;
subscript p is an integer from 0 to 3;
subscript q is an integer from 0 to 3; and
subscript r is an integer from 1 to 3.

From [0016]: The present invention provides a method of using non-hallucinogenic analogs of psychedelic compounds for treatment of a brain disorder. The brain disorder can be a psychiatric disorder including depression, anxiety, and/or post-traumatic stress disorder.

From [0069]: In one aspect, provided herein is a method of increasing neural plasticity. The method includes contacting a neuronal cell with a non-hallucinogenic analog of a psychedelic compound, in an amount sufficient to increase neural plasticity of the neuronal cell, wherein the non-hallucinogenic analog of a psychedelic compound produces a maximum number of dendritic crossings...

3. Int'l Pat. App. Pub. No. WO/2020/176599 "Azepino-indoles and other heterocycles for treating brain disorders" (Published September 3, 2020)

From Claim 1: A compound of Formula I:



wherein:

R1 is hydrogen or C1-6 alkyl;
R3a and R3b are each independently hydrogen, C1-6 alkyl, C3-8 cycloalkyl, or C4-14 alkyl-cycloalkyl;
R3c is hydrogen or C1-6 alkyl;
R4, R5, R6 and R7 are each independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, C1-6 haloalkyl, C1-6 alkylamine, C1-6 alkoxy, C1-6 haloalkoxy, -OR8a, -NO2, -CN, -C(O)R8b, -C(O)OR8b, -OC(O)R8b, -S(O)2N(R8bR8c), C3-8 cycloalkyl, C3-14 alkyl-cycloalkyl, C4-10 heterocycloalkyl, C4-16 alkyl-heterocycloalkyl, C6-12 aryl, C7-18 alkyl-

aryl, C5-10 heteroaryl, or C4- 16 alkyl-heteroaryl, wherein at least one of R4, R5, R6 and R7 is not H; alternatively, R4 and R5, R5 and R6, or R6 and R7 are combined with the atoms to which they are each attached to form a C3-6 cycloalkyl, C3-6 heterocycloalkyl, C6-12 aryl or C5-10 heteroaryl;

R8a, R8b, R8c...are each independently H, C1-6 alkyl;

From [0068]: **“Brain disorder”** refers to a neurological disorder which affects the brain’s structure and function. Brain disorders can include, but are not limited to, Alzheimer’s, Parkinson’s disease, psychological disorder, depression, treatment resistant depression, addiction, anxiety, post-traumatic stress disorder, suicidal ideation, major depressive disorder, bipolar disorder, schizophrenia, stroke, traumatic brain injury, and substance use disorder.

From [0153]: In some embodiments, promotion of neural plasticity includes, for example, increased dendritic spine growth, increased synthesis of synaptic proteins, strengthened synaptic responses, increased dendritic arbor complexity...



P.O. Box 1450
 Alexandria, VA 22313 - 1450
 www.uspto.gov

ELECTRONIC ACKNOWLEDGEMENT RECEIPT

APPLICATION #	RECEIPT DATE / TIME	ATTORNEY DOCKET #
18/723,836	05/05/2025 09:31:25 AM Z ET	

Title of Invention

Application Information

APPLICATION TYPE	PATENT #
CONFIRMATION #	FILED BY Jeremy Rolquin
PATENT CENTER # 70283835	FILING DATE 06/24/2024
CUSTOMER # -	FIRST NAMED INVENTOR
INTL. APPLICATION # -	INTL. FILING DATE -
CORRESPONDENCE ADDRESS -	AUTHORIZED BY -

Documents

TOTAL DOCUMENTS: 11

DOCUMENT	PAGES	DESCRIPTION	SIZE (KB)
third-party-preissuance-submission.pdf	2	Third-Party Submission Under 37 CFR 1.290	53 KB
Third-party-notification-request.pdf	1	Request for Notification of Non-compliant Third-Party Submission	13 KB
Concise-description-generated.pdf	2	Concise Description of Relevance	27 KB
US20250074873 3PS.pdf	126	-	1481 KB
US20250074873 3PS-3P.RELEVANCE.pdf	(1-126) 126	Concise Description of Relevance	1175 KB
US20250074873 3PS-3P.RELEVANCE.pdf	(1-126) 126	Concise Description of Relevance	1175 KB

US20250074873 3PS-3P.RELEVANCE.pdf	(1-126)	126	Concise Description of Relevance	1175 KB
US20250074873 3PS-3P.RELEVANCE.pdf	(1-126)	126	Concise Description of Relevance	1175 KB
1_WO2018064465.pdf		85	-	4171 KB
1_WO2018064465-FOR.pdf	(1-85)	85	Foreign Reference	4171 KB
2_WO1998023587.pdf		71	-	2814 KB
2_WO1998023587-FOR.pdf	(1-71)	71	Foreign Reference	2814 KB
3_WO2020176599.pdf		123	-	5713 KB
3_WO2020176599-FOR.pdf	(1-123)	123	Foreign Reference	5713 KB
4_WO2018204359.pdf		77	-	9662 KB
4_WO2018204359-FOR.pdf	(1-77)	77	Foreign Reference	9662 KB

Digest

DOCUMENT

MESSAGE DIGEST(SHA-512)

third-party-preissuance-submission.pdf	8B30DC87163853FED60EAAEAD94A3597BFCFA7BBE676522A864F1452835647BF493C5AECDBCCF3C8316B74B939FC8D1C2F07A7F8538148838AA1E10F858588A2
Third-party-notification-request.pdf	1741D55FBBA3C30CBD75D42710065077153653B022DE113B28C2F007D81BF0E113584A559099D4E050B6E8BADD810009CD827B30EF6CADDE519F01C47626B548
Concise-description-generated.pdf	7286D7E40215FEAC7879941C51025FC8CD0042469773E580D465A9A1A6D0854EDCA178D72F0DA4AB1C50248B60D985EC144ED88890463E9D30A60D9D694EE713
US20250074873 3PS.pdf	B89B7719F720EFB1645DE312E00176FE0D404C060EECA2E0A8D179C522B162098FA0F1BA7F861DFC58DADDA83BC32C8CF7D2973F3057553264C8B1AA50823DF8
US20250074873 3PS-3P.RELEVANCE.pdf	59787C92AFA2A281C67E686168BE2CFD810A26EE8505B2DF91007CD9E5D718F5651D717E4AF867225BA9F513522B631396F2D8974AD1F948C6B4844F5F98557A
US20250074873 3PS-3P.RELEVANCE.pdf	AA24BF7D45B8C96AD43E995030D5A3A8500286064F388C6FB67F2243E93A7312137132F37A01D0371DCAA2DEC1D0FB857

	60803FE892DE6161CF08591C5A5E37
US20250074873 3PS-3P.RELEVANCE.pdf	36F790FD974F03D8001FC32B66AF77BE7C1763F70B3678F6B BABA5CA198F8896DD900A7AD74450B513E2736AE89D6D780 0175643BF0DCF5F64D1EAF02AB92C5
US20250074873 3PS-3P.RELEVANCE.pdf	CFF80D51C4811D5CDD018CF3D0ADF2E37C3ECD77F9DEEF D852A2C3247E1B301261B0739DD6B67FE6A3CFD757AF0A2C 3BAE60E7D3648E8E3C90E2DE53D926307F
1_WO2018064465.pdf	CAC817059D5AA9C2AD66B70E33A8C48BA33C51AC53CD4135 3E47E35A2B84864CA9525FB374EA902F99E0535494F34867A1 A9068726BBBF91949D635916E4AB4B
1_WO2018064465-FOR.pdf	5E25C3446CBDDAF92DACEF0E36243F0C2DB88EC3837EA63 D8CF74562B37FE9BEF62611FE3A4D0F06BB64050593D2D017 A163E06A3840665DFE731F3638391B5C
2_WO1998023587.pdf	E10C9BED13922C8788E2161B1F213FB0F4EC78011310B4217 4818A5E38C99725A3BC39BA90CD14D57947189538EC1D3D17 067E6AB037097DA6EECF5B00F6E84C
2_WO1998023587-FOR.pdf	1FD39EB716A3F5C2538C2E3F25E23973F4802CFD9BF96EFE2 21871BDF2DFB3B1232A46D23EE2D39CB61568F90A5421AEF B5B342120F120C58CA39BEFB96E2F6F
3_WO2020176599.pdf	28516CC956F43520B4835CA3BBB077D3AC2B2B44569AF0CB59 2490E2C0C9B3D0643A51DC58A942A3A84237E1008D6E45B68 279BEAE919D4DAE36007AAD9202CE7
3_WO2020176599-FOR.pdf	C50D82620D5E7663E8CA84A643ACAAFC5DD2AF3E1DC746 FB0AA21FD30C6E820342E3479509F3732055A59D40D0C9B29 ECB561898147391546132471174AB775
4_WO2018204359.pdf	C5183C5C0B9DBFF90D266403D058FB3898DA536BAA6179C4 18E90A7EAD202E64B507EE3D95083B12CAFF16BA76EC47393 97A1D1FB4BE2ECF2EB31D9D177DB4E4
4_WO2018204359-FOR.pdf	195D2111B9D3CB05060F94B8F9D9610A9537BBA11C1CB6C2F 719F66B9D17B76D8B9444A1248FFC1A326A13450590DD17CB 2CD8A728DCC9714E9413A4AC36214C

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.



UNITED STATES
PATENT AND TRADEMARK OFFICE

P.O. Box 1450
Alexandria, VA 22313 - 1450
www.uspto.gov

ELECTRONIC PAYMENT RECEIPT

APPLICATION #	RECEIPT DATE / TIME	ATTORNEY DOCKET #
18/723,836	05/05/2025 09:31:25 AM Z ET	

Title of Invention

Application Information

APPLICATION TYPE	PATENT #
CONFIRMATION #	FILED BY Jeremy Rolquin
PATENT CENTER # 70283835	AUTHORIZED BY -
CUSTOMER # -	FILING DATE 06/24/2024
INTL. APPLICATION # -	INTL. FILING DATE -
CORRESPONDENCE ADDRESS -	FIRST NAMED INVENTOR

Payment Information

PAYMENT METHOD	PAYMENT TRANSACTION ID	PAYMENT AUTHORIZED BY
CARD / 7409	E202555032058502	Jeremy Rolquin

FEE CODE	DESCRIPTION	ITEM PRICE(\$)	QUANTITY	ITEM TOTAL(\$)
2818	DOCUMENT FEE FOR THIRD-PARTY SUBMISSIONS (SEE 37 CFR 1.290(F))	78.00	1	78.00
			TOTAL AMOUNT:	\$78.00

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C.

371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.